U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10

GENERAL FORM FOR REGISTRATION OF SECURITIES

Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934

EZJR, Inc.
(Exact name of registrant as specified in its charter)

           Nevada                          20-0667864
----------------------------------    ----------------------
(State or other jurisdiction of        (I.R.S. Employer
 incorporation or organization)        Identification No.)

3415 Ocatillo Mesa Way, North Las Vegas, NV 89031
(Address of principal executive offices)(Zip Code)

Issuer's telephone number, including area code: (702) 631-4251

Copies to:
Thomas C. Cook, Esq.
500 N. Rainbow, Suite 300
Las Vegas, NV 89107
Telephone Number: (702) 221-1925
Facsimile Number: (702) 221-1963

Securities to be registered under Section 12(b) of the Act: None

Securities to be registered under section 12(g) of the Act:

Title of Each Class               Name on each exchange on which
to be registered                  each class is to be registered
---------------------             ------------------------------
Common Stock, $0.0001             OTC-Bulletin Board

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

[ ] Large accelerated filer [ ] Accelerated filer
[ ] Non-accelerated filer [X] Smaller reporting company

EXPLANATORY NOTE

We are filing this General Form for Registration of Securities on Form 10 to register our common stock, par value $0.0001 per share (the "Common Stock"), pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Once this registration statement is deemed effective, we will be subject to the requirements of Regulation 13A under the Exchange Act, which will require us to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, and we will be required to comply with all other obligations of the Exchange Act applicable to issuers filing registration statements pursuant to Section 12(g) of the Exchange Act.

Unless otherwise noted, references in this registration statement to the "Registrant," the "Company," "we," "our" or "us" means EZJR, Inc. Our principal place of business is located at 3415 Ocatillo Mesa Way, North Las Vegas, NV 89031. Our telephone number is (702) 631-4251.


                               TABLE OF CONTENTS

                                                                      PAGE
                                                                      ----
ITEM 1. BUSINESS.....................................................   3

ITEM 1A. RISK FACTORS................................................   9

ITEM 2. FINANCIAL INFORMATION........................................  22

ITEM 3. PROPERTIES...................................................  23

ITEM 4. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
        AND MANAGEMENT...............................................  23

ITEM 5. DIRECTORS AND EXECUTIVE OFFICERS.............................  25

ITEM 6. EXECUTIVE COMPENSATION.......................................  26

ITEM 7. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
        AND DIRECTOR INDEPENDENCE....................................  27

ITEM 8. LEGAL PROCEEDINGS............................................  27

ITEM 9. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT'S
        COMMON EQUITY AND RELATED STOCKHOLDER MATTERS................  28

ITEM 10. RECENT SALES OF UNREGISTERED SECURITIES.....................  29

ITEM 11. DESCRIPTION OF REGISTRANT'S SECURITIES TO BE REGISTERED.....  29

ITEM 12. INDEMNIFICATION OF DIRECTORS AND OFFICERS...................  30

ITEM 13. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.................  30

ITEM 14. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
         AND FINANCIAL DISCLOSURE....................................  31

ITEM 15. FINANCIAL STATEMENTS AND EXHIBITS...........................  31

SIGNATURES...........................................................  32

2

FORWARD LOOKING STATEMENTS

There are statements in this registration statement that are not historical facts. These "forward-looking statements" can be identified by use of terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions. You should be aware that these forward- looking statements are subject to risks and uncertainties that are beyond our control. For a discussion of these risks, you should read this entire Registration Statement carefully, especially the risks discussed under the section entitled "Risk Factors." Although management believes that the assumptions underlying the forward looking statements included in this Registration Statement are reasonable, they do not guarantee our future performance, and actual results could differ from those contemplated by these forward looking statements. The assumptions used for purposes of the forward- looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results and events contemplated by the forward-looking statements contained in this Registration Statement will in fact transpire. You are cautioned to not place undue reliance on these forward-looking statements, which speak only as of their dates. We do not undertake any obligation to update or revise any forward- looking statements.

Item 1. Business.

Business History

EZJR, Inc, ("we", "us", "our", the "Company" or the "Registrant") was organized August 14, 2006 (Date of Inception) under the laws of the State of Nevada, as IVPSA Corporation ("IVP"). The Company was incorporated as a subsidiary of Eaton Laboratories, Inc., a Nevada corporation. The Company is a developmental medical device company which plans to produce medical devices, utilizing the outside contract manufacturing facilities.

On July 25, 2008, EZJR, Inc., a Nevada corporation and IVPSA Corporation, entered into an Acquisition Agreement and Plan of Merger whereby IVP acquired EZJR, Inc. in a transaction where IVP is the successor corporation. Upon the merger of the two entities, IVP changed its corporate name to EZJR, Inc.

3

Business of Issuer

EZJR, Inc. is a developmental medical device company which plans to produce medical devices, utilizing the services contract manufacturing facilities. EZJR does not have the resources to conduct any required clinical trails to obtain FDA approval. Therefore, EZJR plans to outsource this task to third parties who have the facilities to conduct any required clinical trials. EZJR also plans to subcontract the manufacturing and production process of any future medical device to a FDA approved contract manufacturing facility which can produce sterile medical devices under Good Manufacturing Practices. The company plans to distribute its product(s) into the marketplace through medical supply wholesalers, hospitals and health maintenance organizations.

Exclusive Option Agreement

EZJR entered into an "Exclusive Option Agreement" with the Cleveland Clinic, Cleveland, Ohio, on March 15, 2007 to investigate and conduct due diligence with respect to the commercial viability of the licensable technology prior to executing a formal License Agreement. The technology consists of a central line catheter with the ability to access the jugular bulb. The jugular bulb is part of the internal jugular vein that collects the blood from the brain, from the superficial parts of the face, and from the neck. This catheter was invented by a physician at the Cleveland Clinic. The Company paid the Cleveland Clinic, a nonrefundable fee of $46,000 for this exclusive option agreement. The agreement terminated in March, 2009. EZJR has not renewed this option agreement or entered into any licensing agreement with the Cleveland Clinic. EZJR has been unable to find a contract manufacturer who can handle the technical design of this proposed catheter.

Central line catheter product

Most patients in the neuro critical care setting as well as patients undergoing neurovascular procedures receive a central line catheter. Jugular bulb oxygen saturation monitoring is a well established method used in neurosurgical intensive care, particularly in context of head injury. Jugular Bulb Saturation measures the efficiency of oxygen use by the brain.

Currently, catheters for measuring jugular venous oxygen saturation are inserted into the jugular vein in a cephalad (toward the head) direction, with a catheter accessing the jugular bulb. The cephalad method is complex, time-consuming and could lead to complications. Traditionally, anesthesiologists and critical care physicians use caudad (toward the feet) catheter insertion to access the central venous system. The fear of complications with introducing a catheter towards the brain has discouraged the clinicians in using this monitoring method.

4

A potential benefit that might be achieved after the development of this catheter will provide anesthesiologists a method for double catheterization (inserting both caudad and cephalad catheters) all within one catheter. In other words, this design provides for one catheter to monitor a patient's vital signs, as compared to using two catheters for the same measurements.

This proposed catheter will give access to the blood exiting the brain, which can help the anesthesiologist monitor brain metabolism and its byproducts. Such information is important to neuro-critical care units and intracranial vascular surgical procedures. This method has also been suggested for monitoring the brain in cardiac surgical procedures.

Prototype Development

EZJR has yet to find a contract manufacturer who can build a working prototype of this catheter. In order to continue with this project, EZJR needs a working prototype that can be readily duplicated by a contract manufacturer at a reasonable price. In November, 2007, EZJR signed a purchase order with Interplex Medical LLC of Midford, OH, to help the Company develop this working prototype. The terms of the purchase order require that EZJR pays up to $25,000 for the development of a prototype catheter. Their engineers were unable to successfully build this prototype. If a working prototype cannot be built, there would be no reason to proceed in attempting to bring this medical device to the market.

The difficulty in building a double catheterization prototype of this catheter rests in its design. It is a catheter within a catheter. The catheter inside the larger catheter must make a 180 degree turn without crimping its opening to server its purpose. In other words, blood must be able to pass within the inner catheter without any blockage, after the inner catheter has made a 180 turn. We have been unable to produce a working catheter which successfully meets these design specifications.

5

Existing or Probable Government Regulations

An investigational device exemption ("IDE") allows the investigational device to be used in a clinical study in order to collect safety and effectiveness data required to support a Premarket Approval ("PMA") application or a Premarket Notification submission to Food and Drug Administration ("FDA"). Clinical studies are most often conducted to support a PMA. Investigational use also includes clinical evaluation of certain modifications or new intended uses of legally marketed devices. All clinical evaluations of investigational devices, unless exempt, must have an approved IDE before the study is initiated. Clinical evaluation of devices that have not been cleared for marketing requires:

o an IDE approved by an institutional review board (IRB). If the study involves a significant risk device, the IDE must also be approved by FDA;

o informed consent from all patients;

o labeling for investigational use only

o monitoring of the study and;

o required records and reports.

In order to conduct a significant risk device study, EZJR must:

o submit a complete IDE application to FDA for review and obtain FDA approval of the IDE;

o submit the investigational plan and report of prior investigations and to the IRB at each institution where the investigation is to be conducted for review and approval; and

o select qualified investigators, provide them with all necessary information on the investigational plan and report of prior investigations, and obtain signed investigator agreements from them.

6

Once an IDE application is approved, the following requirements must be met in order to conduct the investigation in compliance with the IDE regulation:

o Labeling - The device must be labeled in accordance with the labeling provisions of the IDE regulation and must bear the statement "CAUTION Investigational Device. Limited by Federal (or United States) law to investigational use."

o Distribution - Investigational devices can only be distributed to qualified investigators.

o Informed Consent - Each subject must be provided with and sign an informed consent form before being enrolled in the study.

o Monitoring - All investigations must be properly monitored to protect the human subjects and assure compliance with approved protocols.

o Commercialization, promotion, and misrepresentation of an investigational device and prolongation of the study are prohibited.

o Records and Reports - Sponsors and investigators are required to maintain specified records and make reports to investigators, IRBs, and FDA.

EZJR Funding Requirements

EZJR does not have the required capital or funding to complete this initial project. Management anticipates EZJR will require at least $500,000 to complete to perform the required FDA studies and produce inventory. The Company has yet to source this funding.

The Company has been seeking funding from a number of sources, but has yet to secure any funding, especially during this current economic downturn. Management continues to seek different funding sources in order to initiate its business plan. The downturn in the economy has limited our sources of financing. Management continues to seek financing with no success. If the Company is unable to obtain capital to finance its plan of operations or identify alternative capital, it may need to curtail, limit or cease our existing operations.

Future funding could result in potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities and/or amortization of expenses related to goodwill and other intangible assets, which could materially adversely affect the Company's business, results of operations and financial condition. Any future acquisitions of other businesses, technologies, services or product(s) might require the Company to obtain additional equity or debt financing, which might not be available on terms favorable to the Company, or at all, and such financing, if available, might be dilutive.

7

Competition

The medical device industry is highly competitive. Factors contributing to the industry's increasingly competitive market include regulatory changes, product substitution, technological advances, and the entrance of new competitors.

Most of EZJR's competitors have significantly greater financial, marketing, other resources, and larger customer bases than EZJR has and are more financially leveraged. As a result, these competitors may be able to adapt changes in customer requirements more quickly; introduce new and more innovative products more quickly; better adapt to downturns in the economy or other decreases in sales; better withstand pressure for cancelled services, take advantage of acquisition and other opportunities more readily; devote greater resources to the marketing and sale of their products; and adapt more aggressive pricing policies. All of this may contribute to intensifying competition and may affect EZJR's future revenue growth.

Patent, Trademark, License and Franchise Restrictions and Contractual Obligations and Concessions

We currently have no pending or provisional patents or trademark applications.

Research and Development Activities and Costs

The majority of EZJR expenses involved the costs related to the research and development of the central line catheter. These costs included entering into two option contracts ($46,000), with the Cleveland Clinic, and paying for catheter development costs (approximately $17,000).

Compliance With Environmental Laws

We are not aware of any environmental laws that have been enacted, nor are we aware of any such laws being contemplated for the future, that impact issues specific to our business. In our industry, environmental laws are anticipated to apply directly to the owners and operators of companies. They do not apply to companies or individuals providing consulting services, unless they have been engaged to consult on environmental matters. We are not planning to provide environmental consulting services.

8

Employees

We have no employees at the present time. Our sole officer and director is responsible for all planning, developing and operational duties and will continue to do so throughout the early stages of our growth.

He devotes 5-10 hours per week of his time to EZJR's business. All functions including development, strategy, negotiations and clerical work is being provided by the sole officer/director on a voluntary basis, without compensation.

We have no intention of hiring employees until the business has been successfully launched and we have sufficient, reliable revenue from our operations. Our officer and director is planning to do whatever work is required until our business to the point of having positive cash flow. We do not expect to hire any employees during through 2010.

Item 1A. Risk Factors.

An investment in the Company is highly speculative in nature and involves a high degree of risk.

1. SINCE EZJR IS A DEVELOPMENT STAGE MEDICAL DEVICE COMPANY, EZJR HAS GENERATED NO REVENUES, AND THERE ARE NO ASSURANCES THAT ITS BUSINESS PLAN WILL BE SUCCESSFUL.

EZJR expects to incur operating losses in future periods as EZJR incurs significant expenses associated with the initial startup of its business. Further, there are no assurances that EZJR will be successful in realizing revenues or in achieving or sustaining positive cash flow at any time in the future. Any such failure could result in the possible closure of EZJR's business or force the Company to seek additional capital through loans or additional sales of the Company's equity securities to continue business operations, which would dilute the value of any shares owned by the Company's shareholders.

2. IF EZJR'S BUSINESS PLAN IS NOT SUCCESSFUL, EZJR MAY NOT BE ABLE TO CONTINUE OPERATIONS AS A GOING CONCERN AND ITS STOCKHOLDERS MAY LOSE THEIR ENTIRE INVESTMENT IN EZJR.

As discussed in the Notes to the Financial Statements included in this Current Report, at June 30, 2009, EZJR had a working capital deficit of $(480). EZJR had a net loss of approximately $(78,381) from its inception to June 30, 2009.

9

These factors raise substantial doubt that EZJR will be able to continue operations as a going concern, and EZJR's independent auditors included an explanatory paragraph regarding this uncertainty in their report on the financial statements for the period from inception to June 30, 2009. EZJR's ability to continue as a going concern is dependent upon generating cash flow sufficient to fund operations and reducing operating expenses. EZJR's business plan may not be successful in addressing these issues. If EZJR cannot continue as a going concern, its stockholders may lose their entire investment in EZJR.

3. EZJR EXPECTS LOSSES IN THE FUTURE BECAUSE EZJR HAS NO REVENUE.

EZJR has generated no revenues and management expects losses over the next twelve (12) months since there are no revenues to offset the expenses associated in executing EZJR's business plan. EZJR cannot guarantee that it will ever be successful in generating revenues in the future. EZJR recognizes that if the Company is unable to generate revenues, it will not be able to earn profits or continue operations as a going concern. There is no history upon which to base any assumption as to the likelihood that the Company will prove successful, and EZJR can provide selling shareholders with no assurance that it will generate any operating revenues or ever achieve profitable operations.

4. SINCE EZJR'S OFFICER DOES NOT DEVOTE HIS FULL TIME TO THE COMPANY, HIS OTHER ACTIVITIES COULD SLOW DOWN EZJR'S OPERATIONS.

T J Jesky, the sole officer of EZJR does not devote all of his time to the Company's operations. He is semi-retired and devotes his time to his family and personal activities. Therefore, it is possible that a conflict of interest with regard to his time may arise based on his involvement in other activities. His other activities will prevent him from devoting full-time to EZJR's operations which could slow EZJR's operations and may reduce its financial results because of the slow down in operations.

The President and Director of the company, currently devotes approximately 5-10 hours per week to company matters. The responsibility of developing the company's business, and fulfilling the reporting requirements of a public company all fall upon Mr. Jesky. Mr. Jesky was the former President of Eaton Laboratories, the Company that spun off IVPSA Corporation. EZJR has not formulated a plan to resolve any possible conflict of interest with his other business activities. Mr. Jesky intends to limit his role in his other activities and devote more of his time to EZJR after the Company attains a sufficient level of revenue and is able to provide sufficient officers' salaries per its business plan. In the event he is unable to fulfill any aspect of his duties to the company, EZJR may experience a shortfall or complete lack of sales resulting in little or no profits and eventual closure of the business.

10

5. EZJR'S SOLE OFFICER, MR. T J JESKY, HAS NO PRIOR EXPERIENCE IN RUNNING A MEDICAL DEVICE COMPANY.

EZJR's sole executive officer has no experience in operating a medical device company. Mr. Jesky did serve as President of Eaton Laboratories from February 2, 2000 (inception) until March 2007. Due to his lack of experience in running a medical device company, the executive officer may make wrong decisions and choices regarding key decisions on behalf of the Company. Consequently, EZJR may suffer irreparable harm due to management's lack of experience in this industry.

6. IF EZJR IS UNABLE TO OBTAIN ADDITIONAL FUNDING, ITS BUSINESS OPERATIONS WILL BE HARMED. EVEN IF EZJR DOES OBTAIN ADDITIONAL FINANCING ITS THEN EXISTING SHAREHOLDERS MAY SUFFER SUBSTANTIAL DILUTION.

As of June 30, 2009, EZJR had no working cash nor equivalents. EZJR needs at least five hundred dollars ($500,000) in order to obtain FDA (Food and Drug Administration) approval to market its potential medical device. EZJR determined that $500,000 is needed for: 1) engineering design and specifications of the medical device; 2) production of the medical device; 3) FDA application process; 4) conducting the necessary FDA studies; and 5) producing a working inventory of the medical device.

The company has yet to find sourcing for this endeavor. The Company has initial plans to develop a catheter medical device. The regulatory requirements of the FDA will be capital intensive, this project will also require a larger working capital basis to maintain adequate inventories of the approved product. This need for additional funds will be derived from future stock offerings. These future offerings could significantly dilute the value of any previous investor's investment. If and when FDA approval can be obtained for this product, the Company will be required to produce product for distribution. The company anticipates that its budge for $500,000 will include retail inventory of the medical device.

There are no guarantees given that the Company will be able to find the necessary financing or the necessary financing will be available, if required or if available, will be on terms and conditions satisfactory to management. The above outlined capital problems which could significantly affect the value of any Common Shares and could result in the loss of an investor's entire investment.

11

7. EZJR MAY NOT BE ABLE TO RAISE SUFFICIENT CAPITAL OR GENERATE ADEQUATE REVENUE TO MEET ITS OBLIGATIONS AND FUND ITS OPERATING EXPENSES.

Failure to raise adequate capital and generate adequate sales revenues to meet EZJR's obligations and develop and sustain its operations could result in reducing or ceasing EZJR's operations. Additionally, even if EZJR does raise sufficient capital and generate revenues to support its operating expenses, there can be no assurances that the revenue will be sufficient to enable EZJR to develop business to a level where it will generate profits and cash flows from operations. These matters raise substantial doubt about EZJR's ability to continue as a going concern. EZJR's independent auditors currently included an explanatory paragraph in their report on the financial statements regarding concerns about EZJR's ability to continue as a going concern.

8. EZJR MAY NOT BE ABLE TO COMPETE WITH LARGER MEDICAL DEVICE COMPANIES, THE MAJORITY OF WHOM HAVE GREATER RESOURCES AND EXPERIENCE THAN EZJR DOES.

The Company has no way of knowing that other companies may be working on bringing the same medical device into the market. In order to obtain FDA approval to market a medical device, it can take from twelve (12) to eighteen (18) months to obtain approval from the FDA. And, there is no way to know if someone else has submitted similar paperwork beforehand. Therefore, there is always a possibility that similar medical device may enter the market before EZJR's licensed product.

Many of the Company's competitors are significantly larger and have substantially greater financial, distribution, marketing and other resources and have achieved better recognition for their brand names for product lines or certain products than the Company. There is no assurance that the Company will be able to compete successfully against present or future competitors or that competitive pressures faced by the Company will not have a material adverse effect on the Company.

9. IF EZJR RECEIVES REGULATORY APPROVAL EZJR WILL ALSO BE SUBJECT TO ONGOING FDA OBLIGATION AND CONTINUED REGULATORY REVIEW.

Any regulatory approvals that EZJR receives for its products may also be subject to limitations on the indicated uses for which the product may be marketed or contain requirements for potentially costly post-marketing follow-up studies. In addition EZJR or its third party manufacturers may be required to undergo a pre-approval inspection of manufacturing facilities by the FDA and foreign authorities before obtaining marketing approval and will be subject to periodic inspection by the FDA and corresponding foreign regulatory authorities under reciprocal agreements with the FDA. Such inspections may result in compliance issues that could prevent or delay marketing approval or require the expenditure of money or other resources to correct noncompliance.

12

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, EZJR's collaborators, or EZJR, including requiring withdrawal of the product from the market. EZJR's product candidates will also be subject to ongoing FDA requirements for the labeling, packaging, storage, advertising, promotion, record-keeping, and submission of safety and other post-market information on the drug. If EZJR's product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:

o issue warning letters;
o impose civil or criminal penalties;
o withdraw regulatory approval;
o suspend any ongoing clinical trials;
o refuse to approve pending applications or supplements to approved applications filed by EZJR or EZJR's collaborators;
o impose restrictions on operations, including costly new manufacturing requirements; or
o seize or detain products or require a product recall.

If EZJR fails to comply with applicable domestic regulatory requirements, EZJR may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.

10. EZJR FACES THE RISK OF NOT BEING ABLE TO COMPLY WITH EACH OF THE STEPS IN THE FDA PRE-MARKETING APPROVAL PROCESS.

If EZJR is successful in raising the required funds to develop its first medical device, there are no assurances that the Company can comply with the required steps in the FDA pre-marketing approval process. This includes compiling studies accepted by FDA to their satisfaction. Failure to do so, would result in compiling new studies at an added expense to the Company. The Company may not have the required funds to repeat FDA compliance studies. This would mean EZJR would either need to seek more funding or close its business operations.

13

11. THE FDA APPROVAL PROCESS CAN BE VERY LENGTHY AND UNCERTAIN

Upon the completion of the required testing, analysis of the testing, and producing an actual manufacturing lot of the product, the Company will be ready to submit an Application to the FDA for their review and comment. EZJR expects this process could take eleven months after EZJR obtains funding, just to produce the required data for a Submission Application. Once the Application is received by the FDA, they have 180 days to respond to an Application. At that time, based on the data provide, they will most likely comment on the Application in that they will require clarification or more data. The Company expects the FDA approval process to last between 10-12 months. If the FDA requires additional data following the review of EZJR's Application, this will require additional expense and loss of time to bring its product to the market. There exists an uncertainty on how long the actual FDA approval process will taken, as they may require additional information. This uncertainty can adversely effect when EZJR can bring the final product to the marketplace.

12. TO BE SUCCESSFUL, MEDICAL DEVICE(S) MUST BE ACCEPTED BY HEALTH CARE PROFESSIONALS, WHO CAN BE VERY SLOW TO ADOPT OR UNRECEPTIVE TO NEW TECHNOLOGIES AND PRODUCTS.

EZJR's future medical devices, if approved for marketing, may not achieve market acceptance since hospitals, physicians, patients or the medical community in general may decide to not accept and utilize these products. The product candidates that EZJR is attempting to develop represent substantial departures from established treatment methods and will compete with a number of more conventional drugs and therapies manufactured and marketed by major medical device companies. The degree of market acceptance of any of our developed products will depend on a number of factors, including:

o the establishment and demonstration to the medical community of the clinical efficacy and safety of EZJR's product candidates;

o the ability to create products that are superior to alternatives currently on the market, including in terms of pricing and cost-effectiveness, relative convenience, and ease of administration;

o the prevalence and severity of adverse side effects; and

o the ability to establish in the medical community the potential advantage of EZJR's medical device over alternative medical devices.

If the health care community does not accept EZJR's products for any of the foregoing reasons, EZJR's revenues from the sale of any approved product would be significantly reduced.

14

13. IF EZJR IS UNABLE TO OBTAIN AND MAINTAIN PATENT AND OTHER INTELLECTUAL PROPERTY OWNERSHIP RIGHTS RELATING TO THE DEVELOPMENT MEDICAL DEVICES, THEN THE COMPANY MAY NOT BE ABLE TO SELL ANY MEDICAL DEVICES, WHICH WOULD HAVE A MATERIAL ADVERSE IMPACT ON EZJR'S RESULTS OF OPERATIONS AND THE PRICE OF THE COMPANY'S COMMON STOCK.

EZJR currently does not own any right, title or interest in any patent application for any medical device. If in the future EZJR does file a patent application, there are no assurances that it will not be successfully challenged or circumvented by competitors or others. EZJR has no assurance that the United States Patent and Trademark Office will issue the Patent or that the scope of any claims granted in an issued patent will provide broad protection or a competitive advantage to us. If the Patent fails to issue in sufficient scope or at all, or if the patent issues but EZJR fails to maintain and enforce EZJR's rights in the issued patent, or if EZJR fails to maintain and protect its rights in other intellectual property, including know-how, trade secrets and trademarks, such failures, individually and in the aggregate, could have a material adverse effect upon EZJR's business prospects, financial condition and results of operations. If such patents issue, they will be presumed valid, but there is no assurance that they will not be successfully challenged or circumvented by competitors or others.

EZJR also relies upon trade secrets and other unpatented proprietary technology. No assurance can be given that the Company can meaningfully protect its rights with regard to such unpatented proprietary technology or that competitors will not duplicate or independently develop substantially equivalent technology.

14. THE REIMBURSEMENT STATUS OF NEWLY APPROVED HEALTHCARE PRODUCTS AND TREATMENTS IS NO ESTABLISHED AND FAILURE TO OBTAIN ADEQUATE REIMBURSEMENT COULD LIMIT EZJR'S ABILITY TO MARKET ANY PRODUCTS THE COMPANY MAY DEVELOP.

EZJR's ability to commercialize its product candidates in domestic markets successfully will depend in part on the extent to which governmental authorities, private health insurers, managed care programs, and other organizations establish appropriate coverage and reimbursement levels for the cost of EZJR's products and related treatments. There is significant uncertainty related to the reimbursement of newly approved medical devices. Third party payors are increasingly attempting to contain healthcare costs and challenging the prices charged for medical products and services, both by limiting coverage and by reducing the level of reimbursement for medical devices. For example, the trend toward managed health care in the United States, which could significantly influence the purchase of health care services and products, as well as legislative proposals to reform health care or reduce government insurance programs, may result in lower prices for the product candidates or exclusion of any product candidates from coverage and reimbursement programs. If third parties fail to provide adequate reimbursement for EZJR's products, consumers and health care providers may choose not to use EZJR's products, which could significantly reduce EZJR's revenues from the sale of any approved product and prevent EZJR from realizing an acceptable return on the Company's investment in product development.

15

15. EZJR HAS NO COMMERCIAL PRODUCTION CAPABILITY AND EZJR MAY ENCOUNTER PRODUCTION PROBLEMS OR DELAYS, WHICH COULD RESULT IN LOWER REVENUES.

To date, EZJR has not produced any products. To achieve anticipated customer demand levels EZJR will need to find suppliers who can contract manufacturer the products for the Company and provide the Company with adequate levels of inventory. EZJR's contract manufacturers may not be able to maintain acceptable quality standards. If EZJR cannot achieve the required level and quality of production, the Company may need to outsource production or rely on licensing and other arrangements with third parties. EZJR may not be able to successfully outsource its production or enter into licensing or other arrangements under acceptable terms with these third parties, which could adversely affect its business. EZJR's inability to identify potential manufacturers, or to enter into or maintain agreements with them on acceptable terms, could delay or prevent the commercialization of its products, which would adversely affect its ability to generate revenues and could prevent the Company from achieving or maintaining profitability. In addition reliance on third-party manufacturers could reduce EZJR's gross margins and expose the Company to the risks inherent in relying on others. EZJR may also encounter problems with production yields, shortages of qualified personnel, production costs, and the development of advanced manufacturing techniques and process controls.

16. EZJR WILL BE REQUIRED TO COMPLY WITH GOOD MANUFACTURING REQUIREMENTS, AND ITS FAILURE TO DO SO MAY SUBJECT THE COMPANY TO FINES AND OTHER PENALTIES.

EZJR, or its other third party manufacturers of its products must comply with current good manufacturing practice, or cGMP, requirements demanded by customers and enforced by the FDA through its facilities inspection program.

These requirements include quality control, quality assurance, and the maintenance of records and documentation. EZJR, its collaborators, or other third party manufacturers of EZJR's products may be unable to comply with these cGMP requirements and with other FDA, state, and foreign regulatory requirements. These requirements may change over time and EZJR, or third party manufacturers, may be unable to comply with the revised requirements. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any quantities supplied by third-parties is compromised due to their failure to adhere to applicable laws or for other reasons, EZJR may not be able to obtain regulatory approval for, or successfully commercialize, product candidates that the Company may develop.

16

17. EZJR MAY INCUR SUBSTANTIAL LIABILITIES FROM ANY PRODUCT LIABILITY CLAIMS, INCLUDING CLAIMS MADE AGAINST THIRD PARTIES EZJR HAS AGREED TO INDEMNIFY.

EZJR faces an inherent risk of product liability exposure related to the testing of its product candidates in human clinical trials, and will face an even greater risk if the Company sells its product candidates commercially. An individual may bring a liability claim against the Company if one of its product candidates causes, or merely appears to have caused, an adverse effect or injury. These risks will exist even for products developed that may be cleared for commercial sale. If EZJR cannot successfully defend itself against any product liability claims, EZJR may incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in any one or a combination of the following:

o injury to EZJR's reputation;

o withdrawal of clinical trial participants;

o costs of related litigation;

o substantial monetary awards to patients or other claimants;

o decreased demand for EZJR's product candidates;

o loss of revenues; and

o the inability to commercialize EZJR's product candidates.

EZJR intends to secure limited product liability insurance coverage, but the Company may not be able to obtain such insurance on acceptable terms with adequate coverage, or at reasonable or affordable costs. The amount of insurance coverage EZJR obtains may not be adequate to protect the Company from all liabilities. EZJR may not have sufficient resources to pay for any liabilities resulting from a claim beyond the limit of, or excluded from, its insurance coverage.

17

18. EZJR'S SOLE OFFICER/DIRECTOR AND LARGEST SHAREHOLDER OWN A CONTROLLING INTEREST IN EZJR'S VOTING STOCK AND SELLING SHAREHOLDERS WILL NOT HAVE ANY VOICE IN THE COMPANY'S MANAGEMENT, WHICH COULD RESULT IN DECISIONS ADVERSE TO EZJR'S GENERAL SHAREHOLDERS.

EZJR's sole officer/director and its second largest stockholder, in the aggregate, beneficially own approximately or have the right to vote approximately 68.9% of EZJR's outstanding common stock. As a result, these two stockholders, acting together, will have the ability to control substantially all matters submitted to EZJR's stockholders for approval including:

a) election of EZJR's board of directors;

b) removal of any of EZJR's directors;

c) amendment of EZJR's Articles of Incorporation or bylaws; and

d) adoption of measures that could delay or prevent a change in control or impede a merger, takeover or other business combination involving us.

As a result of their ownership and positions, these two individuals have the ability to influence all matters requiring shareholder approval, including the election of directors and approval of significant corporate transactions. In addition, the future prospect of sales of significant amounts of shares held by EZJR's director and executive officer could affect the market price of its common stock if the marketplace does not orderly adjust to the increase in shares in the market and the value of shareholder investment in the company may decrease. Management's stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of EZJR, which in turn could reduce the stock price or prevent the stockholders from realizing a premium over the stock price.

RISKS RELATING TO EZJR'S COMMON SHARES

19. EZJR MAY, IN THE FUTURE, ISSUE ADDITIONAL COMMON SHARES, WHICH WOULD REDUCE SELLING SHAREHOLDERS' PERCENT OF OWNERSHIP AND MAY DILUTE EZJR'S SHARE VALUE.

The future issuance of common stock may result in substantial dilution in the percentage of EZJR's common stock held by EZJR's then existing shareholders. EZJR may value any common stock issued in the future on an arbitrary basis. The issuance of common stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by EZJR's selling shareholders, and might have an adverse effect on any trading market for EZJR's common stock.

19

20. EZJR'S COMMON SHARES ARE SUBJECT TO THE "PENNY STOCK" RULES OF THE SEC AND THE TRADING MARKET IN EZJR'S SECURITIES IS LIMITED, WHICH MAKES TRANSACTIONS IN EZJR'S STOCK CUMBERSOME AND MAY REDUCE THE VALUE OF AN INVESTMENT IN EZJR'S STOCK.

The U. S. Securities and Exchange Commission has adopted Rule 15g-9 which establishes the definition of a "penny stock," for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions.

For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person's account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

In order to approve a person's account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience objectives of the person; and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the Commission relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the "penny stock" rules. This may make it more difficult for selling shareholders to dispose of EZJR's Common shares and cause a decline in the market value of EZJR's stock.

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

20

21. ALTHOUGH OUR STOCK IS LISTED ON THE OTC-BB, A TRADING MARKET HAS NOT DEVELOP, PURCHASERS OF OUR SECURITIES MAY HAVE DIFFICULTY SELLING THEIR SHARES.

There is currently no active trading market in our securities and there are no assurances that a market may develop or, if developed, may not be sustained. If no market is ever developed for our common stock, it will be difficult for you to sell any shares in our Company. In such a case, you may find that you are unable to achieve any benefit from your investment or liquidate your shares without considerable delay, if at all.

22. BECAUSE EZJR DOES NOT INTEND TO PAY ANY CASH DIVIDENDS ON ITS COMMON STOCK, THE COMPANY'S STOCKHOLDERS WILL NOT BE ABLE TO RECEIVE A RETURN ON THEIR SHARES UNLESS THEY SELL THEM.

EZJR intends to retain any future earnings to finance the development and expansion of its business. EZJR does not anticipate paying any cash dividends on its common stock in the foreseeable future. Unless EZJR pays dividends, its stockholders will not be able to receive a return on their shares unless they sell them. There is no assurance that stockholders will be able to sell shares when desired.

23. EZJR MAY ISSUE SHARES OF PREFERRED STOCK IN THE FUTURE THAT MAY ADVERSELY IMPACT SHAREHOLDER RIGHTS AS HOLDERS OF THE COMPANY'S COMMON STOCK.

EZJR's articles of incorporation authorize the Company to issue up to 5,000,000 shares of preferred stock. Accordingly, the board of directors will have the authority to fix and determine the relative rights and preferences of preferred shares, as well as the authority to issue such shares, without further stockholder approval. As a result, the board of directors could authorize the issuance of a series of preferred stock that would grant to holders preferred rights to its assets upon liquidation, the right to receive dividends before dividends are declared to holders of EZJR's common stock, and the right to the redemption of such preferred shares, together with a premium, prior to the redemption of the common stock. To the extent that EZJR does issue such additional shares of preferred stock, the shareholders rights as holders of common stock could be impaired thereby, including, without limitation, dilution of shareholder ownership interests in EZJR. In addition, shares of preferred stock could be issued with terms calculated to delay or prevent a change in control or make removal of management more difficult, which may not be in the best interest as holders of common stock.

21

Item 2. Financial Information.

Management's Discussion and Analysis of Financial Condition and Results of Operations.

Overview of Current Operations

EZJR, Inc., was organized by the filing of Articles of Incorporation with the Secretary of State of the State of Nevada on December 30, 2005.

EZJR, Inc. is a developmental medical device company which plans to produce medical devices, utilizing the services contract manufacturing facilities. EZJR does not have the resources to conduct any required clinical trials to obtain FDA approval. Therefore, EZJR plans to outsource this task to third parties who have the facilities to conduct any required clinical trials. EZJR also plans to subcontract the manufacturing and production process of any future medical device to a FDA approved contract manufacturing facility which can produce sterile medical devices under Good Manufacturing Practices. The company plans to distribute its product(s) into the marketplace through medical supply wholesalers, hospitals and health maintenance organizations.

Results of Operations for the year ended June 30, 2009

We earned no revenues since our inception through June 30, 2009. We do not anticipate earning any significant revenues until such time as we can bring to the market a medical device product. We are presently in the development stage of our business and we can provide no assurance that we will be successful in developing any medical device products.

For the period inception through June 30, 2009, we generated no income. Since our inception on August 14, 2006 we experienced a net loss of $(78,381). Our loss was attributed to organizational expenses and entering into a exclusive option agreement for a medical device. We anticipate our operating expenses will increase as we enhance our operations. The increase will be attributed to professional fees to be incurred in connection with the filing of a registration statement with the Securities Exchange Commission under the Securities Act of 1933. We anticipate our ongoing operating expenses will also increase once we become a reporting company under the Securities Exchange Act of 1934.

For the fiscal year ending June 30, 2009, we experienced a net loss of $(13,190) as compared to a net loss of $(28,761) for the same period last year. The net loss for the year ending June 30, 2009 was contributed to professional fees of $7,410, research and development fees of $280 and auditing fees of $5,500. Our auditor issued an opinion that our financial condition raises substantial doubt about the Company's ability to continue as a going concern.

22

Revenues

We generated no revenues for the period from August 14, 2006 (inception) through June 30, 2009. We do not anticipate generating any revenues for at least 28 months.

Going Concern

Our independent auditors included an explanatory paragraph in their report on the accompanying financial statements regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

Item 3. Properties.

Our corporate headquarters are located at 3415 Ocatillo Mesa Way, North Las Vegas, NV 89031. We believe our current office space is adequate for our immediate needs; however, as our operations expand, we may need to locate and secure additional office space.

Item 4. Security Ownership of Certain Beneficial Owners and Management.

The following table presents information, to the best of our knowledge, about the ownership of our common stock on October 27, 2009 relating to those persons known to beneficially own more than 5% of our capital stock and by our named executive officer and sole director. The percentage of beneficial ownership for the following table is based on 10,873,750 shares of common stock outstanding.

23

Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and does not necessarily indicate beneficial ownership for any other purpose. Under these rules, beneficial ownership includes those shares of common stock over which the stockholder has sole or shared voting or investment power. It also includes shares of common stock that the stockholder has a right to acquire within 60 days after October 27, 2009 pursuant to options, warrants, conversion privileges or other right. The percentage ownership of the outstanding common stock, however, is based on the assumption, expressly required by the rules of the Securities and Exchange Commission, that only the person or entity whose ownership is being reported has converted options or warrants into shares of EZJR's common stock.

                                                     Amount
Title     Name and Address                           of shares      Percent
of        of Beneficial                              held by          of
Class     Owner of Shares         Position           Owner          Class(1)
----------------------------------------------------------------------------
Common     T J Jesky (2)          Pres./Director     4,000,000       36.7%
Common     Mark DeStefano (3)     Shareholder        3,500,000       32.2%
---------------------------------------------------------------------------

All Executive Officers, Directors
as a Group (1 person) 4,000,000 36.7%

(1) The percentages listed in the Percent of Class column are based upon 10,873,750 issued and outstanding shares of Common Stock. (2) T J Jesky, 2235 E. Flamingo, Suite 114, Las Vegas, NV 89119. (3) Mark DeStefano, 500 N. Rainbow, Suite 300, Las Vegas, NV 89107.

24

Item 5. Directors and Executive Officers.

(a) Identification of Directors and Executive Officers.

The following table sets forth certain information regarding our current directors and executive officers. Our executive officers serve one-year terms.

Name                         Age   Positions and Offices Held
---------------              ---   --------------------------
T J Jesky                    62    President, Secretary and Director

The Company is managed by T J Jesky, who has 22-years experience in the pharmaceutical industry. He is a former Division Manager for Procter & Gamble Pharmaceuticals. He began his pharmaceutical career in 1973 with Norwich Pharmacal, whose headquarters were based in Norwich, New York. This company subsequently changed its name to Norwich Eaton, and in 1981 it was purchased by Procter & Gamble. Norwich Eaton subsequently changed its name to Procter & Gamble Pharmaceuticals. Mr. Jesky held various positions in the company, including but not limited to: District Manager, Key Account Manager, Hospital Manager, Region Manager, Division Manager for U.S., Canada and Puerto Rico. He resigned from Procter & Gamble in 1995. He became President, CEO and sole stockholder of Studebaker's, Inc. a restaurant/nightclub and real estate holding company in Arizona. He privately sold this business in 1997. In 1997 through 1998, he owned and operated a restaurant consulting business, named Ionosphere, Inc. In 1998, he resigned from the Company when it was acquired by Axonyx, Inc., which is currently trading on the NASDAQ National Market, under the name TorreyPines Therapeutics, Inc. From 1996 through 1999 he was President and Chairman of the Board of Boppers Holdings, Inc., a Nevada Corporation real estate business; he resigned from the Company when it was acquired by e-Smart Technologies, Inc. which is currently listed on the Pink Sheets. In August, 1998, Mr. Jesky founded Barrington Laboratories, Inc., he resigned from the Company when it was acquired by ModernGroove Entertainment, in January, 2001 and subsequently acquired by Immediatek, Inc. Immediatek is currently traded on the OTC-BB. From February, 2000 to March, 2007, he held the position as President/Director of Eaton Laboratories, Inc. In March, 2007, Eaton Laboratories was acquired by Hydrogen Hybrid Technologies, Inc, a Canadian- based firm which is currently traded on OTC-BB under the stock symbol HYHY. From inception to present, he has held the position as President/ Director of IVPSA Corporation. IVPSA Corporation was a subsidiary of Eaton Laboratories. IVPSA Corporation subsequently merged with EZJR, Inc.

(b) Family Relationships.

None.

(c) Involvement in Certain Legal Proceedings.

There have been no events under any bankruptcy act, no criminal proceedings and no judgments, injunctions, orders or decrees material to the evaluation of the ability and integrity of any director, executive officer, promoter or control person of the Registrant during the past five years.

25

Item 6. Executive Compensation.

The Company's sole officer and sole director have not received any cash remuneration or compensation since inception.

Summary Compensation Table

                                                             All
                             Fiscal                         Other
                             Year                           Compen-
                             Ending  Salary Bonus  Awards   sation    Total
Name and Principal Position  June 30  ($)    ($)    ($)       ($)      ($)
----------------------------------------------------------------------------
T J Jesky          CEO/Dir.  2009    -0-    -0-      -0-     -0-        -0-
                             2008    -0-    -0-      -0-     -0-        -0-
                             2007    -0-    -0-      -0-     -0-        -0-

No retirement, pension, profit sharing, stock option or insurance programs or other similar programs have been adopted by the Company for the benefit of its employees.

We do not have any employment agreements with our officers/directors. We do not maintain key-man life insurance for any our executive officers/directors. We do not have any long-term compensation plans or stock option plans.

Stock Option Grants

We did not grant any stock options to the executive officers or directors from inception through fiscal year end June 30, 2009.

Outstanding Equity Awards at Fiscal Year-Ending June 30, 2009

We did not have any outstanding equity awards as of June 30, 2009.

Option Exercises for Fiscal Year-Ending June 30, 2009

There were no options exercised by our named executive officer in fiscal year ending June 30, 2009.

26

Potential Payments upon Termination or Change in Control

We have not entered into any compensatory plans or arrangements with respect to our named executive officer, which would in any way result in payments to such officer because of his resignation, retirement, or other termination of employment with us or our subsidiaries, or any change in control of, or a change in his responsibilities following a change in control.

Director Compensation

We did not pay our directors any compensation during fiscal years ending June 30, 2009 or June 30, 2008.

Item 7. Certain Relationships and Related Transactions, and Director Independence.

Through a Board Resolution and the approval of the majority of shareholders at the Company's annual shareholder meeting, the Company hired the professional services of Seale and Beers, CPAs, Certified Public Accountants, to perform an audit of the financial statements of the Company. Seale and Beers, CPAs own no stock in the Company. The company has no formal contracts with its accountants and they are paid on a fee for service basis.

Except as otherwise indicated herein, there have been no related party transactions, or any other transactions or relationships required to be disclosed pursuant to Item 404 and Item 407(a) of Regulation S-K.

Item 8. Legal Proceedings.

There are presently no material pending legal proceedings to which the Registrant is a party or as to which any of its property is subject, and no such proceedings are known to the Registrant to be threatened or contemplated against it.

27

Item 9. Market Price of and Dividends on the Registrant's Common Equity and Related Stockholder Matters.

(a) Market Information

Your Event, Inc. Common Stock, $0.001 par value, is traded on the OTC-Bulletin Board under the symbol: EZJR. The stock was cleared for trading on the OTC-Bulletin Board on June 22, 2009.

Since the Company has been cleared for trading, through October 28, 2009, there have been no trades of the Company's stock. There are no assurances that a market will ever develop for the Company's stock.

(b) Holders of Common Stock

As of October 28, 2009, there were approximately 100 holders of record of our Common Stock and 10,873,750 shares outstanding.

(c) Dividends

In the future we intend to follow a policy of retaining earnings, if any, to finance the growth of the business and do not anticipate paying any cash dividends in the foreseeable future. The declaration and payment of future dividends on the Common Stock will be the sole discretion of board of directors and will depend on our profitability and financial condition, capital requirements, statutory and contractual restrictions, future prospects and other factors deemed relevant.

(d) Securities Authorized for Issuance under Equity Compensation Plans

There are no outstanding grants or rights or any equity compensation plan in place.

(e) Recent Sales of Unregistered Securities

The Company did not issue any shares during the fiscal years ended June 30, 2009 or June 30, 2008.

(f) Issuer Purchases of Equity Securities

We did not repurchase any of our equity securities during the years ended June 30, 2009 or June 30, 2008.

28

Item 10. Recent Sales of Unregistered Securities.

EZJR, Inc. was a wholly-owned subsidiary of Eaton Laboratories. The shares of EZJR were issued to each of Eaton's shareholders as a spin-off dividend of Eaton Laboratories, Inc. in October, 2006. There have been no other issuances of stock.

The Company did not issue any shares during the fiscal years ended June 30, 2009, June 30, 2008 or June 30, 2007. No securities have been issued for services. Neither the Registrant nor any person acting on its behalf offered or sold the securities by means of any form of general solicitation or general advertising. No services were performed by any purchaser as consideration for the shares issued.

Item 11. Description of Registrant's Securities to be Registered.

(a) Capital Stock.

The Company is authorized by its Certificate of Incorporation to issue an aggregate of 75,000,000 shares of capital stock, of which 70,000,000 are shares of Common Stock and 5,000,000 are shares of Preferred Stock. As of October 28, 2009, 10,873,750 shares of Common Stock and zero shares of Preferred Stock were issued and outstanding.

Common Stock

All outstanding shares of Common Stock are of the same class and have equal rights and attributes. The holders of Common Stock are entitled to one vote per share on all matters submitted to a vote of stockholders of the Company. All stockholders are entitled to share equally in dividends, if any, as may be declared from time to time by the Board of Directors out of funds legally available. In the event of liquidation, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of all liabilities. The stockholders do not have cumulative or preemptive rights.

Preferred Stock

Our Certificate of Incorporation authorizes the issuance of up to 5,000,000 shares of Preferred Stock with designations, rights and preferences determined from time to time by its Board of Directors. Accordingly, our Board of Directors is empowered, without stockholder approval, to issue Preferred Stock with dividend, liquidation, conversion, voting, or other rights which could adversely affect the voting power or other rights of the holders of the Common Stock. In the event of issuance, the Preferred Stock could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of the Company. Although we have no present intention to issue any shares of our authorized Preferred Stock, there can be no assurance that the Company will not do so in the future.

29

The description of certain matters relating to the securities of the Company is a summary and is qualified in its entirety by the provisions of the Company's Certificate of Incorporation and By-Laws, copies of which have been filed as exhibits to this Form 10.

(b) Debt Securities.

None.

(c) Warrants and Rights.

None.

(d) Other Securities to Be Registered.

None.

Item 12. Indemnification of Directors and Officers.

Our Articles and By-laws provide to the fullest extent permitted by law, our directors or officers, former directors and officers, and persons who act at our request as a director or officer of a body corporate of which we are a shareholder or creditor shall be indemnified by us. We believe that the indemnification provisions in our By-laws are necessary to attract and retain qualified persons as directors and officers. Insofar as indemnification for liabilities arising under the Securities Act of 1933 (the "Act" or "Securities Act") may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.

Item 13. Financial Statements and Supplementary Data.

We set forth below a list of our audited financial statements included in this Registration Statement on Form 10.

PAGE

Independent Auditors' Report                                       F-1
Balance Sheet                                                      F-2
Statements of Operations                                           F-3
Statements of Changes in Stockholders' Equity                      F-4-5
Statements of Cash Flows                                           F-6
Notes to Financials                                                F-7
------------

*Page F-1 follows page 32 to this Registration Statement on Form 10.

30

Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

There are not and have not been any disagreements between the Registrant and its accountants on any matter of accounting principles, practices or financial statement disclosure.

Item 15. Financial Statements and Exhibits.

(a) Financial Statements.

The financial statements included in this Registration Statement on Form 10 are listed in Item 13 and commence following page 32.

(b) Exhibits.

                                                 Incorporated by reference
                                                 -------------------------

                                       Filed           Period          Filing
Exhibit       Exhibit Description     herewith  Form   ending  Exhibit  date
-----------------------------------------------------------------------------
2.1        Acquisition and Plan of       X
           Merger between EZJR, Inc.
           and IVPSA Corporation
           dated July 25, 2008.
-----------------------------------------------------------------------------
3.1        Articles of Incorporation,    X
           as currently in effect
-----------------------------------------------------------------------------
3.2        Bylaws                        X
           as currently in effect
-----------------------------------------------------------------------------
3.3        Articles of Merger            X
           between EZJR, Inc. and
           IVPSA Corporation
-----------------------------------------------------------------------------
10.1       Exclusive Option Agreement    X
           between IVPSA Corporation
           and the Cleveland Clinic,
           dated March 15, 2007
-----------------------------------------------------------------------------
10.2       Extension of Exclusive        X
           Option Agreement between
           IVPSA Corporation and
           the Cleveland Clinic,
           dated April 14, 2008.
-----------------------------------------------------------------------------
23.1       Consent Letter from Seale     X
           and Beers, CPAs
-----------------------------------------------------------------------------

31

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:  October 28, 2009                EZJR, Inc.
       ----------------
                                       By:  /s/  T J Jesky
                                       ---------------------
                                                 T J Jesky
                                                 President, Secretary
                                                 Director
                                                 Principal Executive Officer

32

SEALE AND BEERS, CPAs
PCAOB & CPAB REGISTERED AUDITORS
www.sealebeers.com

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors
EZJR, Inc.
(A Development Stage Company)

We have audited the accompanying balance sheet of EZJR, Inc. (A Development Stage Company) as of June 30, 2009 and 2008, and the related statements of operations, stockholders' equity (deficit) and cash flows for the years then ended, and for the period from inception on August 14, 2006 through June 30, 2009. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conduct our audits in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of EZJR, Inc. (A Development Stage Company) as of June 30, 2009 and 2008, and the related statements of operations, stockholders' equity (deficit) and cash flows for the years then ended, and for the period from inception on August 14, 2006 through June 30, 2009, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has an accumulated deficit of $78,381, which raises substantial doubt about its ability to continue as a going concern. Management's plans concerning these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Seale and Beers, CPAs
-------------------------
    Seale and Beers, CPAs
    Las Vegas, Nevada
    October 10, 2009

6490 West Desert Inn Rd, Las Vegas, NV 89146
(702) 253-7492 Fax (702) 253-7501

F-1

EZJR, Inc.
(A Development Stage Company)

Balance Sheets

                                               June 30,       June 30,
                                                 2009           2008
                                              -----------   -------------
ASSETS

Current assets:
   Funds in escrow                            $         -   $      7,500
   Prepaid expenses                           $     3,500   $          -
                                              -----------   -------------
     Total current assets                           3,500          7,500
                                              ------------  -------------
TOTAL ASSETS                                  $     3,500   $      7,500
                                              ===========   =============

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
   Accounts payable                           $     1,480   $     15,757
   Accrued expense                                  2,500              -
                                              ------------  -------------
     Total liabilities                              3,980         15,757
                                              ------------  -------------

Stockholders' equity:
   Preferred stock, $0.001 par value,
     5,000,000 shares authorized,
     none issued                                        -              -
   Common stock, $0.001 par value, 70,000,000
    shares authorized, 10,873,750 shares and
     and 10,873,750 issued and outstanding
     as of 6/30/09 and 6/30/08 respectively        10,873         10,873
   Additional paid-in capital                      67,028         46,061
   (Deficit) accumulated during development
    stage                                         (78,381)       (65,191)
                                              ------------  -------------
     Total stockholders' equity                      (480)        (8,257)
                                              ------------  -------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY    $     3,500   $      7,500
                                              ============  =============

The accompanying notes are an integral part of these financial statements.

F-2

EZJR, Inc.
(A Development Stage Company)

Statements of Operations

                                                        August 14,
                                  For the years            2006
                                 ended June 30,       (inception) to
                            ------------------------      June 30,
                                2009         2008           2009
                            -----------  -----------   --------------
REVENUE                     $         -  $        -    $           -
                            -----------  -----------   --------------

EXPENSES:
  Audit fees                     5,500        1,500            7,000
  Incorporating fees                 -            -              430
  Option contract                    -       10,000           46,000
  Professional fees              7,410          504            7,914
  Research & Development           280       16,757           17,037
                            -----------  -----------   --------------
   Total expenses               13,190       28,761           78,381
                            -----------  -----------   --------------

Net (loss) before income
 taxes                         (13,190)     (28,761)         (78,381)

Income tax expense                   -             -               -
                            -----------  -----------   --------------

NET (LOSS)                  $  (13,190)  $  (28,761)   $     (78,381)
                            ===========  ===========   ==============

NET (LOSS) PER COMMON
 SHARE                      $    (0.00)  $    (0.00)
                            ===========  ===========

WEIGHTED AVERAGE NUMBER OF
 COMMON SHARES OUTSTANDING  10,873,750   10,873,750
                            ===========  ===========

The accompanying notes are an integral part of these financial statements.

F-3

EZJR, Inc.
(A Development Stage Company)

Statements of Stockholders' Deficit

                                                    (Deficit)
           Preferred                                Accumulated
             Stock        Common Stock   Additional  During
         ------------- ------------------ Paid-in   Development
         Shares Amount   Shares   Amount  Capital    Stage         Total
         ------ ------ ---------- ------- -------- ---------- --------------
August 14,
2006
Contributed
capital                                    36,430                    36,430

August 14,
2006
stock issued
as a dividend
from Eaton
Laboratories
at $0.001
per share              10,873,750  10,873 (10,873)                        -

Net (loss)
for the
year ended
June 30,
2007                                                 (36,430)       (36,430)
         ------ ------ ---------- ------- -------- ---------- --------------

Balance,
June 30,
2007          -      - 10,873,750  10,873   25,557   (36,430)             -

February 2008
Contributed
capital                                      2,500                    2,500

April 2008
Contributed
capital                                     10,000                   10,000

June 2008
Contributed
capital                                      8,004                    8,004


                                      F-4

                                 EZJR, Inc.
                       (A Development Stage Company)
               Statements of Stockholders' Deficit (Continued)


                                                    (Deficit)
           Preferred                                Accumulated
             Stock        Common Stock   Additional  During
         ------------- ------------------ Paid-in   Development
         Shares Amount   Shares   Amount  Capital    Stage         Total
         ------ ------ ---------- ------- -------- ---------- --------------
Net (loss)
for the
year ended
June 30,
2008                                                 (28,761)       (28,761)
         ------ ------ ---------- ------- -------- ---------- --------------

Balance,
June 30,
2008          -     -  10,873,750  10,873  46,061    (65,191)        (8,257)

September
2008
Contributed
capital                                      1,500                     1,500

December
2008
Contributed
capital                                     19,467                    19,467

Net (loss)
for the
year ended
June 30,
2009                                                  (13,190)       (13,190)
         ------ ------ ---------- ------- -------- ----------- --------------

Balance,
June 30,
2009          - $    - 10,873,750 $10,873 $67,028  $  (78,381) $        (480)
         ====== ====== ========== ======= ======== =========== ==============

The accompanying notes are an integral part of these financial statements.

F-5

EZJR, Inc.
(A Development Stage Company)

Statements of Cash Flows

                                                                 August 14,
                                         For the years              2006
                                         ended June 30,        (inception) to
                                     ------------------------     June 30,
                                          2009       2008           2009
                                     -----------  -----------  --------------
OPERATING ACTIVITIES:
Net (loss)                           $  (13,190)  $  (28,761)  $     (78,381)
Adjustments to reconcile net loss
 to net cash provided (used) by
 operating activities:
   (Increase) in prepaid expense         (3,500)           -          (3,500)
   (Decrease) increase in accounts
      payable                           (14,277)      15,757           1,480
   Increase in accrued expense            2,500            -           2,500
                                     -----------  -----------  --------------
Net cash (used) by operating
  activities                            (28,467)     (13,004)        (77,901)
                                     -----------  -----------  --------------

FINANCING ACTIVITIES:
Contributed capital                      20,967       20,504          77,901
                                     -----------  -----------  --------------
Net cash provided by financing
  activities                             20,967       20,504          77,901
                                     -----------  -----------  --------------

NET INCREASE (DECREASE) IN CASH          (7,500)       7,500               -
CASH AND EQUIVALENTS - BEGINNING          7,500            -               -
                                     -----------  -----------  --------------
CASH AND EQUIVALENTS - ENDING        $        -   $    7,500   $           -
                                     ===========  ===========  ==============

SUPPLEMENTAL DISCLOSURES:
   Interest paid                     $        -   $        -   $           -
                                     ===========  ===========  ==============
   Income taxes paid                 $        -   $        -   $           -
                                     ===========  ===========  ==============
   Non-cash transactions             $        -   $        -   $           -
                                     ===========  ===========  ==============

The accompanying notes are an integral part of these financial statements.

F-6

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 1. General Organization and Business

The Company was organized August 14, 2006 (Date of Inception) under the laws of the State of Nevada, as IVPSA Corporation. The Company was incorporated as a wholly owned subsidiary of Eaton Laboratories, Inc., a Nevada corporation. Eaton Laboratories was incorporated February 2, 2002, and, at the time of spin off was listed on the Over the Counter Bulletin Board.

The directors of Eaton Laboratories approved a spin off of its IVPSA subsidiary in the form of a stock dividend as of November 1, 2006 (the "Record Date"). The record shareholders of Eaton received one (1) unregistered common share, par value $0.001, of IVPSA Corporation common stock for every share of Eaton Laboratories common stock owned. The IVPSA Corporation stock dividend was based on 10,873,750 shares of Eaton common stock that were issued and outstanding as of the record date. Since IVPSA's business was related to developing medical devices and Eaton's business was related to developing generic pharmaceutical products, the Eaton directors decided it was in the best interest of Eaton and IVPSA's shareholders to spin off IVPSA to minimize any potential of conflict of interest, in accessing funding.

The spin-off transaction was accomplished by the distribution of certain intellectual property, representing industry contacts, third party relationships and trade secrets. It did not include the transfer of any hard assets or liabilities. This spin off was valued at par value since the company held no assets, was uncertain as to future benefit, the stock was not trading, and the company did not yet receive a stock symbol.

Eaton retained no ownership in IVPSA Corporation following the spin off. IVPSA Corporation is no longer a subsidiary of Eaton Laboratories.

The Company is a development stage enterprise in accordance with Statement of Financial Accounting Standards ("SFAS") No. 7, "Accounting and Reporting by Development Stage Enterprises". The Company plans to develop and market medical devices.

NOTE 2. Summary of Significant Accounting Practices

The Company has assets of $3,500 in prepaid expenses and liabilities of $3,980 as of June 30, 2009. The relevant accounting policies are listed below.

Basis of Accounting
The basis is United States generally accepted accounting principles.

F-7

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 2. Summary of Significant Accounting Practices (Continued)

Earnings per Share
The basic earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity.

The Company has not issued any options or warrants or similar securities since inception.

Revenue recognition
The Company recognizes revenue on an accrual basis as it invoices for services.

Dividends
The Company has not yet adopted any policy regarding payment of dividends. No Dividends have been paid during the period shown.

Income Taxes
The provision for income taxes is the total of the current taxes payable and the net of the change in the deferred income taxes. Provision is made for the deferred income taxes where differences exist between the period in which transactions affect current taxable income and the period in which they enter into the determination of net income in the financial statements.

Year-end
The Company originally selected December 31 as its year-end. On March 31, 2008 the board of directors and majority of shareholders accepted a change of the year-end to June 30.

Advertising
Advertising is expensed when incurred. There has been no advertising during the period.

F-8

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 2. Summary of Significant Accounting Practices (Continued)

Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

NOTE 3 - Going concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplates continuation of the Company as a going concern. As shown in the accompanying financial statements, the Company is a development stage company with no history of operations, limited assets, and has incurred operating losses since inception. These factors, among others, raise substantial doubt about its ability to continue as a going concern.

The financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's continuation as a going concern is dependent upon its ability to obtain additional operating capital, commence operations, provide competitive services, and ultimately to attain profitability. The Company intends to acquire additional operating capital through equity offerings. There is no assurance that the Company will be successful in raising additional funds.

NOTE 4 - Stockholders' equity

The Company is authorized to issue 70,000,000 shares of its $0.001 par value common stock and 5,000,000 shares of its $0.001 par value preferred stock.

The Company was a subsidiary of Eaton Laboratories, Inc. On November 1, 2006, the record shareholders of Eaton received a spin off dividend of one
(1) common share, par value $0.001, of IVPSA Corporation common stock for every share of Eaton Laboratories common stock owned.

As of June 30, 2009, EZJR, Inc. has 10,873,750 of its common stock issued and outstanding and none of its preferred stock issued nor outstanding.

There have been no other issuances of common stock.

F-9

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 5. Related Party Transactions

The Company does not lease or rent any property. Office space is being provided by the Company's director on a rent free basis. The amount is not considered material to the financial statements. The Company believes that its current facilities are adequate for its needs through the next twelve months, and that, should it be needed, suitable additional space will be available to accommodate expansion of the Company's operations on commercially reasonable terms, although there can be no assurance in this regard

The sole officer and director of the Company is involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts.

The sole officer and director of the Company is not compensated for his services. The Company does not anticipate paying compensation to any officer/director until the Company can generate a profit on a regular basis. Further, the executive officer/director of the Company has no plans to take any salary until the Company can generate a profit on a regular basis. There are no Employment Agreements in place, and the sole officer/director will not be compensated for services previously provided. He will receive no accrued remuneration.

The sole officer/director has contributed funds to the operations of the Company, in order to keep it fully reporting and operational for the next twelve (12) months, without seeking reimbursement for funds contributed.

NOTE 6. Provision for Income Taxes

The Company accounts for income taxes under Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("SFAS No. 109"), which requires use of the liability method. SFAS No. 109 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. Deferred tax assets and liabilities at the end of each period are determined using the currently enacted tax rates applied to taxable income in the periods in which the deferred tax assets and liabilities are expected to be settled or realized.

F-10

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 6. Provision for Income Taxes (Continued)

The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences are as follows:

                   U.S federal statutory rate      (34.0%)
                   Valuation reserve                34.0%
                                                   ------
                   Total                               -%


NOTE 7.   Operating Leases and Other Commitments

The Company has no lease or other obligations.

NOTE 8. Recent Pronouncements

June 2009, the FASB issued SFAS No. 166, "Accounting for Transfers of Financial Assets - an amendment of FASB Statement No. 140" ("SFAS 166"). The provisions of SFAS 166, in part, amend the derecognition guidance in FASB Statement No. 140, eliminate the exemption from consolidation for qualifying special-purpose entities and require additional disclosures. SFAS 166 is effective for financial asset transfers occurring after the beginning of an entity's first fiscal year that begins after November 15, 2009. The Company does not expect the provisions of SFAS 166 to have a material effect on the financial position, results of operations or cash flows of the Company.

In June 2009, the FASB issued SFAS No. 167, "Amendments to FASB Interpretation No. 46(R) ("SFAS 167"). SFAS 167 amends the consolidation guidance applicable to variable interest entities. The provisions of SFAS 167 significantly affect the overall consolidation analysis under FASB Interpretation No. 46(R). SFAS 167 is effective as of the beginning of the first fiscal year that begins after November 15, 2009. SFAS 167 will be effective for the Company beginning in 2010. The Company does not expect the provisions of SFAS 167 to have a material effect on the financial position, results of operations or cash flows of the Company.

F-11

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 8. Recent Pronouncements (Continued)

In June 2009, the FASB issued SFAS No. 168, "The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles - a replacement of FASB Statement No. 162" ("SFAS No. 168"). Under SFAS No. 168 the "FASB Accounting Standards Codification" ("Codification") will become the source of authoritative U. S. GAAP to be applied by nongovernmental entities. Rules and interpretive releases of the Securities and Exchange Commission ("SEC") under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. SFAS No. 168 is effective for financial statements issued for interim and annual periods ending after September 15, 2009. On the effective date, the Codification will supersede all then-existing non-SEC accounting and reporting standards. All other non-grandfathered non-SEC accounting literature not included in the Codification will become non-authoritative. SFAS No. 168 is effective for the Company's interim quarterly period beginning July 1, 2009. The Company does not expect the adoption of SFAS No. 168 to have an impact on the financial statements.

In June 2009, the Securities and Exchange Commission's Office of the Chief Accountant and Division of Corporation Finance announced the release of Staff Accounting Bulletin (SAB) No. 112. This staff accounting bulletin amends or rescinds portions of the interpretive guidance included in the Staff Accounting Bulletin Series in order to make the relevant interpretive guidance consistent with current authoritative accounting and auditing guidance and Securities and Exchange Commission rules and regulations. Specifically, the staff is updating the Series in order to bring existing guidance into conformity with recent pronouncements by the Financial Accounting Standards Board, namely, Statement of Financial Accounting Standards No. 141 (revised 2007), Business Combinations, and Statement of Financial Accounting Standards No. 160, Non-controlling Interests in Consolidated Financial Statements. The statements in staff accounting bulletins are not rules or interpretations of the Commission, nor are they published as bearing the Commission's official approval. They represent interpretations and practices followed by the Division of Corporation Finance and the Office of the Chief Accountant in administering the disclosure requirements of the Federal securities laws.

F-12

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 8. Recent Pronouncements (Continued)

In April 2009, the FASB issued FSP No. FAS 107-1 and APB 28-1, Interim Disclosures about Fair Value of Financial Instruments. This FSP amends FASB Statement No. 107, Disclosures about Fair Value of Financial Instruments, to require disclosures about fair value of financial instruments for interim reporting periods of publicly traded companies as well as in annual financial statements. This FSP also amends APB Opinion No. 28, Interim Financial Reporting, to require those disclosures in summarized financial information at interim reporting periods. This FSP shall be effective for interim reporting periods ending after June 15, 2009. The Company does not have any fair value of financial instruments to disclose.

In April 2009, the FASB issued FSP No. FAS 115-2 and FAS 124-2, Recognition and Presentation of Other-Than-Temporary Impairments. This FSP amends the other-than-temporary impairment guidance in U.S. GAAP for debt securities to make the guidance more operational and to improve the presentation and disclosure of other-than-temporary impairments on debt and equity securities in the financial statements. The FSP does not amend existing recognition and measurement guidance related to other-than-temporary impairments of equity securities. The FSP shall be effective for interim and annual reporting periods ending after June 15, 2009. The Company currently does not have any financial assets that are other-than-temporarily impaired.

In April 2009, the FASB issued FSP No. FAS 141(R)-1, Accounting for Assets Acquired and Liabilities Assumed in a Business Combination That Arise from Contingencies, to address some of the application issues under SFAS 141(R). The FSP deals with the initial recognition and measurement of an asset acquired or a liability assumed in a business combination that arises from a contingency provided the asset or liability's fair value on the date of acquisition can be determined. When the fair value can-not be determined, the FSP requires using the guidance under SFAS No. 5, Accounting for Contingencies, and FASB Interpretation (FIN) No. 14, Reasonable Estimation of the Amount of a Loss. This FSP was effective for assets or liabilities arising from contingencies in business combinations for which the acquisition date is on or after January 1, 2009. The adoption of this FSP has not had a material impact on our financial position, results of operations, or cash flows during the six months ended June 30, 2009.

F-13

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 8. Recent Pronouncements (Continued)

In April 2009, the FASB issued FSP No. FAS 157-4, "Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly" ("FSP FAS 157-4"). FSP FAS 157-4 provides guidance on estimating fair value when market activity has decreased and on identifying transactions that are not orderly. Additionally, entities are required to disclose in interim and annual periods the inputs and valuation techniques used to measure fair value. This FSP is effective for interim and annual periods ending after June 15, 2009. The Company does not expect the adoption of FSP FAS 157-4 will have a material impact on its financial condition or results of operation.

In December 2008, the FASB issued FSP No. FAS 140-4 and FIN 46(R)-8, "Disclosures by Public Entities (Enterprises) about Transfers of Financial Assets and Interests in Variable Interest Entities." This disclosure-only FSP improves the transparency of transfers of financial assets and an enterprise's involvement with variable interest entities, including qualifying special-purpose entities. This FSP is effective for the first reporting period (interim or annual) ending after December 15, 2008, with earlier application encouraged. The Company adopted this FSP effective January 1, 2009. The adoption of the FSP had no impact on the Company's results of operations, financial condition or cash flows.

In December 2008, the FASB issued FSP No. FAS 132(R)-1, "Employers' Disclosures about Postretirement Benefit Plan Assets" ("FSP FAS 132(R)- 1"). FSP FAS 132(R)-1 requires additional fair value disclosures about employers' pension and postretirement benefit plan assets consistent with guidance contained in SFAS 157. Specifically, employers will be required to disclose information about how investment allocation decisions are made, the fair value of each major category of plan assets and information about the inputs and valuation techniques used to develop the fair value measurements of plan assets. This FSP is effective for fiscal years ending after December 15, 2009. The Company does not expect the adoption of FSP FAS 132(R)-1 will have a material impact on its financial condition or results of operation.

In October 2008, the FASB issued FSP No. FAS 157-3, "Determining the Fair Value of a Financial Asset When the Market for That Asset is Not Active," ("FSP FAS 157-3"), which clarifies application of SFAS 157 in a market that is not active. FSP FAS 157-3 was effective upon issuance, including prior periods for which financial statements have not been issued. The adoption of FSP FAS 157-3 had no impact on the Company's results of operations, financial condition or cash flows.

F-14

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 8. Recent Pronouncements (Continued)

In September 2008, the FASB issued exposure drafts that eliminate qualifying special purpose entities from the guidance of SFAS No. 140, "Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities," and FASB Interpretation 46 (revised December 2003), "Consolidation of Variable Interest Entities - an interpretation of ARB No. 51," as well as other modifications. While the proposed revised pronouncements have not been finalized and the proposals are subject to further public comment, the Company anticipates the changes will not have a significant impact on the Company's financial statements. The changes would be effective March 1, 2010, on a prospective basis.

In June 2008, the FASB issued FASB Staff Position EITF 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities, ("FSP EITF 03-6-1"). FSP EITF 03-6-1 addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting, and therefore need to be included in the computation of earnings per share under the two-class method as described in FASB Statement of Financial Accounting Standards No. 128, "Earnings per Share." FSP EITF 03-6-1 is effective for financial statements issued for fiscal years beginning on or after December 15, 2008 and earlier adoption is prohibited. We are not required to adopt FSP EITF 03-6-1; neither do we believe that FSP EITF 03-6-1 would have material effect on our consolidated financial position and results of operations if adopted.

In May 2008, the Financial Accounting Standards Board ("FASB") issued SFAS No. 163, "Accounting for Financial Guarantee Insurance Contracts- and interpretation of FASB Statement No. 60". SFAS No. 163 clarifies how Statement 60 applies to financial guarantee insurance contracts, including the recognition and measurement of premium revenue and claims liabilities. This statement also requires expanded disclosures about financial guarantee insurance contracts. SFAS No. 163 is effective for fiscal years beginning on or after December 15, 2008, and interim periods within those years. SFAS No. 163 has no effect on the Company's financial position, statements of operations, or cash flows at this time.

F-15

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 8. Recent Pronouncements (Continued)

In May 2008, the Financial Accounting Standards Board ("FASB") issued SFAS No. 162, "The Hierarchy of Generally Accepted Accounting Principles". SFAS No. 162 sets forth the level of authority to a given accounting pronouncement or document by category. Where there might be conflicting guidance between two categories, the more authoritative category will prevail. SFAS No. 162 will become effective 60 days after the SEC approves the PCAOB's amendments to AU Section 411 of the AICPA Professional Standards. SFAS No. 162 has no effect on the Company's financial position, statements of operations, or cash flows at this time.

In March 2008, the Financial Accounting Standards Board, or FASB, issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging Activities-an amendment of FASB Statement No. 133. This standard requires companies to provide enhanced disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under Statement 133 and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity's financial position, financial performance, and cash flows. This Statement is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008, with early application encouraged. The Company has not yet adopted the provisions of SFAS No. 161, but does not expect it to have a material impact on its consolidated financial position, results of operations or cash flows.

In December 2007, the SEC issued Staff Accounting Bulletin (SAB) No. 110 regarding the use of a "simplified" method, as discussed in SAB No.
107 (SAB 107), in developing an estimate of expected term of "plain vanilla" share options in accordance with SFAS No. 123 (R), Share-Based Payment. In particular, the staff indicated in SAB 107 that it will accept a company's election to use the simplified method, regardless of whether the company has sufficient information to make more refined estimates of expected term. At the time SAB 107 was issued, the staff believed that more detailed external information about employee exercise behavior (e.g., employee exercise patterns by industry and/or other categories of companies) would, over time, become readily available to companies. Therefore, the staff stated in SAB 107 that it would not expect a company to use the simplified method for share option grants after December 31, 2007. The staff understands that such detailed information about employee exercise behavior may not be widely available by December 31, 2007. Accordingly, the staff will continue to accept, under certain circumstances, the use of the simplified method beyond December 31, 2007. The Company currently uses the simplified method for

F-16

EZJR, Inc.
(A Development Stage Company)

Notes to Financial Statements
June 30, 2009

NOTE 8. Recent Pronouncements (Continued)

"plain vanilla" share options and warrants, and will assess the impact of SAB 110 for fiscal year 2009. It is not believed that this will have an impact on the Company's consolidated financial position, results of operations or cash flows.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements-an amendment of ARB No. 51. This statement amends ARB 51 to establish accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. It clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements. Before this statement was issued, limited guidance existed for reporting noncontrolling interests. As a result, considerable diversity in practice existed. So-called minority interests were reported in the consolidated statement of financial position as liabilities or in the mezzanine section between liabilities and equity. This statement improves comparability by eliminating that diversity. This statement is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008 (that is, January 1, 2009, for entities with calendar year-ends). Earlier adoption is prohibited. The effective date of this statement is the same as that of the related Statement 141 (revised 2007). The Company will adopt this Statement beginning March 1, 2009. It is not believed that this will have an impact on the Company's consolidated financial position, results of operations or cash flows.

In December 2007, the FASB, issued FAS No. 141 (revised 2007), Business Combinations'. This Statement replaces FASB Statement No. 141, Business Combinations, but retains the fundamental requirements in Statement 141. This Statement establishes principles and requirements for how the acquirer:
(a) recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree; (b) recognizes and measures the goodwill acquired in the business combination or a gain from a bargain purchase; and (c) determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. This statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. An entity may not apply it before that date. The effective date of this statement is the same as that of the related FASB Statement No. 160, Noncontrolling Interests in Consolidated Financial Statements. The Company will adopt this statement beginning March 1, 2009. It is not believed that this will have an impact on the Company's consolidated financial position, results of operations or cash flows.

F-17

Exhibit 2.1

ACQUISITION AGREEMENT AND PLAN OF MERGER

DATED AS OF JULY 25, 2008

BETWEEN

IVPSA CORPORATION

AND

EZJR, INC.

TABLE OF CONTENTS

ARTICLE 1. The Merger
  Section 1.1.                                          The Merger
  Section 1.2.                                     The Acquisition
  Section 1.3.                                      Effective Time
  Section 1.4.                               Closing of the Merger
  Section 1.5.                               Effects of the Merger
  Section 1.6.              Board of Directors and Officers of IVP
  Section 1.7.          Taking of Necessary Action; Further Action

ARTICLE 2. Representations and Warranties of IVP
  Section 2.1.                       Organization and Qualification
  Section 2.2.                                Capitalization of IVP
  Section 2.3. Authority Relative to this Agreement; Recommendation
  Section 2.4.                    SEC Reports; Financial Statements
  Section 2.5.                                 Information Supplied
  Section 2.6.                Consents and Approvals; No Violations
  Section 2.7.                                           No Default
  Section 2.8.       No Undisclosed Liabilities; Absence of Changes
  Section 2.9.                                           Litigation
  Section 2.10.                      Compliance with Applicable Law
  Section 2.11.               Employee Benefit Plans; Labor Matters
  Section 2.12.                  Environmental Laws and Regulations
  Section 2.13.                                         Tax Matters
  Section 2.14.                                   Title To Property
  Section 2.15.                               Intellectual Property
  Section 2.16.                                           Insurance
  Section 2.17.                                       Vote Required
  Section 2.18.                                       Tax Treatment
  Section 2.19.                                          Affiliates
  Section 2.20.                          Certain Business Practices
  Section 2.21.                                   Insider Interests
  Section 2.22.                        Opinion of Financial Adviser
  Section 2.23.                                             Brokers
  Section 2.24.                                          Disclosure
  Section 2.25.                              No Existing Discussion

                                   i

ARTICLE 3. Representations and Warranties of EZJR.
  Section 3.1.                       Organization and Qualification
  Section 3.2.                               Capitalization of EZJR
  Section 3.3. Authority Relative to this Agreement; Recommendation
  Section 3.4.                    SEC Reports; Financial Statements
  Section 3.5.                                 Information Supplied
  Section 3.6.                Consents and Approvals; No Violations
  Section 3.7.                                           No Default
  Section 3.8        No Undisclosed Liabilities; Absence of Changes
  Section 3.9.                                           Litigation
  Section 3.10.                      Compliance with Applicable Law
  Section 3.11.               Employee Benefit Plans; Labor Matters
  Section 3.12.                  Environmental Laws and Regulations
  Section 3.13.                                         Tax Matters
  Section 3.14.                                   Title to Property
  Section 3.15.                               Intellectual Property
  Section 3.16.                                           Insurance
  Section 3.17.                                       Vote Required
  Section 3.18.                                       Tax Treatment
  Section 3.19.                                          Affiliates
  Section 3.20.                          Certain Business Practices
  Section 3.21.                                   Insider Interests
  Section 3.22.                        Opinion of Financial Adviser
  Section 3.23.                                             Brokers
  Section 3.24.                                          Disclosure
  Section 3.25.                             No Existing Discussions

ARTICLE 4. Covenants
  Section 4.1.                           Conduct of Business of IVP
  Section 4.2.                          Conduct of Business of EZJR
  Section 4.3.                                   Preparation of 8-K
  Section 4.4.                            Other Potential Acquirers
  Section 4.5.                                Access to Information
  Section 4.6.           Additional Agreements; Reasonable Efforts.
  Section 4.7.                                      Indemnification
  Section 4.8.                      Notification of Certain Matters

ARTICLE 5. Conditions to Consummation of the Merger
  Section 5.1.                Conditions to each Party's Obligation
  Section 5.2.                 Conditions to the Obligations of IVP
  Section 5.3.                Conditions to the Obligations of EZJR

ARTICLE 6. Termination; Amendment; Waiver
  Section 6.1.                                          Termination
  Section 6.2.                                Effect of Termination
  Section 6.3.                                    Fees and Expenses
  Section 6.4.                                            Amendment
  Section 6.5.                                    Extension; Waiver


                                      ii

ARTICLE 7. Miscellaneous
  Section 7.1.        Nonsurvival of Representations and Warranties
  Section 7.2.                         Entire Agreement; Assignment
  Section 7.3.                                             Validity
  Section 7.4.                                              Notices
  Section 7.5.                                        Governing Law
  Section 7.6.                                 Descriptive Headings
  Section 7.7.                                  Parties in Interest
  Section 7.8.                                  Certain Definitions
  Section 7.9.                                   Personal Liability
  Section 7.10.                                Specific Performance
  Section 7.11.                                        Counterparts

iii

ACQUISITION AGREEMENT AND PLAN OF MERGER

This Agreement and Plan of Merger (this "Agreement"), dated as of July 25, 2008, is between IVPSA CORPORATION, a Nevada corporation ("IVP"), and EZJR, INC., a Nevada corporation ("EZJR").

Whereas, the Boards of Directors of IVP and EZJR each have, in light of and subject to the terms and conditions set forth herein, (i) determined that the Merger (as defined below) is fair to their respective stockholders and in the best interests of such stockholders and (ii) approved the Acquisition Agreement and Plan of Merger in accordance with this Agreement;

Whereas, for Federal income tax purposes, it is intended that the Merger qualify as a reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended (the "Code"); and

Whereas, IVP and EZJR desire to make certain representations, warranties, covenants and agreements in connection with the Merger and also to prescribe various conditions to the Merger.

Now, therefore, in consideration of the promises and the representations, warranties, covenants and agreements herein contained, and intending to be legally bound hereby, IVP and EZJR hereby agree as follows:

ARTICLE I

The Merger

Section 1.1. The Merger. At the Effective Time (as defined below) and upon the terms and subject to the conditions of this Agreement and in accordance with the Nevada General Corporation Law of the State (the "NGCL"), EZJR shall be merged with and into IVP (as defined below) (the "Merger"). Following the Merger, IVP shall continue as the surviving corporation (the "Successor Corporation"), shall continue to be governed by the laws of the jurisdiction of its incorporation or organization and the separate corporate existence of EZJR shall cease to exist. The Successor Corporation shall continue to adapt the original Articles and By-laws of IVP. Initially the Successor Corporation shall be named EZJR, INC., a Nevada corporation. The Merger is intended to qualify as a tax-free reorganization under Section 368 of the Code as relates to the non-cash exchange of stock referenced herein.

Section 1.2. The Acquisition. IVP shall purchase for cash all of the issued and outstanding shares of EZJR. EZJR has 200,000 common shares issued and outstanding to one shareholder. This shareholder has agreed to sell and IVP has agreed to purchase all 200,000 shares for cash of $4,000. Once IVP purchases all of the common shares of EZJR, IVP will have complete ownership of EZJR.

1

Section 1.3. Effective Time. Subject to the terms and conditions set forth in this Agreement, a Certificate of Merger (the "Merger Certificate") shall be duly executed and acknowledged by each of EZJR and IVP, and thereafter the Merger Certificate reflecting the Merger shall be delivered to the Secretary of State of the State of Nevada for filing pursuant to the NGCL on the Closing Date (as defined in Section 1.3). The Merger shall become effective at such time as a properly executed and certified copy of the Merger Certificate is duly filed by the Secretary of State of the State of Nevada in accordance with the NGCL or such later time as the parties may agree upon and set forth in the Merger Certificate (the time at which the Merger becomes effective shall be referred to herein as the "Effective Time").

Section 1.4. Closing of the Merger. The closing of the Merger (the "Closing") will take place at a time and on a date to be specified by the parties, which shall be no later than the second business day after satisfaction of the latest to occur of the conditions set forth in Article 5 (the "Closing Date"), at a place agreed to in writing by the parties hereto.

Section 1.5. Effects of the Merger. The Merger shall have the effects set forth in the NGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all the properties, rights, privileges, powers of EZJR shall vest in the Successor Corporation, and all debts, liabilities and duties of EZJR shall become the debts, liabilities and duties of the Successor Corporation.

Section 1.6. Board of Directors and Officers of IVP. At or prior to the Effective Time, each of EZJR and IVP agrees to take such action as is necessary (i) to cause the number of directors comprising the full Board of Directors of IVP to remain the same.

Section 1.7. Taking of Necessary Action; Further Action. If, at any time after the Effective Time, EZJR or IVP reasonably determines that any deeds, assignments, or instruments or confirmations of transfer are necessary or desirable to carry out the purposes of this Agreement and to vest IVP with full right, title and possession to all assets, property, rights, privileges, powers and franchises of EZJR, the officers and directors of IVP and EZJR are fully authorized in the name of their respective corporations or otherwise to take, and will take, all such lawful and necessary or desirable action.

ARTICLE 2

Representations and Warranties of IVP

Except as set forth on the Disclosure Schedule delivered by IVP to EZJR (the "IVP Disclosure Schedule"), IVP hereby represents and warrants to EZJR as follows:

Section 2.1. Organization and Qualification.

(a) IVP is duly organized, validly existing and in good standing under

2

the laws of the jurisdiction of its incorporation or organization, has approximately 100 or more round lot (100 or more shares) stockholders and has all requisite power and authority to own, lease and operate its properties and to carry on its businesses as now being conducted, except where the failure to be so organized, existing and in good standing or to have such power and authority would not have a Material Adverse Effect (as defined below) on IVP. When used in connection with IVP, the term "Material Adverse Effect" means any change or effect (i) that is or is reasonably likely to be materially adverse to the business, results of operations, condition (financial or otherwise) or prospects of IVP, other than any change or effect arising out of general economic conditions unrelated to any business in which IVP is engaged, or (ii) that may impair the ability of IVP to perform its obligations hereunder or to consummate the transactions contemplated hereby.

(b) IVP has heretofore delivered to EZJR accurate and complete copies of the Articles of Incorporation and Bylaws (or similar governing documents), as currently in effect, of IVP. Except as set forth on Schedule 2.1 of the IVP Disclosure Schedule, IVP is duly qualified or licensed and in good standing to do business in each jurisdiction in which the property owned, leased or operated by it or the nature of the business conducted by it makes such qualification or licensing necessary, except in such jurisdictions where the failure to be so duly qualified or licensed and in good standing would not have a Material Adverse Effect on IVP.

Section 2.2. Capitalization of IVP.

(a) The authorized capital stock of IVP consists of: (i) Seventy Million (70,000,000) Authorized Shares of Common Stock, $0.001 par value, 10,873,750 Common shares are issued and outstanding as of July 25, 2008, and held by approximately 100 or more round lot (100 or more shares) stockholders; (ii) Five Million (5,000,000) Authorized Shares of Preferred Stock, $0.001 par value, no Preferred Shares have been issued. Pursuant to the Merger Agreement IVP will not issue any shares to EZJR, and purchase the 200,000 issued and outstanding of EZJR for cash at par value of $0.001 per share. These 200,000 shares will be subsequently cancelled. All of the outstanding IVP Shares have been duly authorized and validly issued, and are fully paid, nonassessable and free of preemptive rights. Except as set forth herein, as of the date hereof, there are no outstanding (i) shares of capital stock or other voting securities of IVP, (ii) securities of IVP convertible into or exchangeable for shares of capital stock or voting securities of IVP, (iii) options or other rights to acquire from IVP, except as set forth in 2.2(a) of the Disclosure Schedule, and, no obligations of IVP to issue, any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting securities of IVP, and (iv) equity equivalents, interests in the ownership or earnings of IVP or other similar rights (collectively, "IVP Securities"). As of the date hereof, except as set forth on Schedule 2.2(a) of the IVP Disclosure Schedule there are no outstanding obligations of IVP or its subsidiaries to repurchase,

3

redeem or otherwise acquire any IVP Securities or stockholder agreements, voting trusts or other agreements or understandings to which IVP is a party or by which it is bound relating to the voting or registration of any shares of capital stock of IVP. For purposes of this Agreement, "Lien" means, with respect to any asset (including, without limitation, any security) any mortgage, lien, pledge, charge, security interest or encumbrance of any kind in respect of such asset.

(b) The IVP Shares constitute the only class of equity securities of IVP registered or required to be registered under the Exchange Act.

(c) IVP does not own directly or indirectly more than fifty percent (50%) of the outstanding voting securities or interests (including membership interests) of any entity, other than as specifically disclosed in the disclosure documents.

Section 2.3. Authority Relative to this Agreement; Recommendation. IVP has all necessary corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly and validly authorized by the Board of Directors of IVP (the "IVP Board") and no other corporate proceedings on the part of IVP are necessary to authorize this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered by IVP and constitutes a valid, legal and binding agreement of IVP, enforceable against IVP in accordance with its terms.

Section 2.4. SEC Reports; Financial Statements. SEC Reports; Financial Statements.

(a) IVP does not currently file or is required to file any reports with the U. S. Securities and Exchange Commission.

Section 2.5. Information Supplied. None of the information supplied or to be supplied by IVP for inclusion or incorporation by reference in connection with the Merger will at the date presented to the stockholder of EZJR and at the times of the meeting or meetings of stockholders of IVP to be held in connection with the Merger, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading.

Section 2.6. Consents and Approvals; No Violations. Except for filings, permits, authorizations, consents and approvals as may be required under, and other applicable requirements of, the Securities Act, the Exchange Act, state securities or blue sky laws, the Hart-Scott-Rodino Antitrust Improvements Act of 1916, as amended (the "HSR Act"), the rules of the National Association of Securities Dealers, Inc. ("NASD"), the filing and recordation of the

4

Merger Certificate as required by the NGCL, and as set forth on Schedule 2.6 of the IVP Disclosure Schedule no filing with or notice to, and no permit, authorization, consent or approval of, any court or tribunal or administrative, governmental or regulatory body, agency or authority (a "Governmental Entity") is necessary for the execution and delivery by IVP of this Agreement or the consummation by IVP of the transactions contemplated hereby, except where the failure to obtain such permits, authorizations, consents or approvals or to make such filings or give such notice would not have a Material Adverse Effect on IVP.

Except as set forth in Section 2.6 of the IVP Disclosure Schedule, neither the execution, delivery and performance of this Agreement by IVP nor the consummation by IVP of the transactions contemplated hereby will (i) conflict with or result in any breach of any provision of the respective Articles of Incorporation or Bylaws (or similar governing documents) of IVP,
(ii) result in a violation or breach of, or constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, amendment, cancellation or acceleration or Lien) under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, lease, license, contract, agreement or other instrument or obligation to which IVP is a party or by which any of its properties or assets may be bound, or (iii) violate any order, writ, injunction, decree, law, statute, rule or regulation applicable to IVP or any of its properties or assets, except in the case of (ii) or (iii) for violations, breaches or defaults which would not have a Material Adverse Effect on IVP.

Section 2.7. No Default. Except as set forth in Section 2.7 of the IVP Disclosure Schedule, IVP is not in breach, default or violation (and no event has occurred which with notice or the lapse of time or both would constitute a breach default or violation) of any term, condition or provision of (i) its Articles of Incorporation or Bylaws (or similar governing documents), (ii) any note, bond, mortgage, indenture, lease, license, contract, agreement or other instrument or obligation to which IVP is now a party or by which any of its respective properties or assets may be bound or
(iii) any order, writ injunction, decree, law, statute, rule or regulation applicable to IVP or any of its respective properties or assets, except in the case of (ii) or (iii) for violations, breaches or defaults that would not have a Material Adverse Effect on IVP. Except as set forth in Section 2.7 of the IVP Disclosure Schedule, each note, bond, mortgage, indenture, lease, license, contract, agreement or other instrument or obligation to which IVP is now a party or by which its respective properties or assets may be bound that is material to IVP and that has not expired is in full force and effect and is not subject to any material default thereunder of which IVP is aware by any party obligated to IVP thereunder.

Section 2.8. No Undisclosed Liabilities; Absence of Changes. Except as and to the extent disclosed in the June 30, 2008 audited financial statements, none of IVP or its subsidiaries had any liabilities or obligations of any nature, whether or not accrued, contingent or otherwise, that would be required by generally accepted accounting principles to be reflected on a consolidated balance sheet of IVP and its consolidated subsidiaries (including the notes thereto) or which would have a Material

5

Adverse Effect on IVP. Except as disclosed by IVP, none of IVP or its subsidiaries has incurred any liabilities of any nature, whether or not accrued, contingent or otherwise, which could reasonably be expected to have, and there have been no events, changes or effects with respect to IVP or its subsidiaries having or which could reasonably be expected to have, a Material Adverse Effect on IVP. Except as and to the extent disclosed by IVP there has not been (i) any material change by IVP in its accounting methods, principles or practices (other than as required after the date hereof by concurrent changes in generally accepted accounting principles), (ii) any revaluation by IVP of any of its assets having a Material Adverse Effect on IVP, including, without limitation, any write-down of the value of any assets other than in the ordinary course of business or (iii) any other action or event that would have required the consent of any other party hereto pursuant to Section 4.2 of this Agreement had such action or event occurred after the date of this Agreement.

Section 2.9. Litigation. Except as set forth in Schedule 2.9 of the IVP Disclosure Schedule there is no suit, claim, action, proceeding or investigation pending or, to the knowledge of IVP, threatened against IVP or any of its subsidiaries or any of their respective properties or assets before any Governmental Entity which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect on IVP or could reasonably be expected to prevent or delay the consummation of the transactions contemplated by this Agreement. Except as disclosed by IVP, none of IVP or its subsidiaries is subject to any outstanding order, writ, injunction or decree which, insofar as can be reasonably foreseen in the future, could reasonably be expected to have a Material Adverse Effect on IVP or could reasonably be expected to prevent or delay the consummation of the transactions contemplated hereby.

Section 2.10. Compliance with Applicable Law. Except as disclosed by IVP, IVP and its subsidiaries hold all permits, licenses, variances, exemptions, orders and approvals of all Governmental Entities necessary for the lawful conduct of their respective businesses (the "IVP Permits"), except for failures to hold such permits, licenses, variances, exemptions, orders and approvals which would not have a Material Adverse Effect on IVP. Except as disclosed by IVP, IVP and its subsidiaries are in compliance with the terms of the IVP Permits, except where the failure so to comply would not have a Material Adverse Effect on IVP. Except as disclosed by IVP, the businesses of IVP and its subsidiaries are not being conducted in violation of any law, ordinance or regulation of any Governmental Entity except that no representation or warranty is made in this Section 2.10 with respect to Environmental Laws and except for violations or possible violations which do not, and, insofar as reasonably can be foreseen, in the future will not, have a Material Adverse Effect on IVP. Except as disclosed by IVP no investigation or review by any Governmental Entity with respect to IVP or its subsidiaries is pending or, to the knowledge of IVP, threatened, nor, to the knowledge of IVP, has any Governmental Entity indicated an intention to conduct the same, other than, in each case, those which IVP reasonably believes will not have a Material Adverse Effect on IVP.

6

Section 2.11. Employee Benefit Plans; Labor Matters.

(a) Except as set forth in Section 2.11(a) of the IVP Disclosure Schedule with respect to each employee benefit plan, program, policy, arrangement and contract (including, without limitation, any "employee benefit plan," as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended ("ERISA")), maintained or contributed to at any time by IVP or any entity required to be aggregated with IVP pursuant to Section 414 of the Code (each, a "IVP Employee Plan"), no event has occurred and to the knowledge of IVP, no condition or set of circumstances exists in connection with which IVP could reasonably be expected to be subject to any liability which would have a Material Adverse Effect on IVP.

(b) (i) No IVP Employee Plan is or has been subject to Title IV of ERISA or Section 412 of the Code; and (ii) each IVP Employee Plan intended to qualify under Section 401(a) of the Code and each trust intended to qualify under Section 501(a) of the Code is the subject of a favorable Internal Revenue Service determination letter, and nothing has occurred which could reasonably be expected to adversely affect such determination.

(c) Section 2.11(c) of the IVP Disclosure Schedule sets forth a true and complete list, as of the date of this Agreement, that no person holds or owns and IVP Stock Options or IVP Warrants. Further, IVP has not taken any action that would result in the issuance of any IVP Stock Options.

(d) There shall be no payment, accrual of additional benefits, acceleration of payments, or vesting in any benefit under any IVP Employee Plan or any agreement or arrangement disclosed under this Section 2.11 solely by reason of entering into or in connection with the transactions contemplated by this Agreement.


(e) There are no controversies pending or, to the knowledge of IVP, threatened, between IVP and any of their employees, which controversies have or could reasonably be expected to have a Material Adverse Effect on IVP. Neither IVP nor any of its subsidiaries is a party to any collective bargaining agreement or other labor union contract applicable to persons employed by IVP or any of its subsidiaries (and neither IVP nor any of its subsidiaries has any outstanding material liability with respect to any terminated collective bargaining agreement or labor union contract), nor does IVP know of any activities or proceedings of any labor union to organize any of its or employees. IVP has no knowledge of any strike, slowdown, work stoppage, lockout or threat thereof, by or with respect to any of its employees.

Section 2.12. Environmental Laws and Regulations.

(a) Except as disclosed by IVP, (i) IVP is in material compliance with all applicable federal, state, local and foreign laws and regulations relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, ground water,

7

land surface or subsurface strata) (collectively, "Environmental Laws"), except for non-compliance that would not have a Material Adverse Effect on IVP, which compliance includes, but is not limited to, the possession by IVP of all material permits and other governmental authorizations required under applicable Environmental Laws, and compliance with the terms and conditions thereof; (ii) IVP has not received written notice of, or, to the knowledge of IVP, is the subject of, any action, cause of action, claim, investigation, demand or notice by any person or entity alleging liability under or non- compliance with any Environmental Law (an ``Environmental Claim") that could reasonably be expected to have a Material Adverse Effect on IVP; and (iii) to the knowledge of IVP, there are no circumstances that are reasonably likely to prevent or interfere with such material compliance in the future.

(b) Except as disclosed by IVP, there are no Environmental Claims which could reasonably be expected to have a Material Adverse Effect on IVP that are pending or, to the knowledge of IVP, threatened against IVP or, to the knowledge of IVP, against any person or entity whose liability for any Environmental Claim IVP has or may have retained or assumed either contractually or by operation of law.

Section 2.13. Tax Matters.

(a) Except as set forth in Section 2.13 of the IVP Disclosure Schedule:
(i) IVP has filed or has had filed on its behalf in a timely manner (within any applicable extension periods) with the appropriate Governmental Entity all income and other material Tax Returns (as defined herein) with respect to Taxes (as defined herein) of IVP and all Tax Returns were in all material respects true, complete and correct; (ii) all material Taxes with respect to IVP have been paid in full or have been provided for in accordance with GAAP on IVP's most recent balance sheet which is part of the IVP SEC Documents.
(iii) there are no outstanding agreements or waivers extending the statutory period of limitations applicable to any federal, state, local or foreign income or other material Tax Returns required to be filed by or with respect to IVP; (iv) to the knowledge of IVP none of the Tax Returns of or with respect to IVP is currently being audited or examined by any Governmental Entity; and (v) no deficiency for any income or other material Taxes has been assessed with respect to IVP which has not been abated or paid in full.

(b) For purposes of this Agreement, (i) "Taxes" shall mean all taxes, charges, fees, levies or other assessments, including, without limitation, income, gross receipts, sales, use, ad valorem, goods and services, capital, transfer, franchise, profits, license, withholding, payroll, employment, employer health, excise, estimated, severance, stamp, occupation, property or other taxes, customs duties, fees, assessments or charges of any kind whatsoever, together with any interest and any penalties, additions to tax or additional amounts imposed by any taxing authority and (ii) "Tax Return" shall mean any report, return, documents declaration or other information or filing required to be supplied to any taxing authority or jurisdiction with respect to Taxes.

8

Section 2.14. Title to Property. IVP has good and defensible title to all of its properties and assets, free and clear of all liens, charges and encumbrances except liens for taxes not yet due and payable and such liens or other imperfections of title, if any, as do not materially detract from the value of or interfere with the present use of the property affected thereby or which, individually or in the aggregate, would not have a Material Adverse


Effect on IVP; and, to IVP's knowledge, all leases pursuant to which IVP leases from others real or personal property are in good standing, valid and effective in accordance with their respective terms, and there is not, to the knowledge of IVP, under any of such leases, any existing material default or event of default (or event which with notice of lapse of time, or both, would constitute a default and in respect of which IVP has not taken adequate steps to prevent such a default from occurring) except where the lack of such good standing, validity and effectiveness, or the existence of such default or event, would not have a Material Adverse Effect on IVP.

Section 2.15. Intellectual Property.

(a) IVP does not own, or possess licenses or other valid rights to use, all existing United States and foreign patents, trademarks, trade names, service marks, copyrights, trade secrets and applications therefore that are material to its business as currently conducted (the "IVP Intellectual Property Rights").

(b) The validity of the IVP Intellectual Property Rights and the title thereto of IVP is not being questioned in any litigation to which IVP is a party.

(c) Except as set forth in Section 2.15(c) of the IVP Disclosure Schedule, the conduct of the business of IVP as now conducted does not, to IVP's knowledge, infringe any valid patents, trademarks, trade names, service marks or copyrights of others. The consummation of the transactions completed hereby will not result in the loss or impairment of any IVP Intellectual Property Rights.

(d) IVP has taken steps it believes appropriate to protect and maintain its trade secrets as such, except in cases where IVP has elected to rely on patent or copyright protection in lieu of trade secret protection.

Section 2.16. Insurance. IVP does not currently maintains any general liability and other business insurance.

Section 2.17. Vote Required. Approval of this Acquisition Agreement and Plan of Merger by the Stockholders of IVP is not required pursuant to current Nevada law.

9

Section 2.18. Tax Treatment. Neither IVP nor, to the knowledge of IVP, any of its affiliates has taken or agreed to take action that would prevent the Merger from constituting a reorganization qualifying under the provisions of Section 368(a) of the Code.

Section 2.19. Affiliates. Except for the director and one major shareholder of IVP, each of whom is listed, there are no persons who, to the knowledge of IVP, may be deemed to be affiliates of IVP under Rule 1-02(b) of Regulation S-X of the SEC (the "IVP Affiliates").

Section 2.20. Certain Business Practices. None of IVP or any directors, officers, agents or employees of IVP has (i) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns or violated any provision of the Foreign Corrupt Practices Act of 1977, as amended (the "FCPA"), or (iii) made any other unlawful payment.

Section 2.21. Insider Interests. Except as set forth in Section 2.21 of the IVP Disclosure Schedule, neither any officer or director of IVP has any interest in any material property, real or personal, including without limitation, any computer software or IVP Intellectual Property Rights, used in or pertaining to the business of IVP, expect for the ordinary rights of a stockholder or employee stock option holder.

Section 2.22. Opinion of Financial Adviser. No advisers, as of the date hereof, have delivered to the IVP Board a written opinion to the effect that, as of such date, the exchange ratio contemplated by the Merger is fair to the holders of IVP Shares.

Section 2.23. Brokers. No broker, finder or investment banker (other than the IVP Financial Adviser, a true and correct copy of whose engagement agreement has been provided to EZJR) is entitled to any brokerage, finder's or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of IVP.

Section 2.24. Disclosure. No representation or warranty of IVP in this Agreement or any certificate, schedule, document or other instrument furnished or to be furnished to EZJR pursuant hereto or in connection herewith contains, as of the date of such representation, warranty or instrument, or will contain any untrue statement of a material fact or, at the date thereof, omits or will omit to state a material fact necessary to make any statement herein or therein, in light of the circumstances under which such statement is or will be made, not misleading.

Section 2.25. No Existing Discussions. As of the date hereof, IVP is not engaged, directly or indirectly, in any discussions or negotiations with any other party with respect to any Third Party Acquisition (as defined in
Section 4.4).

10

ARTICLE 3

Representations and Warranties of EZJR

Except as set forth on the Disclosure Schedule delivered by EZJR to IVP (the "EZJR Disclosure Schedule"), EZJR hereby represents and warrants to IVP as follows:

Section 3.1. Organization and Qualification.

(a) Each of EZJR and its subsidiaries is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization and has all requisite power and authority to own, lease and operate its properties and to carry on its businesses as now being conducted, except where the failure to be so organized, existing and in good standing or to have such power and authority would not have a Material Adverse Effect (as defined below) on EZJR. When used in connection with EZJR, the term "Material Adverse Effect" means any change or effect (i) that is or is reasonably likely to be materially adverse to the business, results of operations, condition (financial or otherwise) or prospects of EZJR and its subsidiaries, taken as a whole, other than any change or effect arising out of general economic conditions unrelated to any businesses in which EZJR and its subsidiaries are engaged, or (ii) that may impair the ability of EZJR to consummate the transactions contemplated hereby.

(b) EZJR has heretofore delivered to IVP accurate and complete copies of the Articles of Incorporation and Bylaws (or similar governing documents), as currently in effect, of EZJR. Each of EZJR and its subsidiaries is duly qualified or licensed and in good standing to do business in each jurisdiction in which the property owned, leased or operated by it or the nature of the business conducted by it makes such qualification or licensing necessary except in such jurisdictions where the failure to be so duly qualified or licensed and in good standing would not have a Material Adverse Effect on EZJR.

Section 3.2. Capitalization of EZJR.

(a) As of July 25, 2008, the authorized capital stock of EZJR consists of Seventy-five Million (75,000,000) EZJR common Shares, $0.001 par value, of which 200,000 common Shares are issued and outstanding. All of the outstanding EZJR Shares have been duly authorized and validly issued, and are fully paid, nonassessable and free of preemptive rights.

(b) Except as set forth in Section 3.2(b) of the EZJR Disclosure Schedule, Edward Zimmerman, Jr. is the record and beneficial owner of all of the issued and outstanding shares of capital stock of its subsidiaries.

(c) Except as set forth in Section 3.2(c) of the EZJR Disclosure Schedule, between December 31, 2007 and the date hereof, no shares of EZJR's capital stock have been issued and no EZJR Stock options have been granted. Except as set forth in Section 3.2(a) above, as of the date hereof, there are no outstanding (i) shares of capital stock or other voting securities of EZJR,

11

(ii) securities of EZJR or its subsidiaries convertible into or exchangeable for shares of capital stock or voting securities of EZJR, (iii) options or other rights to acquire from EZJR or its subsidiaries, or obligations of EZJR or its subsidiaries to issue, any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting securities of EZJR, or (iv) equity equivalents, interests in the ownership or earnings of EZJR or its subsidiaries or other similar rights (collectively, "EZJR Securities"). As of the date hereof, there are no outstanding obligations of EZJR or any of its subsidiaries to repurchase, redeem or otherwise acquire any EZJR Securities. There are no stockholder agreements, voting trusts or other agreements or understandings to which EZJR is a party or by which it is bound relating to the voting or registration of any shares of capital stock of EZJR.

(d) Except as set forth in Section 3.2(d) of the EZJR Disclosure Schedule, there are no securities of EZJR convertible into or exchangeable for, no options or other rights to acquire from EZJR, and no other contract, understanding, arrangement or obligation (whether or not contingent) providing for the issuance or sale, directly or indirectly, of any capital stock or other ownership interests in, or any other securities of, any subsidiary of EZJR.

(e) The EZJR Shares constitute the only class of equity securities of EZJR or its subsidiaries.

(f) Except as set forth in Section 3.2(f) of the EZJR Disclosure Schedule, EZJR does not own directly or indirectly any outstanding voting securities or interests (including membership interests) of any entity.

Section 3.3. Authority Relative to this Agreement; Recommendation.

(a) EZJR has all necessary corporate power and authority to execute and deliver this Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly and validly authorized by the Board of Directors of EZJR (the "EZJR Board"), and no other corporate proceedings on the part of EZJR are necessary to authorize this Agreement or to consummate the transactions contemplated hereby, except, as referred to in
Section 3.17, the approval and adoption of this Agreement by the holders of at least a majority of the then outstanding EZJR Shares. This Agreement has been duly and validly executed and delivered by EZJR and constitutes a valid, legal and binding agreement of EZJR, enforceable against EZJR in accordance with its terms.

(b) The EZJR Board has resolved to recommend that the sole stockholder of EZJR approved and adopted this Agreement.

12

Section 3.4. SEC Reports; Financial Statements.

(a) EZJR has filed all required forms, reports and documents with the Securities and Exchange Commission (the "SEC") since March 27, 2006, each of which has complied in all material respects with all applicable requirements of the Securities Act of 1933, as amended (the "Securities Act"), and the Exchange Act (and the rules and regulations promulgated thereunder, respectively), each as in effect on the dates such forms, reports and documents were filed. EZJR has heretofore delivered or promptly will deliver prior to the Effective Date to EZJR, in the form filed with the SEC (including any amendments thereto but excluding any exhibits), (i) its initial Registration Statement on Form 10SB12G filed March 27, 2006, (ii) its Form 10-KSB filed on March 30, 2007 and April 14, 2008, (iii) all other reports or registration statements filed by EZJR with the SEC since March 27, 2006 (all of the foregoing, collectively, the "EZJR SEC Reports"). None of such EZJR SEC Reports, including, without limitation, any financial statements or schedules included or incorporated by reference therein, contained, when filed, any untrue statement of a material fact or omitted to state a material fact required to be stated or incorporated by reference therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The audited financial statements of EZJR included in the EZJR SEC Reports fairly present, in conformity with generally accepted accounting principles applied on a consistent basis (except as may be indicated in the notes thereto), the financial position of EZJR as of the dates thereof and its results of operations and changes in financial position for the periods then ended. All material agreements, contracts and other documents required to be filed as exhibits to any of the EZJR SEC Reports have been so filed.

(b) EZJR has heretofore made available or promptly will make available to IVP a complete and correct copy of any amendments or modifications which are required to be filed with the SEC but have not yet been filed with the SEC, to agreements, documents or other instruments which previously had been filed by EZJR with the SEC pursuant to the Exchange Act.

Section 3.5. Information Supplied. None of the information supplied or to be supplied by EZJR for inclusion or incorporation by reference to the 8-K will, at the time the 8-K is filed with the SEC and at the time it becomes effective under the Securities Act, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading.

Section 3.6. Consents and Approvals; No Violations. Except as set forth in Section 3.6 of the EZJR Disclosure Schedule, and for filings, permits, authorizations, consents and approvals as may be required under, and other applicable requirements of, the Securities Act, the Exchange Act, state securities or blue sky laws, the HSR Act, the rules of the NASD, and the filing and recordation of the Merger Certificate as required by the NGCL, no filing with or notice to, and no permit, authorization, consent or approval of, any Governmental Entity is necessary for the execution and delivery by

13

EZJR of this Agreement or the consummation by EZJR of the transactions contemplated hereby, except where the failure to obtain such permits, authorizations consents or approvals or to make such filings or give such notice would not have a Material Adverse Effect on EZJR.

Neither the execution, delivery and performance of this Agreement by EZJR nor the consummation by EZJR of the transactions contemplated hereby will (i) conflict with or result in any breach of any provision of the respective Articles of Incorporation or Bylaws (or similar governing documents) of EZJR or any of EZJR's subsidiaries, (ii) result in a violation or breach of, or constitute (with or without due notice or lapse of time or both) a default (or give rise to any right of termination, amendment, cancellation or acceleration or Lien) under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, lease, license, contract, agreement or other instrument or obligation to which EZJR or any of EZJR's subsidiaries is a party or by which any of them or any of their respective properties or assets may be bound or (iii) violate any order, writ, injunction, decree, law, statute, rule or regulation applicable to EZJR or any of EZJR's subsidiaries or any of their respective properties or assets, except in the case of (ii) or (iii) for violations, breaches or defaults which would not have a Material Adverse Effect on EZJR.

Section 3.7. No Default. EZJR is not in breach, default or violation (and no event has occurred which with notice or the lapse of time or both would constitute a breach, default or violation) of any term, condition or provision of (i) its Articles of Incorporation or Bylaws (or similar governing documents), (ii) any note, bond, mortgage, indenture, lease, license, contract, agreement or other instrument or obligation to which EZJR or any of its subsidiaries is now a party or by which any of them or any of their respective properties or assets may be bound or (iii) any order, writ, injunction, decree, law, statute, rule or regulation applicable to EZJR, its subsidiaries or any of their respective properties or assets, except in the case of (ii) or (iii) for violations, breaches or defaults that would not have a Material Adverse Effect on EZJR. Each note, bond, mortgage, indenture, lease, license, contract, agreement or other instrument or obligation to which EZJR or any of its subsidiaries is now a party or by which any of them or any of their respective properties or assets may be bound that is material to EZJR and its subsidiaries taken as a whole and that has not expired is in full force and effect and is not subject to any material default thereunder of which EZJR is aware by any party obligated to EZJR or any subsidiary thereunder.

Section 3.8. No Undisclosed Liabilities; Absence of Changes. Except as set forth in Section 2.8 of the EZJR Disclosure Schedule and except as and to the extent publicly disclosed by EZJR in the EZJR SEC Reports, as of December 31, 2007, EZJR does not have any liabilities or obligations of any nature, whether or not accrued, contingent or otherwise, that would be required by generally accepted accounting principles to be reflected on a balance sheet of EZJR (including the notes thereto) or which would have a Material Adverse Effect on EZJR. Except as publicly disclosed by EZJR, since December 31, 2007, EZJR has not incurred any liabilities of any nature,

14

whether or not accrued, contingent or otherwise, which could reasonably be expected to have, and there have been no events, changes or effects with respect to EZJR having or which reasonably could be expected to have, a Material Adverse Effect on EZJR. Except as and to the extent publicly disclosed by EZJR in the EZJR SEC Reports and except as set forth in Section 2.8 of the EZJR Disclosure Schedule, since December 31, 2007, there has not been (i) any material change by EZJR in its accounting methods, principles or practices (other than as required after the date hereof by concurrent changes in generally accepted accounting principles), (ii) any revaluation by EZJR of any of its assets having a Material Adverse Effect on EZJR, including, without limitation, any write-down of the value of any assets other than in the ordinary course of business or (iii) any other action or event that would have required the consent of any other party hereto pursuant to Section 4.1 of this Agreement had such action or event occurred after the date of this Agreement.

Section 3.9. Litigation. Except as publicly disclosed by EZJR in the EZJR SEC Reports, there is no suit, claim, action, proceeding or investigation pending or, to the knowledge of EZJR, threatened against EZJR or any of its subsidiaries or any of their respective properties or assets before any Governmental Entity which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect on EZJR or could reasonably be expected to prevent or delay the consummation of the transactions contemplated by this Agreement. Except as publicly disclosed by EZJR in the EZJR SEC Reports, EZJR is not subject to any outstanding order, writ, injunction or decree which, insofar as can be reasonably foreseen in the future, could reasonably be expected to have a Material Adverse Effect on EZJR or could reasonably be expected to prevent or delay the consummation of the transactions contemplated hereby.

Section 3.10. Compliance with Applicable Law. Except as publicly disclosed by EZJR in the EZJR SEC Reports, EZJR holds all permits, licenses, variances, exemptions, orders and approvals of all Governmental Entities necessary for the lawful conduct of their respective businesses (the "EZJR Permits"), except for failures to hold such permits, licenses, variances, exemptions, orders and approvals which would not have a Material Adverse Effect on EZJR. Except as publicly disclosed by EZJR in the EZJR SEC Reports, EZJR is in compliance with the terms of the EZJR Permits, except where the failure so to comply would not have a Material Adverse Effect on EZJR. Except as publicly disclosed by EZJR in the EZJR SEC Reports, the business of EZJR is not being conducted in violation of any law, ordinance or regulation of any Governmental Entity except that no representation or warranty is made in this Section 2.10 with respect to Environmental Laws (as defined in Section 2.12 below) and except for violations or possible violations which do not, and, insofar as reasonably can be foreseen, in the future will not, have a Material Adverse Effect on EZJR. Except as publicly disclosed by EZJR in the EZJR SEC Reports, no investigation or review by any Governmental Entity with respect to EZJR is pending or, to the knowledge of EZJR, threatened, nor, to the knowledge of EZJR, has any Governmental Entity indicated an intention to conduct the same, ther than, in each case, those which EZJR reasonably believes will not have a Material Adverse Effect on EZJR.

15

Section 3.11. Employee Benefit Plans; Labor Matters.

(a) With respect to each employee benefit plan, program, policy, arrangement and contract (including, without limitation, any "employee benefit plan," as defined in Section 3(3) of ERISA), maintained or contributed to at any time by EZJR, any of its subsidiaries or any entity required to be aggregated with EZJR or any of its subsidiaries pursuant to

Section 414 of the Code (each, a "EZJR Employee Plan"), no event has occurred and, to the knowledge of EZJR, no condition or set of circumstances exists in connection with which EZJR or any of its subsidiaries could reasonably be expected to be subject to any liability which would have a Material Adverse Effect on EZJR.

(b) (i) No EZJR Employee Plan is or has been subject to Title IV of ERISA or Section 412 of the Code; and (ii) each EZJR Employee Plan intended to qualify under Section 401(a) of the Code and each trust intended to qualify under Section 501(a) of the Code is the subject of a favorable Internal Revenue Service determination letter, and nothing has occurred which could reasonably be expected to adversely affect such determination.

(c) Section 3.11(c) of the EZJR Disclosure Schedule sets forth a true and complete list, as of the date of this Agreement, of each person who holds any EZJR Stock Options, together with the number of EZJR Shares which are subject to such option, the date of grant of such option, the extent to which such option is vested (or will become vested as a result of the Merger), the option price of such option (to the extent determined as of the date hereof), whether such option is a nonqualified stock option or is intended to qualify as an incentive stock option within the meaning of Section 422(b) of the Code, and the expiration date of such option. Section 3.11(c) of the EZJR Disclosure Schedule also sets forth the total number of such incentive stock options and such nonqualified options. EZJR has furnished IVP with complete copies of the plans pursuant to which the EZJR Stock Options were issued. Other than the automatic vesting of EZJR Stock Options that may occur without any action on the part of EZJR or its officers or directors, EZJR has not taken any action that would result in any EZJR Stock Options that are unvested becoming vested in connection with or as a result of the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby.

(d) Except as disclosed in Section 3.11(e) of the EZJR Disclosure Schedule there shall be no payment, accrual of additional benefits, acceleration of payments, or vesting in any benefit under any EZJR Employee Plan or any agreement or arrangement disclosed under this Section 3.11 solely by reason of entering into or in connection with the transactions contemplated by this Agreement.

16

(e) There are no controversies pending or, to the knowledge of EZJR threatened, between EZJR or any of its subsidiaries and any of their respective employees, which controversies have or could reasonably be expected to have a Material Adverse Effect on EZJR. Neither EZJR nor any of its subsidiaries is a party to any collective bargaining agreement or other labor union contract applicable to persons employed by EZJR or any of its subsidiaries (and neither EZJR nor any of its subsidiaries has any outstanding material liability with respect to any terminated collective bargaining agreement or labor union contract), nor does EZJR know of any activities or proceedings of any labor union to organize any of its or any of its subsidiaries' employees. EZJR has no knowledge of any strike, slowdown, work stoppage, lockout or threat thereof by or with respect to any of its or any of its subsidiaries' employees.

Section 3.12. Environmental Laws and Regulations.

(a) Except as disclosed by EZJR, (i) each of EZJR and its subsidiaries is in material compliance with all Environmental Laws, except for non- compliance that would not have a Material Adverse Effect on EZJR, which compliance includes, but is not limited to, the possession by EZJR and its subsidiaries of all material permits and other governmental authorizations required under applicable Environmental Laws, and compliance with the terms and conditions thereof;(ii) none of EZJR or its subsidiaries has received written notice of, or, to the knowledge of EZJR, is the subject of, any Environmental Claim that could reasonably be expected to have a Material Adverse Effect on EZJR; and (iii) to the knowledge of EZJR, there are no circumstances that are reasonably likely to prevent or interfere with such material compliance in the future.

(b) Except as disclosed by EZJR, there are no Environmental Claims which could reasonably be expected to have a Material Adverse Effect on EZJR that are pending or, to the knowledge of EZJR, threatened against EZJR or any of its subsidiaries or, to the knowledge of EZJR, against any person or entity whose liability for any Environmental Claim EZJR or its subsidiaries has or may have retained or assumed either contractually or by operation of law.

Section 3.13. Tax Matters. Except as set forth in Section 3.13 of the EZJR Disclosure Schedule: (i) EZJR and each of its subsidiaries has filed or has had filed on its behalf in a timely manner (within any applicable extension periods) with the appropriate Governmental Entity all income and other material Tax Returns with respect to Taxes of EZJR and each of its subsidiaries and all Tax Returns were in all material respects true, complete and correct; (ii) all material Taxes with respect to EZJR and each of its subsidiaries have been paid in full or have been provided for in accordance with GAAP on EZJR's most recent balance sheet which is part of the EZJR SEC Documents; (iii) there are no outstanding agreements or waivers extending the statutory period of limitations applicable to any federal, state, local or foreign income or other material Tax Returns required to be filed by or with respect to EZJR or its subsidiaries; (iv) to the knowledge of EZJR none of the Tax Returns of or with respect to EZJR or any of its subsidiaries is

17

currently being audited or examined by any Governmental Entity; and (v) no deficiency for any income or other material Taxes has been assessed with respect to EZJR or any of its subsidiaries which has not been abated or paid in full.

Section 3.14. Title to Property. EZJR and each of its subsidiaries have good and defensible title to all of their properties and assets, free and clear of all liens, charges and encumbrances except liens for taxes not yet due and payable and such liens or other imperfections of title, if any, as do not materially detract from the value of or interfere with the present use of the property affected thereby or which, individually or in the aggregate, would not have a Material Adverse Effect on EZJR; and, to EZJR's knowledge, all leases pursuant to which EZJR or any of its subsidiaries lease from others real or personal property are in good standing, valid and effective in accordance with their respective terms, and there is not, to the knowledge of EZJR, under any of such leases, any existing material default or event of default (or event which with notice or lapse of time, or both, would constitute a material default and in respect of which EZJR or such subsidiary has not taken adequate steps to prevent such a default from occurring) except where the lack of such good standing, validity and effectiveness, or the existence of such default or event of default would not have a Material Adverse Effect on EZJR.

Section 3.15. Intellectual Property.

(a) EZJR does not own, or possess any licenses or other valid rights to use, all existing United States and foreign patents, trademarks, trade names, services marks, copyrights, trade secrets, and applications therefore that are material to its business as currently conducted (the "EZJR Intellectual Property Rights").

(b) Except as set forth in Section 3.15(b) of the EZJR Disclosure Schedule the validity of the EZJR Intellectual Property Rights and the title thereto of EZJR or any subsidiary, as the case may be, is not being questioned in any litigation to which EZJR or any subsidiary is a party.

(c) The conduct of the business of EZJR as now conducted does not, to EZJR's knowledge, infringe any valid patents, trademarks, tradenames, service marks or copyrights of others. The consummation of the transactions contemplated hereby will not result in the loss or impairment of any EZJR Intellectual Property Rights.

(d) EZJR has taken steps it believes appropriate to protect and maintain its trade secrets as such, except in cases where EZJR has elected to rely on patent or copyright protection in lieu of trade secret protection.

Section 3.16. Insurance. EZJR currently does not maintain general liability and other business insurance.

Section 3.17. Vote Required. The affirmative vote of the holder of all the outstanding EZJR Shares is the only vote of the holder of any class or series of EZJR's capital stock necessary to approve and adopt this Agreement and the Merger.

18

Section 3.18. Tax Treatment. Neither EZJR nor, to the knowledge of EZJR, any of its affiliates has taken or agreed to take any action that would prevent the Merger from constituting a reorganization qualifying under the provisions of Section 368(a) of the Code.

Section 3.19. Affiliates. Except for the directors and executive officers of EZJR, each of whom is listed in Section 3.19 of the EZJR Disclosure Schedule, there are no persons who, to the knowledge of EZJR, may be deemed to be affiliates of EZJR under Rule 1-02(b) of Regulation S-X of the SEC (the "EZJR Affiliates").

Section 3.20. Certain Business Practices. None of EZJR, any of its subsidiaries or any directors, officers, agents or employees of EZJR or any of its subsidiaries has (i) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns or violated any provision of the FCPA, or (iii) made any other unlawful payment.

Section 3.21. Insider Interests. Except as set forth in Section 3.21 of the EZJR Disclosure Schedule, no officer or director of EZJR has any interest in any material property, real or personal, including without limitation, any computer software or EZJR Intellectual Property Rights, used in or pertaining to the business of EZJR or any subsidiary, except for the ordinary rights of a stockholder or employee stock optionholder.

Section 3.22. Opinion of Financial Adviser. No advisers, as of the date hereof, have delivered to the EZJR Board a written opinion to the effect that, as of such date, the exchange ratio contemplated by the Merger is fair to the holders of EZJR Shares.

Section 3.23. Brokers. No broker, finder or investment banker (other than the EZJR Financial Adviser, a true and correct copy of whose engagement agreement has been provided to IVP) is entitled to any brokerage, finders or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of EZJR.

Section 3.24. Disclosure. No representation or warranty of EZJR in this Agreement or any certificate, schedule, document or other instrument furnished or to be furnished to IVP pursuant hereto or in connection herewith contains, as of the date of such representation, warranty or instrument, or will contain any untrue statement of a material fact or, at the date thereof, omits or will omit to state a material fact necessary to make any statement herein or therein, in light of the circumstances under which such statement is or will be made, not misleading.

Section 3.25. No Existing Discussions. As of the date hereof, EZJR is not engaged, directly or indirectly, in any discussions or negotiations with any other party with respect to any Third Party Acquisition (as defined in
Section 5.4).

19

ARTICLE 4

Covenants

Section 4.1. Conduct of Business of IVP. Except as contemplated by this Agreement or as described in Section 4.1 of the IVP Disclosure Schedule, during the period from the date hereof to the Effective Time, IVP will conduct its operations in the ordinary course of business consistent with past practice and, to the extent consistent therewith, with no less diligence and effort than would be applied in the absence of this Agreement, seek to preserve intact its current business organization, keep available the service of its current officers and employees and preserve its relationships with customers, suppliers and others having business dealings with it to the end that goodwill and ongoing businesses shall be unimpaired at the Effective Time. Without limiting the generality of the foregoing, except as otherwise expressly provided in this Agreement or as described in Section 4.1 of the IVP Disclosure Schedule, prior to the Effective Time, IVP will not, without the prior written consent of EZJR:

(a) amend its Articles of Incorporation or Bylaws (or other similar governing instrument);

(b) amend the terms of any stock of any class or any other securities (except bank loans) or equity equivalents.

(c) split, combine or reclassify any shares of its capital stock, declare, set aside or pay any dividend or other distribution (whether in cash, stock or property or any combination thereof) in respect of its capital stock, make any other actual, constructive or deemed distribution in respect of its capital stock or otherwise make any payments to stockholders in their capacity as such, or redeem or otherwise acquire any of its securities;

(d) adopt a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of IVP (other than the Merger);

(e) (i) incur or assume any long-term or short-term debt or issue any debt securities except for borrowings or issuances of letters of credit under existing lines of credit in the ordinary course of business; (ii) assume, guarantee, endorse or otherwise become liable or responsible (whether directly, contingently or otherwise) for the obligations of any other person.
(iii) make any loans, advances or capital contributions to, or investments in, any other person; (iv) pledge or otherwise encumber shares of capital stock of IVP; or (v) mortgage or pledge any of its material assets, or create or suffer to exist any material Lien thereupon (other than tax Liens for taxes not yet due);

20

(f) except as may be required by law, enter into, adopt or amend or terminate any bonus, profit sharing, compensation, severance, termination, stock option, stock appreciation right, restricted stock, performance unit, stock equivalent, stock purchase agreement, pension, retirement, deferred compensation, employment, severance or other employee benefit agreement, trust, plan, fund or other arrangement for the benefit or welfare of any director, officer or employee in any manner, or increase in any manner the compensation or fringe benefits of any director, officer or employee or pay any benefit not required by any plan and arrangement as in effect as of the date hereof (including, without limitation, the granting of stock appreciation rights or performance units); provided, however, that this paragraph (f) shall not prevent IVP from (i) entering into employment


agreements or severance agreements with employees in the ordinary course of business and consistent with past practice or (ii) increasing annual compensation and/or providing for or amending bonus arrangements for employees or fiscal 2000 in the ordinary course of year-end compensation reviews consistent with past practice and paying bonuses to employees for fiscal 2000 in amounts previously disclosed to EZJR (to the extent that such compensation increases and new or amended bonus arrangements do not result in a material increase in benefits or compensation expense to IVP);

(g) acquire, sell, lease or dispose of any assets in any single transaction or series of related transactions (other than in the ordinary course of business);

(h) except as may be required as a result of a change in law or in generally accepted accounting principles, change any of the accounting principles or practices used by it;

(i) revalue in any material respect any of its assets including, without limitation, writing down the value of inventory or writing-off notes or accounts receivable other than in the ordinary course of business;

(j) (i) acquire (by merger, consolidation, or acquisition of stock or assets) any corporation, partnership or other business organization or division thereof or any equity interest therein; (ii) enter into any contract or agreement other than in the ordinary course of business consistent with past practice which would be material to IVP; (iii) authorize any new capital expenditure or expenditures which, individually is in excess of $10,000 or, in the aggregate, are in excess of $25,000; provided, however that none of the foregoing shall limit any capital expenditure required pursuant to existing contracts;

(k) make any tax election or settle or compromise any income tax liability material to IVP;

(l) settle or compromise any pending or threatened suit, action or claim which (i) relates to the transactions contemplated hereby or (ii) the settlement or compromise of which could have a Material Adverse Effect on IVP;

21

(m) commence any material research and development project or terminate any material research and development project that is currently ongoing, in either case, except pursuant to the terms of existing contracts or in the ordinary course of business; or

(n) take, or agree in writing or otherwise to take, any of the actions described in Sections 4.1(a) through 4.1(m) or any action which would make any of the representations or warranties of contained in this Agreement untrue or incorrect.

Section 4.2. Conduct of Business of EZJR. Except as contemplated by this Agreement or as described in Section 4.2 of the EZJR Disclosure Schedule during the period from the date hereof to the Effective Time, EZJR will conduct its operations in the ordinary course of business consistent with past practice and, to the extent consistent therewith, with no less diligence and effort than would be applied in the absence of this Agreement, seek to preserve intact its current business organization, keep available the service of its current officers and employees and preserve its relationships with customers, suppliers and others having business dealings with it to the end that goodwill and ongoing businesses shall be unimpaired at the Effective Time. Without limiting the generality of the foregoing, except as otherwise expressly provided in this Agreement or as described in Section 4.2 of the EZJR Disclosure Schedule, prior to the Effective Time, EZJR will not, without the prior written consent of:

(a) amend its Articles of Incorporation or Bylaws (or other similar governing instrument);

(b) authorize for issuance, issue, sell, deliver or agree or commit to issue, sell or deliver (whether through the issuance or granting of options, warrants, commitments, subscriptions, rights to purchase or otherwise) any stock of any class or any other securities (except bank loans) or equity equivalents (including, without limitation, any stock options or stock appreciation rights;

(c) split, combine or reclassify any shares of its capital stock, declare, set aside or pay any dividend or other distribution (whether in cash, stock or property or any combination thereof) in respect of its capital stock, make any other actual, constructive or deemed distribution in respect of its capital stock or otherwise make any payments to stockholders in their capacity as such, or redeem or otherwise acquire any of its securities;

(d) adopt a plan of complete or partial liquidation, dissolution, merger consolidation, restructuring, recapitalization or other reorganization of EZJR (other than the Merger);

22

(e) (i) incur or assume any long-term or short-term debt or issue any debt securities except for borrowings or issuances of letters of credit under existing lines of credit in the ordinary course of business. (ii) assume, guarantee, endorse or otherwise become liable or responsible (whether directly, contingently or otherwise) for the obligations of any other person;
(iii) make any loans, advances or capital contributions to or investments in, any other person; (iv) pledge or otherwise encumber shares of capital stock of EZJR or its subsidiaries; or (v) mortgage or pledge any of its material assets, or create or suffer to exist any material Lien thereupon (other than tax Liens for taxes not yet due);

(f) except as may be required by law, enter into, adopt or amend or terminate any bonus, profit sharing, compensation, severance, termination, stock option, stock appreciation right, restricted stock, performance unit stock equivalent, stock purchase agreement, pension, retirement, deferred compensation, employment, severance or other employee benefit agreement, trust, plan, fund or other arrangement for the benefit or welfare of any director, officer or employee in any manner, or increase in any manner the compensation or fringe benefits of any director, officer or employee or pay any benefit not required by any plan and arrangement as in effect as of the date hereof (including, without limitation, the granting of stock appreciation rights or performance units); provided, however, that this paragraph (f) shall not prevent EZJR or its subsidiaries from (i) entering into employment agreements or severance agreements with employees in the ordinary course of business and consistent with past practice or (ii) increasing annual compensation and/or providing for or amending bonus arrangements for employees for fiscal 2007 in the ordinary course of yearend compensation reviews consistent with past practice and paying bonuses to employees for fiscal 2007 in amounts previously disclosed to (to the extent that such compensation increases and new or amended bonus arrangements do not result in a material increase in benefits or compensation expense to EZJR);

(g) acquire, sell, lease or dispose of any assets in any single transaction or series of related transactions other than in the ordinary course of business;

(h) except as may be required as a result of a change in law or in generally accepted accounting principles, change any of the accounting principles or practices used by it;

(i) revalue in any material respect any of its assets, including, without limitation, writing down the value of inventory of writing-off notes or accounts receivable other than in the ordinary course of business;

23

(j) (i) acquire (by merger, consolidation, or acquisition of stock or assets) any corporation, partnership, or other business organization or division thereof or any equity interest therein; (ii) enter into any contract or agreement other than in the ordinary course of business consistent with past practice which would be material to EZJR; (iii) authorize any new capital expenditure or expenditures which, individually, is in excess of $1,000 or, in the aggregate, are in excess of $5,000: provided, however that none of the foregoing shall limit any capital expenditure required pursuant to existing contracts;

(k) make any tax election or settle or compromise any income tax liability material to EZJR and its subsidiaries taken as a whole;

(l) settle or compromise any pending or threatened suit, action or claim which (i) relates to the transactions contemplated hereby or (ii) the settlement or compromise of which could have a Material Adverse Effect on EZJR;

(m) commence any material research and development project or terminate any material research and development project that is currently ongoing, in either case, except pursuant to the terms of existing contracts or except in the ordinary course of business; or

(n) take, or agree in writing or otherwise to take, any of the actions described in Sections 4.2(a) through 4.2(m) or any action which would make any of the representations or warranties of the EZJR contained in this Agreement untrue or incorrect.

Section 4.3. Preparation of 8-K. EZJR and IVP shall promptly prepare and file with the SEC an 8-K disclosing this merger with audited financials of IVP along with pro forma combined statements.

Section 4.4. Other Potential Acquirers.

(a) EZJR, its affiliates and their respective officers, directors, employees, representatives and agents shall immediately cease any existing discussions or negotiations, if any, with any parties conducted heretofore with respect to any Third Party Acquisition.

Section 4.5. Access to Information.

(a) Between the date hereof and the Effective Time, IVP will give EZJR and its authorized representatives, and EZJR will give IVP and its authorized representatives, reasonable access to all employees, plants, offices, warehouses and other facilities and to all books and records of itself and its subsidiaries, will permit the other party to make such inspections as such party may reasonably require and will cause its officers and those of its subsidiaries to furnish the other party with such financial and operating data and other information with respect to the business and properties of itself and its subsidiaries as the other party may from time to time reasonably request.

24

(b) Between the date hereof and the Effective Time, IVP shall furnish to EZJR, and EZJR will furnish to IVP, within 25 business days after the end of each quarter, quarterly statements prepared by such party in conformity with its past practices) as of the last day of the period then ended.

(c) Each of the parties hereto will hold and will cause its consultants and advisers to hold in confidence all documents and information furnished to it in connection with the transactions contemplated by this Agreement.

Section 4.6. Additional Agreements, Reasonable Efforts. Subject to the terms and conditions herein provided, each of the parties hereto agrees to use all reasonable efforts to take, or cause to be taken, all action, and to do, or cause to be done, all things reasonably necessary, proper or advisable under applicable laws and regulations to consummate and make effective the transactions contemplated by this Agreement, including, without limitation,
(i) cooperating in the preparation and filing of the 8-K, any filings that may be required under the HSR Act, and any amendments to any thereof; (ii) obtaining consents of all third parties and Governmental Entities necessary, proper or advisable for the consummation of the transactions contemplated by this Agreement; (iii) contesting any legal proceeding relating to the Merger and (iv) the execution of any additional instruments necessary to consummate the transactions contemplated hereby. Subject to the terms and conditions of this Agreement, EZJR and IVP agree to use all reasonable efforts to cause the Effective Time to occur as soon as practicable after the stockholder votes with respect to the Merger. In case at any time after the Effective Time any further action is necessary to carry out the purposes of this Agreement, the proper officers and directors of each party hereto shall take all such necessary action.

Section 4.7. Indemnification.

(a) To the extent, if any, not provided by an existing right under one of the parties' directors and officers liability insurance policies, from and after the Effective Time, IVP shall, to the fullest extent permitted by applicable law, indemnify, defend and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director, officer or employee of the parties hereto or any subsidiary thereof (each an "Indemnified Party" and, collectively, the "Indemnified Parties") against all losses, expenses (including reasonable attorneys' fees and expenses), claims, damages or liabilities or, subject to the proviso of the next succeeding sentence, amounts paid in settlement

25

arising out of actions or omissions occurring at or prior to the Effective Time and whether asserted or claimed prior to, at or after the Effective Time) that are in whole or in part (i) based on, or arising out of the fact that such person is or was a director, officer or employee of such party or a subsidiary of such party or (ii) based on, arising out of or pertaining to the transactions contemplated by this Agreement. In the event of any such loss expense, claim, damage or liability (whether or not arising before the Effective Time), (i) IVP shall pay the reasonable fees and expenses of counsel selected by the Indemnified Parties, which counsel shall be reasonably satisfactory to IVP, promptly after statements therefore are received and otherwise advance to such Indemnified Party upon request reimbursement of documented expenses reasonably incurred, in either case to the extent not prohibited by the NGCL or its Articles of Incorporation or bylaws, (ii) IVP will cooperate in the defense of any such matter and (iii) any determination required to be made with respect to whether an Indemnified Party's conduct complies with the standards set forth under the NGCL and IVP's Articles of Incorporation and bylaws shall be made by independent counsel mutually acceptable to IVP and the Indemnified Party; provided, however, that IVP shall not be liable for any settlement effected without its written consent (which consent shall not be unreasonably withheld). The Indemnified Parties as a group may retain only one law firm with respect to each related matter except to the extent there is, in the opinion of counsel to an Indemnified Party, under applicable standards of professional conduct, conflict on any significant issue between positions of any two or more Indemnified Parties.

(b) In the event IVP or any of its successors or assigns (i) consolidates with or merges into any other person and shall not be the continuing or surviving corporation or entity or such consolidation or merger or (ii) transfers all or substantially all of its properties and assets to any person, then and in either such case, proper provision shall be made so that the successors and assigns of IVP shall assume the obligations set forth in this Section 4.9.

(c) To the fullest extent permitted by law, from and after the Effective Time, all rights to indemnification now existing in favor of the employees, agents, directors or officers of IVP and EZJR and their subsidiaries with respect to their activities as such prior to the Effective Time, as provided in IVP's and EZJR's Articles of Incorporation or bylaws, in effect on the date thereof or otherwise in effect on the date hereof, shall survive the Merger and shall continue in full force and effect for a period of not less than two years from the Effective Time.

(d) The provisions of this Section 4.8 are intended to be for the benefit of, and shall be enforceable by, each Indemnified Party, his or her heirs and his or her representatives.

26

Section 4.8. Notification of Certain Matters. The parties hereto shall give prompt notice to the other parties, of (i) the occurrence or nonoccurrence of any event the occurrence or nonoccurrence of which would be likely to cause any representation or warranty contained in this Agreement to be untrue or inaccurate in any material respect at or prior to the Effective Time, (ii) any material failure of such party to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder, (iii) any notice of, or other communication relating to, a default or event which, with notice or lapse of time or both, would become a default, received by such party or any of its subsidiaries subsequent to the date of this Agreement and prior to the Effective Time, under any contract or agreement material to the financial condition, properties, businesses or results of operations of such party and its subsidiaries taken as a whole to which such party or any of its subsidiaries is a party or is subject, (iv) any notice or other communication from any third party alleging that the consent of such third party is or may be required in connection with the transactions contemplated by this Agreement, or (v) any material adverse change in their respective financial condition, properties, businesses, results of operations or prospects taken as a whole, other than changes resulting from general economic conditions; provided, however, that the delivery of any notice pursuant to this Section 4.10 shall not cure such breach or non-compliance or limit or otherwise affect the remedies available hereunder to the party receiving such notice.

ARTICLE 5

Conditions to Consummation of the Merger

Section 5.1. Conditions to Each Party's Obligations to Effect the Merger. The respective obligations of each party hereto to effect the Merger are subject to the satisfaction at or prior to the Effective Time of the following conditions:

(a) this Agreement shall have been approved and adopted by the requisite vote of the stockholders of EZJR;

(b) this Agreement shall have been approved and adopted by the Board of Directors of IVP and EZJR;

(c) no statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or enforced by any United States court or United States governmental authority which prohibits, restrains, enjoins or restricts the consummation of the Merger;

(d) any waiting period applicable to the Merger under the HSR Act shall have terminated or expired, and any other governmental or regulatory notices or approvals required with respect to the transactions contemplated hereby shall have been either filed or received; and

27

Section 5.2. Conditions to the Obligations of IVP. The obligation of IVP to effect the Merger is subject to the satisfaction at or prior to the Effective Time of the following conditions:

(a) the representations of EZJR contained in this Agreement or in any other document delivered pursuant hereto shall be true and correct (except to the extent that the breach thereof would not have a Material Adverse Effect on EZJR) at and as of the Effective Time with the same effect as if made at and as of the Effective Time (except to the extent such representations specifically related to an earlier date, in which case such representations shall be true and correct as of such earlier date), and at the Closing EZJR shall have delivered to IVP a certificate to that effect;

(b) each of the covenants and obligations of EZJR to be performed at or before the Effective Time pursuant to the terms of this Agreement shall have been duly performed in all material respects at or before the Effective Time and at the Closing EZJR shall have delivered to IVP a certificate to that effect;

(d) EZJR shall have obtained the consent or approval of each person whose consent or approval shall be required in order to permit the Merger as relates to any obligation, right or interest of EZJR under any loan or credit agreement, note, mortgage, indenture, lease or other agreement or instrument, except those for which failure to obtain such consents and approvals would not, in the reasonable opinion of IVP, individually or in the aggregate, have a Material Adverse Effect on EZJR;

(e) there shall have been no events, changes or effects with respect to EZJR or its subsidiaries having or which could reasonably be expected to have a Material Adverse Effect on EZJR; and

Section 5.3. Conditions to the Obligations of EZJR. The respective obligations of EZJR to effect the Merger are subject to the satisfaction at or prior to the Effective Time of the following conditions:

(a) the representations of IVP contained in this Agreement or in any other document delivered pursuant hereto shall be true and correct (except to the extent that the breach thereof would not have a Material Adverse Effect on IVP) at and as of the Effective Time with the same effect as if made at and as of the Effective Time (except to the extent such representations specifically related to an earlier date, in which case such representations shall be true and correct as of such earlier date), and at the Closing IVP shall have delivered to EZJR a certificate to that effect;

(b) each of the covenants and obligations of IVP to be performed at or before the Effective Time pursuant to the terms of this Agreement shall have been duly performed in all material respects at or before the Effective Time and at the Closing IVP shall have delivered to EZJR a certificate to that effect;

28

(c) there shall have been no events, changes or effects with respect to IVP having or which could reasonably be expected to have a Material Adverse Effect on IVP.

ARTICLE 6

Termination; Amendment; Waiver

Section 6.1. Termination. This Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time, whether before or after approval and adoption of this Agreement by IVP's or EZJR's stockholders:

(a) by mutual written consent of IVP and EZJR;

(b) by EZJR or IVP if (i) any court of competent jurisdiction in the United States or other United States Governmental Entity shall have issued a final order, decree or ruling or taken any other final action restraining, enjoining or otherwise prohibiting the Merger and such order, decree, ruling or other action is or shall have become nonappealable or (ii) the Merger has not been consummated by July 25, 2008; provided, however, that no party may terminate this Agreement pursuant to this clause (ii) if such party's failure to fulfill any of its obligations under this Agreement shall have been the reason that the Effective Time shall not have occurred on or before said date;

(c) by IVP if (i) there shall have been a breach of any representation or warranty on the part of EZJR set forth in this Agreement, or if any representation or warranty of EZJR shall have become untrue, in either case such that the conditions set forth in Section 5.2(a) would be incapable of being satisfied by July 31, 2008 (or as otherwise extended), (ii) there shall have been a breach by EZJR of any of their respective covenants or agreements hereunder having a Material Adverse Effect on EZJR or materially adversely affecting (or materially delaying) the consummation of the Merger, and EZJR, as the case may be, has not cured such breach within 20 business days after notice by IVP thereof, provided that IVP has not breached any of its obligations hereunder, (iii) IVP shall have convened a meeting of its stockholders to vote upon the Merger and shall have failed to obtain the requisite vote of its stockholders; or (iv) IVP shall have convened a meeting of its Board of Directors to vote upon the Merger and shall have failed to obtain the requisite vote;

(d) by EZJR if (i) there shall have been a breach of any representation or warranty on the part of IVP set forth in this Agreement, or if any representation or warranty of IVP shall have become untrue, in either case such that the conditions set forth in Section 5.3(a) would be incapable of being satisfied by July 31, 2008 (or as otherwise extended), (ii) there shall have been a breach by IVP of its covenants or agreements hereunder having a Material Adverse Effect on IVP or materially adversely affecting (or materially delaying) the consummation of the Merger, and IVP, as he case

29

may be, has not cured such breach within twenty business days after notice by EZJR thereof, provided that EZJR has not breached any of its obligations hereunder, (iii) the IVP Board shall have recommended to IVP's stockholders a Superior Proposal, (iv) the IVP Board shall have withdrawn, modified or changed its approval or recommendation of this Agreement or the Merger, or hold a stockholders' meeting to vote upon the Merger, or shall have adopted any resolution to effect any of the foregoing, (v) EZJR shall have convened a meeting of its stockholders to vote upon the Merger and shall have failed to obtain the requisite vote of its stockholders.

Section 6.2. Effect of Termination. In the event of the termination and abandonment of this Agreement pursuant to Section 6.1, this Agreement shall forthwith become void and have no effect, without any liability on the part of any party hereto or its affiliates, directors, officers or stockholders, other than the provisions of this Section 6.2 and Sections 4.7(c) and 6.3 hereof. Nothing contained in this Section 6.2 shall relieve any party from liability for any breach of this Agreement.

Section 6.3. Fees and Expenses. Except as specifically provided in this
Section 6.3, each party shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby.

Section 6.4. Amendment. This Agreement may be amended by action taken by IVP and EZJR at any time before or after approval of the Merger by the stockholders of IVP and EZJR (if required by applicable law) but, after any such approval, no amendment shall be made which requires the approval of such stockholders under applicable law without such approval. This Agreement may not be amended except by an instrument in writing signed on behalf of the parties hereto.

Section 6.5. Extension; Waiver. At any time prior to the Effective Time, each party hereto may (i) extend the time for the performance of any of the obligations or other acts of any other party, (ii) waive any inaccuracies in the representations and warranties of any other party contained herein or in any document, certificate or writing delivered pursuant hereto or (iii) waive compliance by any other party with any of the agreements or conditions contained herein. Any agreement on the part of any party hereto to any such extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such party. The failure of any party hereto to assert any of its rights hereunder shall not constitute a waiver of such rights.

30

ARTICLE 7

Miscellaneous

Section 7.1. Nonsurvival of Representations and Warranties. The representations and warranties made herein shall not survive beyond the Effective Time or a termination of this Agreement. This Section 7.1 shall not limit any covenant or agreement of the parties hereto which by its terms requires performance after the Effective Time.

Section 7.2. Entire Agreement; Assignment. This Agreement (a) constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all other prior agreements and understandings both written and oral, between the parties with respect to the subject matter hereof and (b) shall not be assigned by operation of law or otherwise.

Section 7.3. Validity. If any provision of this Agreement, or the application thereof to any person or circumstance, is held invalid or unenforceable, the remainder of this Agreement, and the application of such provision to other persons or circumstances, shall not be affected thereby, and to such end, the provisions of this Agreement are agreed to be severable.

Section 7.4. Notices. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by facsimile or by registered or certified mail (postage prepaid, return receipt requested), to each other party as follows:

If to EZJR:

EZJR, INC.

Attn: Edward Zimmerman, Jr.
3415 Ocatillo Mesa Way
North Las Vegas, NV 89031

if to IVP:

IVPSA Corporation
Attn: T J Jesky
2235 E. Flamingo, Suite 114
Las Vegas, NV 89119

31

or to such other address as the person to whom notice is given may have previously furnished to the others in writing in the manner set forth above.

Section 7.5. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada, without regard to the principles of conflicts of law thereof.

Section 7.6. Descriptive Headings. The descriptive headings herein are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement.

Section 7.7. Parties in Interest. This Agreement shall be binding upon and inure solely to the benefit of each party hereto and its successors and permitted assigns, and except as provided in Sections 4.9 and 4.11, nothing in this Agreement, express or implied, is intended to or shall confer upon any other person any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement.

Section 7.8. Certain Definitions. For the purposes of this Agreement, the term:

(a) "affiliate" means (except as otherwise provided in Sections 2.19 and 3.19 a person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, the first mentioned person;

(b) "business day" means any day other than a day on which Nasdaq is closed;

(c) "capital stock" means common stock, preferred stock, partnership interests, limited liability company interests or other ownership interests entitling the holder thereof to vote with respect to matters involving the issuer thereof;

(d) "knowledge" or "known" means, with respect to any matter in question, if an executive officer of IVP or EZJR or its subsidiaries, as the case may be, has actual knowledge of such matter;

(e) "person" means an individual, corporation, partnership, limited liability company, association, trust, unincorporated organization or other legal entity; and

(f) "subsidiary" or "subsidiaries" of IVP, EZJR or any other person, means any corporation, partnership, limited liability company, association, trust, unincorporated association or other legal entity of which IVP, EZJR or any such other person, as the case may be (either alone or through or together with any other subsidiary), owns, directly or indirectly, 50% or more of the capital stock, the holders of which are generally entitled to vote for the election of the board of directors or other governing body of such corporation or other legal entity.

32

Section 7.9. Personal Liability. This Agreement shall not create or be deemed to create or permit any personal liability or obligation on the part of any direct or indirect stockholder of IVP, EZJR or any officer, director, employee, agent, representative or investor of any party hereto.

Section 7.10. Specific Performance. The parties hereby acknowledge and agree that the failure of any party to perform its agreements and covenants hereunder, including its failure to take all actions as are necessary on its part to the consummation of the Merger, will cause irreparable injury to the other parties for which damages, even if available, will not be an adequate remedy. Accordingly, each party hereby consents to the issuance of injunctive relief by any court of competent jurisdiction to compel performance of such party's obligations and to the granting by any court of the remedy of specific performance of its obligations hereunder; provided, however, that, if a party hereto is entitled to receive any payment or reimbursement of expenses pursuant to Sections 6.3(a), (b) or (c), it shall not be entitled to specific performance to compel the consummation of the Merger.

Section 7.11. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement.

In Witness Whereof, each of the parties has caused this Agreement to be duly executed on its behalf as of the day and year first above written.

IVPSA CORPORATION

By: /s/ T J Jesky
----------------------
Name:   T J Jesky
Title:  President

EZJR, INC.

By: /s/ Edward Zimmerman, Jr.
-----------------------------
Name:   Edward Zimmerman, Jr.
Title:  President

33

IVP DISCLOSURE SCHEDULE

Schedule 2.1 Organization See Articles/Bylaws

Schedule 2.2(a) Options, Stock Preference Rights Not Applicable

Schedule 2.6   Consents & Approvals               None Provided

Schedule 2.7   No Default                         Not Applicable

Schedule 2.8   No Undisclosed Liability           None Exist

Schedule 2.9   Litigation                         Not Applicable

Schedule 2.10  Compliance with Applicable Law     None

Schedule 2.11 Employee Benefit Plans              None

Schedule 2.12 Environmental Laws and Regs         Not Applicable

Schedule 2.13 Tax Matters                         None Exist

Schedule 2.14 Title to Property                   None Exist

Schedule 2.15 Intellectual Property               None Exist

Schedule 2.16 Insurance                           None Exist

Schedule 2.17  Vote Required                      None Required

Schedule 2.18 Tax Treatment                       Not Applicable

Schedule 2.19 Affiliates                          T J Jesky and Mark DeStefano

Schedule 2.20 Certain Business Practices          None Exist

Schedule 2.21 Insider Interest                    Not Applicable

Schedule 2.22 Opinion of Financial Adviser        Waived - None Exist

Schedule 2.23 Broker                              None Exist

Schedule 4.1 Conduct of Business                  None Provided


EZJR DISCLOSURE SCHEDULE

Schedule 3.2(b) Subsidiary Stock                  None Exist

Schedule 3.2(c) Capital Stock Rights              None Exist other than as
                                                  in Articles

Schedule 3.2(d) Securities conversions            None Exist

Schedule 3.2 (f) Subsidiaries                     None Exist

Schedule 3.6   Consents & Approvals               Provided

Schedule 3.7   No Default                         Not Applicable

Schedule 3.8   No Undisclosed Liability           None Exist

Schedule 3.9   Litigation                         None Exist

Schedule  3.10   Compliance with Applicable Law   Not Applicable - full
                                                  disclosed in 10-KSB

Schedule 3.11 Employee Benefit Plans              Section 3.11( c)No Options
                                                  Exist

Section 3.11(e)                                   No Agreements Exist

Schedule 3.12 Environmental Laws and Regs         Not Applicable

Schedule 3.13 Tax Matters                         None Exist

Schedule 3.14 Title to Property                   None Exist

Schedule 3.15(b) Intellectual Property            None Exist

Schedule 3.16 Insurance                           None Exist

Schedule   3.17    Vote  Required                 See Shareholder Meeting
                                                  Certificate

Schedule 3.18 Tax Treatment                       Not Applicable

Schedule 3.19 Affiliates                          Edward Zimmerman, Jr.

Schedule 3.20 Certain Business Practices          None Exist

Schedule 3.21 Insider Interest                    None Exist

Schedule 3.22 Opinion of Financial Adviser        Waived - None Exist

Schedule 3.23 Broker                              None Exist

Schedule 4.2 Conduct of Business                  See Amended Articles


Exhibit A

RESOLUTION IN LIEU OF STOCKHOLDERS MEETING

THE UNDERSIGNED, being all the Stockholders of EZJR, Inc., a Nevada Corporation,in lieu of a Stockholders meeting, hereby consent to the following resolutions:

RESOLVED, that the Corporation enter into an Acquisition Agreement and Plan of Merger with IVPSA CORPORATION (A copy of which is attached) with IVPSA CORPORATION remaining as the surviving corporation, and be it

FURTHER RESOLVED, that the Corporation officers are hereby authorized to execute any and all documents necessary to accomplish the merger.

DATED: July 25, 2008

                                   /s/ Edward Zimmerman, Jr.
                                   -------------------------
                                       Edward Zimmerman, Jr.


Exhibit 3.1

Entity # E0613282006-3 Document Number:


20060522875-77
Date Filed
8/14/2006 6:26:47 AM
In the office of

/s/ Dean Heller
Dean Heller
Secretary of State


DEAN HELLER

              Secretary of State
/State Seal/  101 North Carson Street, Suite 3
              Carson City, Nevada 89701-4299
              (775) 684 5708
              Website: secretaryofstate.biz

                         ------------------------
                         /     Articles of      /
                         /    Incorporation     /

/ (PURSUANT TO NRS 78) /

1. Name of Corporation:          IVPSA Corporation
   --------------------

2. Resident Agent Name and       T. J. Jesky
   Street Address:               --------------------------------------------
   (must be a Nevada address     Name
   where process may be
   served)                       1515 E. Tropicana, Suite 710-U     Las Vegas
   -------------------------     --------------------------------------------
                                 Street Address                      City

                                 NEVADA     89119
                                          ----------
                                          Zip Code

3. Shares:                       Number of shares 70,000,000 Common
   (number of shares             with par value:   5,000,000 Preferred
   corporation                                    ----------
   authorized to issue)
   --------------------          Par Value per share:  $0.001
                                                       ------
                                 Number of shares
                                 without par value:   None.
                                                    --------

4. Names, Addresses,
   Number of Board of
   Directors/Trustees:
   -------------------
                                 1. T. J. Jesky
                                    -----------------------------------------
                                    Name

                                    500 N. Rainbow, Suite 300
                                    -----------------------------------------
                                    Street Address

                                    Las Vegas            NV       89107
                                    -----------------  ------  --------------
                                    City               State   Zip Code

5. Purpose: (optional- The purpose of this Corporation shall be:
see instructions) Any lawful purpose.

6. Names, Address                Eaton Laboratories, Inc.    /s/ T. J. Jesky
   and Signature of              ------------------------    Its:  Pres/CEO
   Incorporator:                 Name                        ----------------
   (attach additional page                                   Signature
   if there is more than 1       500 N. Rainbow, Suite 300
   incorporator)                 --------------------------------------------
   -----------------------       Address

                                 Las Vegas              NV         89107
                                 -------------------  ------  ---------------
                                 City                 State   Zip Code

7. Certificate of                I, hereby accept appointment as Resident
   Acceptance of                 Agent for the above named corporation.
   Appointment of
   Resident Agent:               /s/ T. J. Jesky                     8/5/2006
   ---------------               ----------------------------------- ----------
                                 Authorized Signature of R.A. or     Date
                                 On Behalf of R.A. Company

This form must be accompanied by the appropriate fees.


Exhibit 3.2

BY-LAWS OF EZJR, INC.

ARTICLE I
OFFICES

1. THE PRINCIPAL OFFICES of the corporation shall be in the City of Las Vegas, State of Nevada. The corporation may have such other offices within or without the State of Nevada as the Board of Directors may designate or as the business of the corporation may from time to time require

ARTICLE II
STOCKHOLDERS

1. ANNUAL MEETING. The annual meeting of the stockholders shall be held on the first Monday in April of every other year commencing with the year 2007 at the hour of 10:00 a.m. for the purpose of electing directors and officers and for the transaction of other business that may come up before the meeting. If the day fixed for the annual meeting shall be declared a legal holiday, such meeting shall be held on the next succeeding business day. If the election of Directors shall not be held on the day designated herein for any annual meeting of the shareholders, or at any adjournment thereof, the Board of Directors shall cause the election to be held at a special meeting of the shareholders as soon thereafter as soon as conveniently may be.

2. SPECIAL MEETING. Special meeting of the stockholders may be called by the directors, or by the President. Special meetings shall be called any time upon the request of the stockholders owning not less than fifty percent (50%) of the outstanding stock of the corporation entitled to vote at such meeting.

3. PLACE OF MEETING. All meetings of the stockholders shall be held at the principal office of the corporation in the City of North Las Vegas, State of Nevada or at such other place as shall be determined from time to time by the Board of Directors. If the place of the meeting is not at the principal offices of the corporation, the place of such meeting shall be stated in the call of the meeting.

4. NOTICE OF MEETING. Notice of the time and place of the annual meeting of stockholders shall be given by mailing written notice of the meeting at least ten (10) days prior to the meeting to each stockholder of record of the corporation entitled to vote at such meeting, such notice shall be deemed to be delivered when deposited in the United States mail so addressed, with postage prepaid thereon. The notice of the time and place of special meetings shall be given by written notice or by personal notice five
(5) days prior to the meeting to each stockholder of record of the corporation entitled to vote at such meeting.

1

5. CLOSING OF TRANSFER BOOKS. For the purpose of determining the stockholders entitled to notice of or entitled to vote at any regular meeting of stockholders or any special meeting, or of determining the stockholders entitled to receive payment of any dividend, or in order to make a determination of stockholders for any other purpose, the Directors of the corporation shall provide that the stock transfer books be closed for a stated period, but not to exceed in any case fifty (50) days. If the stock transfer books are to be closed for or the purpose of determining stockholders entitled to noticed of a special meeting or of the annual meeting of stockholders, such book shall be closed for at least fourteen (14) days immediately preceding such meeting. In lieu of closing the stock transfer books, the Board of Directors may fix in advance a date as the record date for any such determination of shareholders, such date in any case to be not more than fifty (50) days and, in the case of a meeting of shareholders, not less than (10) days prior to the date on which a particular action requiring such determination of shareholders is to be taken. If the stock transfer books are not closed and no record date is fixed for determination of shareholders entitled to notice of or to vote at the meeting of shareholders, or shareholders entitled to received payment of a dividend, the date on which notice of the meeting is mailed or the date on which the resolution of the Board of Directors declaring such dividend is adopted, as the case may be, shall be record date for such determination of shareholders entitled to vote at any meeting of shareholders has been made as provided in this section, such determination shall apply to any adjournment thereof.

6. VOTING LISTS. The officer or agent in charge of the stock transfer books for the corporation shall prepare before each meeting of stockholders a complete list of stockholders entitled to vote at the meeting arranged in alphabetical order with the address of and number of shares held by each person. The list shall be prepared five (5) days prior to the stockholders' meeting and shall be keep on file at the principal office of the corporation and subject to inspection during normal business hours by any stockholder. The list shall also be produced and kept open at the stockholders' meeting and shall be subject to inspection by any stockholder during the meeting.

7. QUORUM. The quorum at any annual of special meeting of stockholder shall consist of stockholders representing, capital stock of the corporation entitled to vote at such meetings, except as otherwise specifically provided by law or in the Articles of Incorporation. If a quorum is not present at a properly called stockholders' meeting, the meeting shall be adjourned by then present and an additional and further notice sent to all stockholders notifying them of the adjournment of the meeting and the date and time and place of the adjourned meeting. At such adjourned meeting. At such adjourned meeting, at which a quorum is present or represented, business may be transacted which might have been transacted at the meeting as originally notified.

8. PROXIES. At all meetings of stockholders, a stockholder may vote by proxy executed in writing by the stockholder or by their duly authorized attorney in fact. Such proxy shall be filed with the secretary of the Corporation before or at the time of the meeting.

2

9. VOTING OF SHARES. Subject to a special voting rights or restrictions attached to a class of shares, each shareholder shall be entitled to one vote for each share of stock in his or her own name on the books of the corporation, whether represented in person or by proxy.

10. VOTING OF SHARES BY CERTAIN HOLDERS. Shares standing in the name of another corporation may be voted by such officer, agent or proxy as the Bylaws of such corporation may prescribe or in the absence of such provision, as the Board of Directors of such corporation may determine. Shares held by an administrator, executor, guardian or conservator may be voted by him, either in person or by proxy, without a transfer of such into her name. Shares standing the name of a trustee may be voted by him, either in person or by proxy, but no trustee shall be entitled to vote shares held by him without a transfer of such shares into her name. Shares standing in the name of a receiver may be voted by such receiver, and the shares held by or under the control of a receiver may be voted by such receiver without the transfer thereof into her name, if authority to do so be contained in an appropriate order of the court by which such receiver was appointed. A shareholder whose shares are pledged shall be entitled to vote such shares until the shares have been transferred into the name of the pledgee, and thereafter the pledgee shall be entitled to vote the shares so transferred. Shares of it own stock belonging to the Corporation shall be voted, directly or indirectly, at any meeting, and shall not be counted in determining the total number of outstanding shares at any given time.

11. ORDER OF BUSINESS. The order of business at all meetings of stockholders shall be as follows:

a. Roll call.

b. Proof of notice of meeting or waiver of notice.

c. Reading of minutes of preceding meeting.

d. Reports of Officers.

e. Reports of Committees.

f. Election of Directors.

g. Unfinished Business.

h. New Business.

3

12. INFORMAL ACTION BY SHAREHOLDERS. Unless otherwise provided in the Nevada Corporate Law, any action that may be taken at any annual or special meeting of shareholders may be taken without a meeting and without prior notice if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote on such action were present and voted. Unless the consents of all shareholders entitled to vote have been solicited in writing, and unless the unanimous written consent of all shareholders has been received, the Secretary shall give prompt notice of the corporate action approved by the shareholders without a meeting.

ARTICLE III
BOARD OF DIRECTORS

1. GENERAL POWERS. The business and affairs of the corporation shall be managed by the Board of Directors consisting of not less than one or more than nine directors. The Board of Directors shall be elected for a term of two years and shall hold office until the successors are elected and qualified. Directors need not be stockholders. In addition to the power and authority granted by the By-Laws and the Articles of Incorporation, the Board of Directors may exercise all such powers of the corporation and do all such lawful acts and things that are not forbidden by statute, Articles of Incorporation, or by these By-Laws.

2. VACANCIES. All vacancies in the Board of Directors, whether caused by resignation, death of otherwise, may be filled by a majority vote of the remaining director or directors, even though they constitute less than a quorum, or by a majority vote of the stockholders. This may be accomplished at any special or regular meeting of the Board of Directors or by the stockholders at any regular or special meeting. A director thus elected to fill any vacancies shall hold office for the unexpired term of their predecessor and until their successor is elected and qualified.

3. REGULAR MEETINGS. A regular meeting of the directors shall be held at the same time as the annual meeting of stockholders. No notice of the regular meeting of the Board of Directors shall be sent. The directors may provide by resolution the time and place for the holding of additional regular meetings other than the meeting at the annual meeting of stockholders, by giving notice under their same provisions as that notice given of a stockholders meeting.

4. SPECIAL MEETINGS. Special meetings of the Board of Directors may be called at any time by the President, or in her absence, by the Vice President, or by any two directors, to be held at the time and place designated in notice of special meeting. The notice of special meeting shall be in the same form and done in the same manner as the notice given for stockholders' meeting.

4

5. NOTICE. Notice of any special meeting shall be given at least two
(2) days previous thereto by written notice delivered personally or mailed to each director at h is business address, or by telegram. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail so addressed, with postage thereon prepaid. If notice be given by telegram, such notice shall be deemed to be delivered when the notice be given to the telegraph company. Any directors may waive notice of any meeting. The attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except; where a director attends a meeting for the purpose of objecting to the transaction of any business because the meeting is not lawfully called or convened.

6. TELEPHONIC MEETING. A meeting of the Board of Directors may be had by means of a telephone conference or similar communications equipment by which all persons participating in the meeting can hear each other, and the participation in a meeting under such circumstances shall constitute presence at the meeting.

7. QUORUM. The majority of the Board of Directors shall be necessary at all meetings to constitute a quorum for the transaction of business. If less than a quorum is present, the meeting shall be adjourned. Any resolution adopted in writing and executed and signed by a majority of the Board of Directors, accompanied with a showing that the resolution had been presented to all directors, shall constitute and be a valid resolution as if the resolution had been adopted at a meeting at which all directors shall in all respects bind the corporation and constitute full and complete authority for the officers acting pursuant to it.

8. MANNER OF ACTING. The act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.

9. ACTION WITHOUT A MEETING. Any action that may be taken by the Board of Directors at a meeting may be taken without a meeting if a consent in writing, setting forth the action so to be taken, shall be signed before such action by all of the directors.

10. REMOVAL. Any director may be removed for cause by the majority vote of the stockholders or by a majority vote of the Board of Directors. Any director may be removed without cause by a majority vote of the stockholders.

11. RESIGNATION. Any director may resign at any time by giving written notice to the Board of Directors and the President or the Secretary or the corporation. The resignation shall be effective upon receipt of the notice and the acceptance of the resignation shall not be necessary to make it effective.

5

12. COMPENSATION. No compensation shall be paid to directors as such for their services but the Board of Directors by resolution can fix a sum for expenses for actual attendance at each regular or special meeting of the Board. Nothing contained herein shall be construed to preclude any director from serving the corporation in any other capacity and receiving a compensation therefore.

13. CONTRACTS. No contract or other transaction between this Corporation and any other corporation shall be impaired, affected or invalidated, nor shall any director be liable in any way by reason of the fact that one or more the directors of this Corporation is or are interested in, or is a director or officer, or are directors or officers of such other corporations, provided that such facts are disclosed or made known to the Board of Directors, prior to their authorizing such transaction. Any director may be a party to or may be interested in any contract or transaction of this Corporation , and no directors shall be liable in any way by reason of such interest, provided that the fact of such interest be disclosed or made known to the Board of Directors prior to their authorization of such contract or transaction, and provided that the Board of Directors shall authorize, approve or ratify such contract or transaction by the vote (not counting the vote of any such Director) of a majority of a quorum, notwithstanding the presence of any such director at the meeting at which such action is taken. Such director or directors may be counted in determining the presence of a quorum at such meeting. This Section shall not be construed to impair, invalidate or in any way affect any contract or other transaction which would otherwise be valid under the law (common, statutory or otherwise) applicable thereto.

14. COMMITTEES. The Board of Directors, by resolution adopted by a majority of the entire Board, may from time to time designated from among its members an executive committee and such other committees, and alternative members thereof, as they may deem desirable, with such powers and authority (to the extent permitted by law) as may be provided in such resolution. Each such committee shall serve at the pleasure of the Board.

15. PRESUMPTION OF ASSENT. A director of a corporation who is present at a meeting of the Board of Directors at which action on any corporate matter has been taken, will be presumed to have assented to the action taken unless their dissent is entered in the minutes of the meeting or unless they had filed their written dissent to such action with the person acting as the Secretary at the adjournment thereof, or shall forward such dissent by registered mail to the Secretary of the Corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a director who voted in favor of such action.

6

ARTICLE IV
OFFICERS

1. OFFICERS. The officers of the corporation shall be a President, Vice-Presidents (if needed), a Secretary (if needed) and a Treasurer (if needed), each of whom shall be elected by the Board of Directors. Such officers and assistant officers as may be deemed necessary may be elected or appointed by the Board of Directors, including a Chairman of the Board. In its discretion, the Board of Directors may leave unfilled for any such period as it may determine any office except those of President and Secretary. Any two or more officers may be held by the same person. Officers may be directors or shareholders of the Corporation.

2. ELECTION AND TERM OF OFFICERS. The officers of the corporation shall be elected annually at the regular meeting of the Board of Directors. Each officer shall hold office for one year or until their successor shall have been duly elected and qualified. They can resign by giving written noticed to any member of the Board of Directors of the corporation. The resignation shall take effect upon receipt thereof and the acceptance shall not be necessary to make it effective.

3. RESIGNATION. Any officer may resign at any time by giving written notice of such resignation to the Board of Directors, or to the President or the Secretary of the Corporation. Unless otherwise specified in such written notice, such resignation shall take effect upon receipt thereof by the Board of Directors or by such officer, and the acceptance of such resignation shall not be necessary to make it effective.

4. REMOVAL. Any officer or agent elected or appointed by the Board of Directors may be removed by the Board of Directors whenever in their judgment, the best interests of the corporation would be served by such removal. Such removal shall be without prejudice to the contractual rights, if any, of the persons so removed.

5. VACANCIES. A vacancy in any office because of death, resignation, removal, disqualification or otherwise, may be filled by the directors for the unexpired position of the term.

6. PRESIDENT. The President shall be the principal executive officer, shall generally supervise and control all the business and affairs of the corporation. The President shall preside at all meetings of stockholders and of directors. she shall sign with the Secretary, Certificates for share of Common Stock. The President shall also sign deeds, mortgages, bonds, contracts of any other instrument which the directors have authorized to be executed by the President. The President shall be responsible for the Corporate Books, unless this is delegated to another officer. The President in general shall perform all the duties incident to the office of President and such other during as may be prescribed by she directors from time to time.

7

7. VICE-PRESIDENTS. In the absence of the President, or in the event of a death, inability or refusal to act, the Vice-President shall perform the duties of the President. When they are so acting, they shall have all the powers of and by subject to all the restrictions of the President. The Vice-President shall perform such other duties as from time to time may be assigned to him by the President or by the directors. The Vice-President shall serve in equal capacity.

8. SECRETARY. The secretary shall keep the minutes of the stockholders and of the directors meetings and shall see that all notices are duly given in accordance with the provisions of these By-Laws. The secretary shall issue the notices for all meetings except that a notice of a special meeting of the directors called at the request of two directors may be issued by those directors. The secretary shall keep a register of the post office address of each stockholder and shall have general charge of the stock transfer books unless this duty is given to a Transfer Agent. The secretary shall make reports and perform such other duties as are incident to their office or are properly required of them by the Board of Directors or the President.

9. TREASURER. The treasurer shall have charge and custody of and be responsible for all funds and securities of the corporation. He/she shall receive monies due to the corporation and give receipts therefore and shall disperse the funds of the corporation in payment of the demands against the corporation as directed by the officers and the Board of Directors. He/she shall perform all duties incident to this office of as properly required of him/her by the officers or the Board of Directors. If required by the directors, the treasurer shall give a bond for faithful discharge of his/her duties in such sum as the directors shall determine.

10. SALARIES. The salaries of the officers shall be fixed from time to time by the Board of Directors, and no officers shall be prevented from receiving such salary by reason of the fact the he/she is also a director of the Corporation. Salaries of all officers of the corporation shall be fixed by a vote of the Board of Directors.

11. INABILITY TO ACT. In case of absence or inability to act of any officer of the corporation, the Board of Directors may from time to time delegate the powers or duties of such officer to any other officer of the corporation.

12. SURETIES AND BONDS. In the case the Board of Directors shall so require any officer, employee or agent of the Corporation shall execute to the Corporation a bond in such sum, and with such surety or sureties as the Board of Directors may direct, conditioned upon the faithful performance of his/her duties to the Corporation, including responsibility for negligence for the accounting for all property, funds or securities of the Corporation which may come into his/her hands.

8

13. SHARES OF STOCK OF OTHER CORPORATIONS. Whenever the Corporation is the holder of shares of stock of any other corporation, any right of power of the Corporation as such shareholder (including the attendance, acting and voting at shareholders' meetings and execution of waivers, consents, proxies or other instruments) may be exercised on behalf of the Corporation by the President, any Vice President or such other person as the Board of Directors my authorize.

ARTICLE V
INDEMNITY

1. INDEMNITY. The Corporation shall indemnify its directors, officers and employees as follows:

Every director, officer, or employee of the Corporation shall be indemnified by the Corporation against all expenses and liabilities, including counsel fees, reasonably incurred by or imposed upon him/her in connection with any proceeding to which he/she may be made a party, or in which he/she may become involved, by reason of being or having been a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of the Corporation, partnership, joint venture, trust or enterprise, or any settlement thereof, whether or not he/she is a director, officer, employee or agent at the time such expenses are incurred, except in such cases wherein the director, officer, employee or agent is adjudged guilty of willful misfeasance or malfeasance in the performance of his/her duties; provided that in the event of a settlement the indemnification herein shall apply only when the Board of Directors approves such settlement and reimbursement as being for the best interests of the Corporation.

The Corporation shall provide to any person who is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of the corporation, partnership, joint venture, trust or enterprise, the indemnity against expenses of a suit, litigation or other proceedings which is specifically permissible under applicable law.

The Board of Directors may, in its discretion, direct the purchase of liability insurance by way of implementing the provisions of this Article.

ARTICLE VI
CONTRACTS, LOANS, CHECKS AND DEPOSITS

1. CONTRACTS. The Board of Directors may authorize any officer or officers, agent or agents, to enter into any contract or execute and deliver any instrument in the name of and on behalf of the Corporation, and such authority may be general or confined to specific instances.

9

2. LOANS. No loans shall be contracted on behalf of the Corporation and no evidences of indebtedness shall be issued in its name unless authorized by a resolution of the Board of Directors. Such authority may be general or confined to specific instances.

3. CHECKS, DRAFTS, ETC. All checks, drafts or other orders for the payment of money, notes or other evidences of indebtedness issued in the name of the Corporation, shall be signed by such officer or officers, agent or agents of the Corporation and in such manner as shall from time to time be determined by resolution of the Board of Directors.

4. DEPOSITS. All funds of the Corporation not otherwise employed shall be deposited from time to time to the credit of the Corporation in such banks, trust companies or other depositories as the Board of Directors may select.

ARTICLE VII
SHARES OF STOCK

1. CERTIFICATES. Certificates representing share of the corporation shall be in a form designated by the directors. Such certificates shall be signed by the President and Secretary. All certificates for shares shall be consecutively numbered. The name and address of the stockholder, the number of shares, and date of issue, shall be entered on the stock transfer books of the corporation. All certificates surrendered to the corporation for transfer shall be canceled and no new certificates shall be issued until, the former certificate for a like number of share has been surrendered and canceled. The exception is the case of a lost or destroyed or mutilated certificate and in such case a new one may be issued when the person claiming that certificate is lost or destroyed or mutilated certifies to the corporation of that fact and indemnifies the corporation.

2. TRANSFER OF SHARES. A transfer of stock shall be made only upon the transfer books of the corporation kept at the office of the corporation or of the corporation or so elected held at a Transfer Agent office. Only registered stockholders in the transfer books of the corporation shall be entitled to be treated by the corporation as the holders in fact of stock. The corporation shall not be bound to recognize any equitable or other claims to or any interest in any share of stock which is not recorded upon the transfer books of the corporation in a manner prescribed by these By-Laws except as expressly provided by the laws of the State of Nevada.

ARTICLE VIII
FISCAL YEAR

1. FISCAL YEAR. The fiscal year of the corporation shall begin on the 1st day of July in each year and end on the 30 day of June.

10

ARTICLE IX
DIVIDENDS

1. DIVIDENDS. The directors may from time to time declare and the corporation may pay, dividends on its outstanding shares in the manner and upon the terms and conditions provided by these By-Laws.

ARTICLE X
SEAL

1. SEAL. The directors shall provide a corporate seal which shall be circular in form and shall have inscribed thereon, the name EZJR, Inc. State of Nevada, 2006, and the words "corporate seal."

ARTICLE XI
WAIVER OF NOTICE

1. WAIVER. Unless otherwise provided by law, whenever any notice is required to be given to any stockholder or director of the corporation under the provisions of these By-Laws or under the provisions of the Articles of Incorporation, or under the provisions of the applicable Business Corporation Act, a waiver thereof in writing signed by the person or persons entitled to such notice, whether made before or after the time stated thereon, shall be deemed equivalent to giving of such notice.

ARTICLE XII
AMENDMENTS

1. AMENDMENTS. Alterations or amendments may be made by an affirmative vote of at least fifty-one percent of the stockholders in any duly called special or regular meeting or by a majority of the Board of Directors at any duly called regular or special meeting.

The above Bylaws are certified to have been adopted by the Board of Directors of the Corporation on the 15th day of August, 2006 and revised on July 30, 2008.

/s/ T J Jesky
-----------------------
    T J Jesky
    Corporate Secretary


Exhibit 3.3 Articles of Merger

ROSS MILLER
Secretary of State

[state seal] 204 North Carson Street, Suite 1 Carson City, Nevada 89701-4299 (775) 684 5708
Website: secretaryofstate.biz


- Articles of Merger - - (Pursuant to NRS 92A.200) - - Page 1 -

(Pursuant to Nevada Revised Statutes Chapter 92A)

(excluding 92A.200(4b))

1) Name and jurisdiction of organization of each constituent entity (NRS 92A. 200). If there are more than four merging entities, check box [ ] and attach an 8 1/2" X 11" blank sheet containing the required information for each additional entity.

EZJR, Inc. (Entity # E0909592005-6)

Name of merging entity

Nevada                               Corporation
------------                         ------------
Jurisdiction                         Entity type*


-------------------
Name of merging entity


------------                         -----------------------------
Jurisdiction                         Entity type*


-------------------
Name of merging entity


------------                         ------------
Jurisdiction                         Entity type*


-------------------
Name of merging entity


------------                         ------------
Jurisdiction                         Entity type*

and,

IVPSA Corporation (Entity # E0613282006-3)

Name of surviving entity

Nevada                               Corporation
------------                         ------------
Jurisdiction                         Entity type*

* Corporation, non-profit corporation, limited partnership, limited-liability company or business trust.

Filing Fee: $350.00

This form must be accompanied by appropriate fees.


ROSS MILLER

               Secretary of State
[state seal]   204 North Carson Street, Suite 1
               Carson City, Nevada 89701-4299
               (775) 684 5708
               Website: secretaryofstate.biz


-----------------------------------------------

- Articles of Merger - - (Pursuant to NRS 92A.200) - - Page 2 -

2) Forwarding address where copies of process may be sent by the Secretary of State of Nevada (if a foreign entity is the survivor in the merger NRS 92A.1 90):

Attn: T. J. Jesky

c/o: EZJR, Inc.

3415 Ocatillo Mesa Way

North Las Vegas, NV 89031

3) (Choose one)

[X] The undersigned declares that a plan of merger has been adopted by each constituent entity (NRS 92A.200).

[ ] The undersigned declares that a plan of merger has been adopted by the parent domestic entity (NRS 92A.180)

4) Owner's approval (NRS 92A.200)(options a, b, or c must be used, as applicable, for each entity)(if there are more than four merging entities, check box [ ] and attach an 8 1/2" X 11" blank sheet containing the required information for each additional entity):

(a) Owner's approval was not required from


Name of merging entity, if applicable


Name of merging entity, if applicable


Name of merging entity, if applicable


Name of merging entity, if applicable

and, or;


Name of surviving entity, if applicable

This form must be accompanied by appropriate fees.


ROSS MILLER

               Secretary of State
[state seal]   204 North Carson Street, Suite 1
               Carson City, Nevada 89701-4299
               (775) 684 5708
               Website: secretaryofstate.biz


-----------------------------------------------

- Articles of Merger - - (Pursuant to NRS 92A.200) - - Page 3 -

(b) The plan was approved by the required consent of the owners of*:

EZJR, Inc.

Name of merging entity, if applicable


Name of merging entity, if applicable


Name of merging entity, if applicable


Name of merging entity, if applicable

and, or;

IVPSA Corporation

Name of surviving entity, if applicable

* Unless otherwise provided in the certificate of trust or governing instrument of a business trust, a merger must be approved by all the trustees and beneficial owners of each business trust that is a constituent entity in the merger.

This form must be accompanied by appropriate fees.


ROSS MILLER

               Secretary of State
[state seal]   204 North Carson Street, Suite 1
               Carson City, Nevada 89701-4299
               (775) 684 5708
               Website: secretaryofstate.biz


-----------------------------------------------

- Articles of Merger - - (Pursuant to NRS 92A.200) - - Page 4 -

(c) Approval of plan of merger for Nevada non-profit corporation (NRS 92A.160):

The plan of merger has been approved by the directors of the corporation and by each public officer or other person whose approval of the plan of merger is required by the articles of incorporation of the domestic corporation.


Name of merging entity, if applicable


Name of merging entity, if applicable


Name of merging entity, if applicable


Name of merging entity, if applicable

and, or;


Name of suriving entity, if applicable

This form must be accompanied by appropriate fees.


ROSS MILLER

               Secretary of State
[state seal]   204 North Carson Street, Suite 1
               Carson City, Nevada 89701-4299
               (775) 684 5708
               Website: secretaryofstate.biz


-----------------------------------------------

- Articles of Merger - - (Pursuant to NRS 92A.200) - - Page 5 -

5) Amendments, if any, to the articles or certificate of the surviving entity. Provide article numbers, if available. (NRS 92A.200)*:

Article I. Name of corporation

The name of the corporation shall be:

EZJR, Inc.

6) Location of Plan of Merger (check a or b):

[ ] (a) The entire plan of merger is attached;

or,

[X] (b) The entire plan of merger is on file at the registered office of the surviving corporation, limited-liability company or business trust, or at the records office address if a limited partnership, or other place of business of the surviving entity (NRS 92A.200).

7) Effective date (optional)**:

* Amended and restated articles may be attached as an exhibit or integrated into the articles of merger. Please entitle them "Restated" or "Amended and Restated," accordingly. The form to accompany restated articles prescribed by the secretary of state must accompany the amended and/or restated articles. Pursuant to NRS 92A.180 (merger of subsidiary into parent Nevada parent owning 90% or more of subsidiary), the articles of merger may not contain amendments to the constituent documents of the surviving entity except that the name of the surviving entity may be changed.

** A merger takes effect upon filing the articles of merger or upon a later date as specified in the articles, which must not be more than 90 days after the articles are filed (NRS 92A.240).

This form must be accompanied by appropriate fees.


ROSS MILLER

               Secretary of State
[state seal]   204 North Carson Street, Suite 1
               Carson City, Nevada 89701-4299
               (775) 684 5708
               Website: secretaryofstate.biz


-----------------------------------------------

- Articles of Merger - - (Pursuant to NRS 92A.200) - - Page 6 -

8) Signatures - Must be signed by: An officer of each Nevada corporation; All general partners of each Nevada limited partnership; All general partners of each Nevada limited partnership; A manager of each Nevada limited- liability company with managers or all the members if there are no managers; A trustee of each Nevada business trust (NRS 92A.230)*

(If there are more than four merging entities, check box [ ] and attach an 8 1/2" X 11" blank sheet containing the required information for each additional entity.):

EZJR, Inc.
---------------------------------------------
Name of merging entity

/s/ T. J. Jesky                  President            7/25/2008
------------------------         ---------            ----------
Signature                        Title                Date


------------------------
Name of merging entity


------------------------         ---------            ----------
Signature                        Title                Date


------------------------
Name of merging entity


------------------------         --------             ----------
Signature                        Title                Date


------------------------
Name of merging entity


------------------------         --------             ----------
Signature                        Title                Date

IVPSA Corporation
------------------------
Name of surviving entity

/s/ T. J. Jesky                  President            7/25/2008
------------------------         -------------------  ----------
Signature                        Title                Date

* The articles of merger must be signed by each foreign constituent entity in the manner provided by the law governing it (NRS 92A.230). Additional signature blocks may be added to this page or as an attachment, as needed.

IMPORTANT: Failure to include any of the above information and submit the proper fees may cause this filing to be rejected.

This form must be accompanied by appropriate fees.


Exhibit 10.1

06011-001

EXCLUSIVE OPTION AGREEMENT

This Exclusive Option Agreement (hereinafter called "Agreement"), to be effective as of the 15th day of March, 2007 (hereinafter called "Effective Date"), is by and among The Cleveland Clinic Foundation (hereinafter, "CCF") with its principal location at 9500 Euclid Ave., Cleveland, Ohio 44195 and IVPSA, with its principal location at 500 N. Rainbow, Suite 300, Las Vegas, NV 89107 (hereinafter, "OPTIONEE"). Collectively, both entities may hereinafter be referenced to as "Party" or "Parties."

RECITALS:

Whereas, CCF owns the Licensable Technology as defined below;

Whereas, OPTIONEE specializes in developing technology and bringing new technologies to market;

Whereas, OPTIONEE desires to investigate and conduct due diligence with respect to the commercial viability of the Licensable Technology prior to executing the License Agreement;

NOW, THEREFORE, for and in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereto expressly agree as fellows:

1. DEFINITIONS

A. "Affiliates" means any corporation or other business entity which controls, is controlled by or is under common control with OPTIONEE. For purposes of this Section 1.1, "control" shall mean direct or indirect ownership of (i) at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors, or (ii) in any country where the local law shall not permit foreign equity participation of at least fifty percent (50%) then the maximum percentage of such outstanding stock or voting rights permitted by local law.

B. "Confidential Information" means any confidential or proprietary information furnished by one party (the "Disclosing Party") to the other party (the "Receiving Party") in connection with this Agreement, provided that such information is specifically designated as confidential. Confidential Information shall include, but not be limited to, the following when specifically designated as confidential: business information, trade secrets, technical information, know-how, engineering process, intellectual property, business plans and strategies, business operations and systems, marketing techniques, material pricing policies, information concerning employees, customers, licensees and/or vendors, patent applications, patent prosecution, inventions, ideas, procedures, formulae or data, The term Confidential Information shall not be deemed to include information which (a) is now, or hereafter becomes, through no act or failure of the Receiving Party, in the public domain; (b) is known by the Receiving Party at the time of receipt of such information; (c) is hereafter furnished to the Receiving Party by a. third party, who is not subject to any restriction on disclosure at the time of disclosure to the Receiving Party; or (d) has been developed by the Receiving Party completely independent of the delivery of Confidential Information hereunder.

C. "Field" shall mean clinical use as a catheter for insertion into the vascular system of a patient to direct fluid flow, sampling of fluids and oxygenation monitoring.

1 of 7

D. "Licensable Know How" shall mean any and all information, including but not limited to, confidential, proprietary and trade secret information owned, controlled, originated, conceived, reduced to practice, developed or otherwise in the possession of CCF as of the Effective Date necessary to practice Licensable Patents, including without limitation, all methods, processes, processing techniques, products, compositions, formulas, test data, and designs.

E. "Licensable Patents" shall refer to and mean US Patent Application # 60/797,433 entitled "Intra-jugular Catheter" and any U.S. or foreign patent applications, reissues, extensions, renewals, reexaminations, certificates of invention, substitutions, divisions, continuations, and continuations-in-part thereof having the Principal Investigator as an inventor and having the same priority date as the parent applications.

G. "Licensable Technology" shall mean Licensable Patents and Licensable Know How,

H. "Principal Investigator" shall mean Dr. Rafi Avitsian while an employee of CCF.

2. OPTION GRANT

2.1 Option Period For a period of twelve (12) months immediately following the Effective Date of this Agreement ("Option Period"), CCF agrees that it will not enter into any exclusive agreement with any third party with respect to the transfer of rights in the Field to the Licensable Technology, whether by license or otherwise,

2.2 Negotiation for a License Agreement During the Option Period, Parties shall negotiate a License Agreement having terms and conditions generally agreeable to CCF not limited to but including an upfront license fee, milestones and a royalty. Binding obligations for such a license agreement will only be created by the execution and delivery of a definitive written agreement between the Parties and shall be dependant on OPTIONEE providing a product development plan for the Licensable Technology that is acceptable to CCF at its sole discretion. If an agreement has not been reached within said Option Period, the parties shall have no further obligations under this Agreement and CCF shall be free to license any and all rights under the Licensable Technology to any third party without any further obligation to OPTIONEE.

The license agreement shall include at least the following provisions. license fees, royalty payments, required terms for granting sublicenses (if any), a commitment by OPTIONEE and any sublicensee to exert their best efforts to introduce the licensed material into public use as rapidly as practicable, the right of CCF to terminate the license should OPTIONEE not meet specified due-diligence milestones, and indemnity and insurance provisions satisfactory to CCF. Provided other terms of a license agreement negotiated by the Parties upon OPTIONEE's exercise of the Option generally conform with CCF's standard practices and license terms, such license agreement shall include financial terms to be negotiated within the following ranges: (i) OPTIONEE shall pay CCF a License Fee in amounts that total not less than seventy-five thousand dollars ($75,000) nor more than one hundred thousand dollars ($100,000); and (ii) OPTIONEE shall remit royalties to CCF on a quarterly basis based on a percentage of net sales of the products subject to the license agreement of not less than 7.5% nor more than 15%.

2 of 7

3. PAYMENTS

3.1 Option Fee. Within fifteen (l5)days of the Effective Date of this Agreement, OPTIONEE shall pay CCF a nonrefundable fee equal to thirty-six thousand dollars ($36,000).

3.2 Patent Prosecution and Maintenance. CCF shall notify OPTIONEE of any and all costs associated with prosecuting and maintaining the Licensable Patents throughout the Option Period, and OPTIONEE shall reimburse CCF up to $2,500 any and all reasonable costs associated therewith, Reimbursement payments shall be due within 15 days of receiving invoices from CCF. If OPTIONEE fails to make such reimbursement payments, it shall automatically relinquish all rights under this Agreement.

4. INTELLECTUAL PROPERTY RIGHTS

Title to all Licensable Technology (including but not limited to prototypes developed by the OPTIONEE) shall remain in CCF. Any materials developed by OPTIONEE shall be returned to CCF at the end of the Option Period.

5. TERMINATION

5.1 Term Unless otherwise terminated by operation of law or by acts of the

parties in accordance with the terms of this Agreement, this Agreement shall automatically terminate upon conclusion of the Option Period.

5.2 Termination for Breach

(a) This Agreement shall be terminable upon the material breach of either party. In the event of a material breach by a party ("Defaulting Party") the other party ("Non-Defaulting Party") shall give the Defaulting Party written notice of the default and its termination of this Agreement, subject to a thirty (30) day right to cure. If the Defaulting Party (i) fails to cure the breach within thirty (30) days after receipt of notice from the Non-Defaulting Party, or (ii) fails to provide a written explanation satisfactory to the Non-Defaulting Party for the cure or other resolution of the default, then this Agreement shall be terminated as of the date of the notice. All termination rights shall be in addition to and not in substitution for any other remedies that may be available to the Non- Defaulting Party.

(b) Termination pursuant to this section shall not relieve the Defaulting Party from liability and damages to the Non-Defaulting Party for default. Waiver by either party of a single default or a succession of defaults shall not deprive such party of any right to terminate this Agreement arising by reason of a subsequent default

5.3 Termination Without Cause. Either party may terminate this Agreement at any time prior to the expiration of the Option Period, by providing thirty
(30) days written notice of same to the non-terminating party..

5.4 Effects of Termination. Any termination of this Agreement for any reason, does not relieve either party of any obligation or liability accrued prior to the termination or rescind anything done by either party and the termination does not affect in any manner any rights of either party arising under

3 of 7

this Agreement prior to the termination. Upon expiration of this Agreement, the obligations set forth in Sections 8, 9.2, 9.3, 9.7 and 9.13, 9.14 shall survive.

6. ASSIGNABILITY

This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective assigns and successors in interest. The Agreement may not be assigned by either Party without the consent in writing of the other Party.

7. ADDRESSES

All notices, reports or other required, material communications pursuant to this Agreement shall be sent to such Party via (i) United States Postal Service certified mail, return receipt requested, postage prepaid, (ii) overnight courier, charges prepaid or (iii) facsimile transmission, addressed to it at its address set forth below or as it shall designate by written notice given to the other Parties. Notice shall be sufficiently made or given
(a) on the date of mailing, (b) when deposited with the overnight courier, or
(c) when facsimile printer reflects receipt.

CCF:

CCF Innovations - Mailstop D20
The Cleveland Clinic Foundation
500 Euclid Avenue
Cleveland, OH 44195
Attn: Neil Veloso
Facsimile No. 216-445-6514

With copy to:

Office of General Counsel - Mailstop
Attn: Karen Shanahan, Esq.
Facsimile No. 216-297-7005

OPTIONEE:

IVPSA

500 N. Rainbow, Suite 300,
Las Vegas NV _89107

8. DISPUTE RESOLUTION

8.1 Except in the event that a party shall reasonably determine that it must seek a preliminary injunction, temporary restraining order or other provisional relief; upon the occurrence of a dispute between parties, including, without limitation, any breach of this Agreement or any obligation relating thereto, the matter shall be referred first to authorized officers of CCF and OPTIONEE, or their designees. The authorized officers or their designees as the CCF may be, shall negotiate in good faith to resolve such dispute in a mutually satisfactory manner for thirty (30) days. If such efforts do not result in mutually satisfactory resolution of the dispute, the matter shall be handled by arbitration in accordance with Section 8.2.

4 of 7

8.2 Any arbitration shall be conducted in Cleveland, Ohio in accordance with the Commercial Dispute Resolution Procedures of the American Arbitration Association and in the English language. The arbitrators shall include one nominee of CCF and one nominee of OPTIONEE, and a third person selected by said nominees. The parties agree that any arbitration panel shall include members knowledgeable as to evaluation of the biotechnology industry. Judgment upon the award rendered may be entered in the highest court or forum, state or federal, having jurisdiction; provided however that the provisions of this Section 8 (Dispute Resolution) shall not apply to any dispute or controversy as to which any treaty or law prohibits such arbitration,

8.3 Notwithstanding the foregoing, nothing in this Section 8 shall be construed to waive any rights or timely performance of any obligations existing under this Agreement.

9. ADDITIONAL PROVISIONS

9.1 Use of Parties' Names. Each Party agrees that it shall not use in any way the name or logo of the other Party without the prior consent of the Party whose name is to be used.

9.2 Independent Contractors. The Parties hereby acknowledge and agree that each is an independent contractor and that no Party shall be considered to be the agent, representative, master or servant of any other Party for any purpose whatsoever, and that no Party has any authority to enter into a contract, to assume any obligation or to give warranties or representations on behalf of any other Party. Nothing in this relationship shall he construed to create a relationship of joint venture, partnership, fiduciary or other similar relationship between or among the Parties,

9.3 Indemnification OPTIONEE shall indemnify, hold harmless and defend CCF and its respective trustees, officers, employees and agents (the "Indemnitees") against any and all claims and suits of third parties ("Third Party Claims"), and any damages, costs, fees, and expenses incurred by the Indemnitees in connection with such Third Party Claims, resulting from or arising out of this Option Agreement (each a "Loss"). OPTIONEE shall have no obligation to indemnify any Indemnitees to the extent that a Loss arises out of the gross negligence or intentional misconduct of an Indemnitee or the breach of this Agreement by an Indemnitee.

9.4 Representations and Warranties. Each Party represents and warrants that it has the right, power and authority 1.0 enter into this Agreement. CCF represents and warrants to OPTIONEE that it owns the Licensable Technology. CCF represents that to its knowledge, as of the Effective Date of this Agreement, there are no third party infringement claims against the Licensed Patents.

9.5 Disclaimer of Further Warranties. Other than as specifically provided in section 9.4, CCF makes no warranties or representations, express or implied, with respect to the Licensable Technology including, but not limited to, warranties of fitness or merchantability.

9.6 Non-Waiver. The Parties covenant and agree that if a Party fails or neglects for any reason to take advantage of any of the terms providing for the termination of this Agreement or if a Party, having the right to declare this Agreement terminated, shall fail to do so, any such failure or neglect by such Party shall not be a waiver or be deemed or be construed to be a waiver of any cause for the termination of this Agreement subsequently arising, or as a waiver of any of the terms, covenants or conditions of this Agreement or of the performance thereof None of the terms, covenants and conditions of this Agreement may be waived by a Party except by its written consent.

5 of 7

9.7 Confidentiality. CCF and OPTIONEE agree for the Term and three (3) years thereafter to hold all Confidential Information in confidence, and to use the same only in accordance with this Agreement, unless required to do so by federal or stale securities laws. OPTIONEE shall have the right to share Confidential Information with affiliates, partners, and consultants, provided such third party enters into a confidentiality agreement with OPTIONEE having terms at least as protective as set forth in this Agreement. Except as required by applicable law, CCF and the OPTIONEE will hold, and will cause its respective directors, officers, employees, accountants, counsel, financial advisors and other representatives and affiliates to hold, any nonpublic information in confidence.

9.8 Publications and Copyrights. CCF will be free to publish the results of its research during the Term of this Agreement.

9.9 Reformation. The Parties hereby agree that no Party intends to violate any public policy, statutory or common law, rule, regulation, treaty or decision of any government agency or executive body thereof of any country or community or association of countries, and that if any word, sentence, paragraph or clause or combination thereof of this Agreement is found, by a court or executive body with judicial powers having jurisdiction over this Agreement or any of the Parties hereto, in a final, unappealable order to be in violation of any such provision in any country or community or association of countries, such words, sentences, paragraphs or clauses or combination shall be inoperative in such country or community or association of countries, and the remainder of this Agreement shall remain binding upon the Parties hereto.

9.10 Execution in Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original and executed versions sent by facsimile transmission shall also be deemed to be originals.

9.11 Disclaimers. The parties acknowledge and agree that, unless and until the Option is exercised, neither OPTIONEE nor any affiliate of OPTIONEE has any right or interest in the Licensable Technology.

9.12 Governing Law This Agreement shall he governed by the laws of the State of Ohio.

9.13 Press Releases. Both OPTIONEE and CCF will not, without the other party's prior review and express written consent, issue any press release, or issue or make any other public comment, or publish or broadcast any advertisement in any media, or disseminate any sales promotion or solicitation materials, that in any way refers to the other party, or any subsidiary or affiliate of the other party, or to the specific terms of this Agreement unless such item is substantially similar to that which has already been approved by the other party.

9.14 Access to Records. If Section 952 of the Omnibus Reconciliation Act of 1980, which amended Section l861(v)(1) of the Social Security Act, and the regulations promulgated there under, applies to this Agreement, each party will make available to the Secretary of Health and Human Services, and to the Comptroller General of the United States upon written request, such books, documents and records necessary to verify the nature and extent of the costs of the services provided hereunder. Access will be granted until the expiration of four (4) years after the furnishing of services hereunder. Access will also be granted to any books, documents or records related to this Agreement between a party and organizations related to that party, but only an as needed basis.

9.15 Compliance with Laws. By entering into this Agreement, the parties specifically intend to comply with all applicable laws, rules and regulations as they may be amended from time to time. In the event that any part of this Agreement is determined to violate federal, state, or local laws, rules, or

6 of 7

regulations, the parties agree to negotiate in good faith revisions to the provision or provisions that are in violation. In the event the parties are unable to agree to new or modified terms as required to bring the entire Agreement into compliance, either party may terminate this Agreement without penalty upon thirty (30) days written notice to the other party.

9.16 Debarment. IVPSA hereby represents and warrants that it has not been debarred, suspended, excluded or otherwise determined to be ineligible to participate in federal healthcare programs (collectively, "Debarred") and acknowledges that CCF shall have the right to terminate this Agreement immediately in the event that IVPSA is Debarred.

IN WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement in multiple originals by their duly authorized officers and representatives on the respective dates shown below, hut effective as of the Agreement Date.

IVPSA                                  THE CLEVELAND CLINIC FOUNDATION

By: /s/ T. J. Jesky                    By: /s/ Michael P. O'Boyle
    ---------------                        ----------------------

Name:   T. J. Jesky                      Name: Michael P. O'Boyle
    ---------------                        ----------------------

Title: President/CEO                   Title: Chief Operating Officer
       -------------                          -----------------------

Date: March 20, 2007                   Date: 3-27, 2007
      --------------                         ----------


                                               APPROVED AS TO FORM
                                                  CCF-OFFICE OF
                                                 GENERAL COUNSEL
                                                      BY KDS
                                                         ---
                                                   DATE 3/26/07
                                                        -------
                                                   CMSI#
                                                         ------

7 of 7

Exhibit 10.2

EXCLUSIVE OPTION AGREEMENT

This Exclusive Option Agreement (hereinafter called "Agreement"), to be effective as of the 14th day of April, 2008 (hereinafter called "Effective Date"), is by and among The Cleveland Clinic Foundation (hereinafter, "CCF") with its principal location at 9500 Euclid Ave., Cleveland, Ohio 44195 and IVPSA, with its principal location at 500 N. Rainbow, Suite 300, Las Vegas, NV 89107 (hereinafter, "OPTIONEE"). Collectively, both entities may hereinafter be referred to as "Party" or "Parties."

RECITALS:

Whereas, CCF owns the Licensable Technology as defined below;

Whereas, OPTIONEE specializes in developing technology and bringing new technologies to market;

Whereas, OPTIONEE desires to investigate and conduct due diligence with respect to the commercial viability of the Licensable Technology prior to executing the License Agreement;

NOW, THEREFORE, for and in consideration of the premises and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties hereto expressly agree as follows:

1. DEFINITIONS

A. "Affiliates" means any corporation or other business entity which controls, is controlled by or is under common control with OPTIONEE. For purposes of this Section 1.1, "control" shall mean direct or indirect ownership of (i) at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors, or (ii) in any country where the local law shall not permit foreign equity participation of at least fifty percent (50%) then the maximum percentage of such outstanding stock or voting rights permitted by local law.

B. "Confidential Information" means any confidential or proprietary information furnished by one party (the "Disclosing Party") to the other party (the "Receiving Party") in connection with this Agreement, provided that such information is specifically designated as confidential. Confidential Information shall include, but not be limited to, the following when specifically designated as confidential: business information, trade secrets, technical information, know-how, engineering process, intellectual property, business plans and strategies, business operations and systems, marketing techniques, material pricing policies, information concerning employees, customers, licensees and/or vendors, patent applications, patent prosecution, inventions, ideas, procedures, formulae or data. The term Confidential Information shall not be deemed to include information which (a) is now, or hereafter becomes, through no act or failure of the Receiving Party, in the public domain; (b) is known by the Receiving Party at the time of receipt of such information; (c) is hereafter furnished to the Receiving Party by a third party, who is not subject to any restriction on disclosure at the time of disclosure to the Receiving Party; or (d) has been developed by the Receiving Party completely independent of the delivery of Confidential Information hereunder.

C. "Field" shall mean clinical use as a catheter for insertion into the vascular system of a patient to direct fluid flow, sampling of fluids and oxygenation monitoring.

1 of 7

D. "Licensable Know How" shall mean any and all information, including but not limited to, confidential, proprietary and trade secret information owned, controlled, originated, conceived, reduced to practice, developed or otherwise in the possession of CCF as of the Effective Date necessary to practice Licensable Patents, including without limitation, all methods, processes, processing techniques, products, compositions, formulas, test data, and designs.

E. "Licensable Patents" shall refer to and mean US Patent Application # 60/797,433 entitled "Intra-jugular Catheter" and any U.S. or foreign patent applications, reissues, extensions, renewals, reexaminations, certificates of invention, substitutions, divisions, continuations, and continuations-in-part thereof having the Principal Investigator as an inventor and having the same priority date as the parent applications.

F. "Licensable Technology" shall mean Licensable Patents and Licensable Know How.

G. "Principal Investigator" shall mean Dr. Rafi Avitsian while an employee of CCF.

2. OPTION GRANT

2.1 Option Period For a period of twelve (12) months immediately following the Effective Date of this Agreement ("Option Period"), CCF agrees that it will not enter into any exclusive agreement with any third party with respect to the transfer of rights in the Field to the Licensable Technology, whether by license or otherwise.

2.2 Negotiation for a License Agreement During the Option Period, Parties shall negotiate a License Agreement having terms and conditions generally agreeable to CCF not limited to but including an upfront license fee, milestones and a royalty. Binding obligations for such a license agreement will only be created by the execution and delivery of a definitive written agreement between the Parties and shall be dependant on OPTIONEE providing a product development plan for the Licensable Technology that is acceptable to CCF at its sole discretion. If an agreement has not been reached within said Option Period, the parties shall have no further obligations under this Agreement and CCF shall be free to license any and all rights under the Licensable Technology to any third party without any further obligation to OPTIONEE.

The license agreement shall include at least the following provisions:
license fees, royalty payments, required terms for granting sublicenses (if any), a commitment by OPTIONEE and any sublicensee to exert their best efforts to introduce the licensed material into public use as rapidly as practicable, the right of CCF to terminate the license should OPTIONEE not meet specified due-diligence milestones, and indemnity and insurance provisions satisfactory to CCF. Provided other terms of a license agreement negotiated by the Parties upon OPTIONEE's exercise of the Option generally conform with CCF's standard practices and license terms, such license agreement shall include financial terms to be negotiated within the following ranges: (i) OPTIONEE shall pay CCF a License Fee in amounts that total not less than eighty thousand dollars ($80,000) nor more than one hundred thousand dollars ($100,000); and (ii) OPTIONEE shall remit royalties to CCF on a quarterly basis based on a percentage of net sales of the products subject to the license agreement of not less than 7% nor more than 10%.

2 of 7

3. PAYMENTS

3.1 Option Fee. Within fifteen (15) days of the Effective Date of this Agreement, OPTIONEE shall pay CCF a nonrefundable fee equal to ten thousand dollars ($10,000).

3.2 Patent Prosecution and Maintenance. CCF shall notify OPTIONEE of any and all costs associated with prosecuting and maintaining the Licensable Patents throughout the Option Period, and OPTIONEE shall reimburse CCF up to $6,500 any and all reasonable costs associated therewith. Reimbursement payments shall be due within 15 days of receiving invoices from CCF. If OPTIONEE fails to make such reimbursement payments, it shall automatically relinquish all rights under this Agreement.

4. INTELLECTUAL PROPERTY RIGHTS

Title to all Licensable Technology (including but not limited to prototypes developed by the OPTIONEE) shall remain in CCF. Any materials developed by OPTIONEE shall be returned to CCF at the end of the Option Period.

5. TERMINATION

5.1 Term Unless otherwise terminated by operation of law or by acts of the

parties in accordance with the terms of this Agreement, this Agreement shall automatically terminate upon conclusion of the Option Period.

5.2 Termination for Breach

(a) This Agreement shall be terminable upon the material breach of either party. In the event of a material breach by a party ("Defaulting Party") the other party ("Non-Defaulting Party") shall give the Defaulting Party written notice of the default and its termination of this Agreement, subject to a thirty (30) day right to cure. If the Defaulting Party (i) fails to cure the breach within thirty (30) days after receipt of notice from the Non-Defaulting Party, or (ii) fails to provide a written explanation satisfactory to the Non- Defaulting Party for the cure or other resolution of the default, then this Agreement shall be terminated as of the date of the notice. All termination rights shall be in addition to and not in substitution for any other remedies that may be available to the Non-Defaulting Party.

(b) Termination pursuant to this section shall not relieve the Defaulting Party from liability and damages to the Non-Defaulting Party for default. Waiver by either party of a single default or a succession of defaults shall not deprive such party of any right to terminate this Agreement arising by reason of a subsequent default

5.3 Termination Without Cause. Either party may terminate this Agreement at any time prior to the expiration of the Option Period, by providing thirty
(30) days written notice of same to the non-terminating party..

5.4 Effects of Termination. Any termination of this Agreement for any reason, does not relieve either party of any obligation or liability accrued prior to the termination or rescind anything done by either party and the termination does not affect in any manner any rights of either party arising under this Agreement prior to the termination. Upon expiration of this Agreement, the obligations set forth in Sections 8, 9.2, 9.3, 9.7 and 9.13, 9.14 shall survive.

3 of 7

6. ASSIGNABILITY

This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective assigns and successors in interest. The Agreement may not be assigned by either Party without the consent in writing of the other Party.

7. ADDRESSES

All notices, reports or other required, material communications pursuant to this Agreement shall be sent to such Party via (i) United States Postal Service certified mail, return receipt requested, postage prepaid, (ii) overnight courier, charges prepaid or (iii) facsimile transmission, addressed to it at its address set forth below or as it shall designate by written notice given to the other Parties. Notice shall be sufficiently made or given (a) on the date of mailing, (b) when deposited with the overnight courier, or (c) when a facsimile printer reflects receipt.

CCF:

CCF Innovations - Mailstop D20
The Cleveland Clinic Foundation
500 Euclid Avenue
Cleveland, OH 44195
Attn: Neil Veloso
Facsimile No. 216-445-6514

With copy to:

Office of General Counsel
The Cleveland Clinic Foundation
3050 Science Park Drive - AC321
Beachwood, OH 44122
Attn: Chief Legal Officer
Facsimile No. 216-448-0201

OPTIONEE:

IVPSA Corporation
500 N. Rainbow, Suite 300
Las Vegas, NV _89107
Facsimile No. (702) 221-1963

8. DISPUTE RESOLUTION

8.1 Except in the event that a party shall reasonably determine that it must seek a preliminary injunction, temporary restraining order or other provisional relief, upon the occurrence of a dispute between parties, including, without limitation, any breach of this Agreement or any obligation relating thereto, the matter shall be referred first to authorized officers of CCF and OPTIONEE, or their designees. The authorized officers or their designees as the CCF may be, shall negotiate in good faith to resolve such dispute in a mutually satisfactory manner for thirty (30) days. If such efforts do not result in mutually satisfactory resolution of the dispute, the matter shall be handled by arbitration in accordance with Section

4 of 7

8.2 Any arbitration shall be conducted in Cleveland, Ohio in accordance with the Commercial Dispute Resolution Procedures of the American Arbitration Association and in the English language. The arbitrators shall include one nominee of CCF and one nominee of OPTIONEE and a third person selected by said nominees. The parties agree that any arbitration panel shall include members knowledgeable as to evaluation of the biotechnology industry. Judgment upon the award rendered may be entered in the highest court or forum, state or federal, having jurisdiction; provided however, that the provisions of this
Section 8 (Dispute Resolution) shall not apply to any dispute or controversy as to which any treaty or law prohibits such arbitration.

8.3 Notwithstanding the foregoing, nothing in this Section 8 shall be construed to waive any rights or timely performance of any obligations existing under this Agreement.

9. ADDITIONAL PROVISIONS

9.1 Use of Parties' Names. Each Party agrees that it shall not use in any way the name or logo of the other Party without the prior consent of the Party whose name is to be used.

9.2 Independent Contractors. The Parties hereby acknowledge and agree that each is an independent contractor and that no Party shall be considered to be the agent, representative, master or servant of any other Party for any purpose whatsoever, and that no Party has any authority to enter into a contract, to assume any obligation or to give warranties or representations on behalf of any other Party. Nothing in this relationship shall be construed to create a relationship of joint venture, partnership, fiduciary or other similar relationship between or among the Parties.

9.3 Indemnification OPTIONEE shall indemnify, hold harmless and defend CCF and its respective trustees, officers, employees and agents (the "Indemnitees") against any and all claims and suits of third parties ("Third Party Claims"), and any damages, costs, fees, and expenses incurred by the Indemnitees in connection with such Third Party Claims, resulting from or arising out of this Option Agreement (each a "Loss"). OPTIONEE shall have no obligation to indemnify any Indemnitees to the extent that a Loss arises out of the gross negligence or intentional misconduct of an Indemnitee or the breach of this Agreement by an Indemnitee.

9.4 Representations and Warranties. Each Party represents and warrants that it has the right, power and authority to enter into this Agreement. CCF represents and warrants to OPTIONEE that it owns the Licensable Technology. CCF represents that to its knowledge, as of the Effective Date of this Agreement, there are no third party infringement claims against the Licensed Patents.

9.5 Disclaimer of Further Warranties. Other than as specifically provided in section 9.4, CCF makes no warranties or representations, express or implied, with respect to the Licensable Technology including, but not limited to, warranties of fitness or merchantability.

9.6 Non-Waiver. The Parties covenant and agree that if a Party fails or neglects for any reason to take advantage of any of the terms providing for the termination of this Agreement or if a Party, having the right to declare this Agreement terminated, shall fail to do so, any such failure or neglect by such Party shall not be a waiver or be deemed or be construed to be a waiver of any cause for the termination of this Agreement subsequently arising, or as a waiver of any of the terms, covenants or conditions of this Agreement or of the performance thereof. None of the terms, covenants and conditions of this Agreement may be waived by a Party except by its written consent.

5 of 7

9.7 Confidentiality. CCF and OPTIONEE agree for the Term and three (3) years thereafter to hold all Confidential Information in confidence, and to use the same only in accordance with this Agreement, unless required to do so by federal or state securities laws. OPTIONEE shall have the right to share Confidential Information with affiliates, partners, and consultants, provided such third party enters into a confidentiality agreement with OPTIONEE having terms at least as protective as set forth in this Agreement. Except as required by applicable law, CCF and the OPTIONEE will hold, and will cause its respective directors, officers, employees, accountants, counsel, financial advisors and other representatives and affiliates to hold, any nonpublic information in confidence.

9.8 Publications and Copyrights. CCF will be free to publish the results of its research during the Term of this Agreement.

9.9 Reformation. The Parties hereby agree that no Party intends to violate any public policy, statutory or common law, rule, regulation, treaty or decision of any government agency or executive body thereof of any country or community or association of countries, and that if any word, sentence, paragraph or clause or combination thereof of this Agreement is found, by a court or executive body with judicial powers having jurisdiction over this Agreement or any of the Parties hereto, in a final, unappealable order to be in violation of any such provision in any country or community or association of countries, such words, sentences, paragraphs or clauses or combination shall be inoperative in such country or community or association of countries, and the remainder of this Agreement shall remain binding upon the Parties hereto.

9.10 Execution in Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original and executed versions sent by facsimile transmission shall also be deemed to be originals.

9.11 Disclaimers. The parties acknowledge and agree that, unless and until the Option is exercised, neither OPTIONEE nor any affiliate of OPTIONEE has any right or interest in the Licensable Technology.

9.12 Governing Law This Agreement shall be governed by the laws of the State of Ohio.

9.13 Press Releases. Both OPTIONEE and CCF will not, without the other party's prior review and express written consent, issue any press release, or issue or make any other public comment, or publish or broadcast any advertisement in any media, or disseminate any sales promotion or solicitation materials, that in any way refers to the other party, or any subsidiary or affiliate of the other party, or to the specific terms of this Agreement unless such item is substantially similar to that which has already been approved by the other party.

9.14 Access to Records. If Section 952 of the Omnibus Reconciliation Act of 1980, which amended Section 1861(v)(1) of the Social Security Act, and the regulations promulgated there under, applies to this Agreement, each party will make available to the Secretary of Health and Human Services, and to the Comptroller General of the United States upon written request, such books, documents and records necessary to verify the nature and extent of the costs of the services provided hereunder. Access will be granted until the expiration of four (4) years after the furnishing of services hereunder. Access will also be granted to any books, documents or records related to this Agreement between a party and organizations related to that party, but only an as needed basis.

9.15 Compliance with Laws. By entering into this Agreement, the parties specifically intend to comply with all applicable laws, rules and regulations as they may be amended from time to time. In the event that any part of this Agreement is determined to violate federal, state, or local laws, rules, or regulations, the parties agree to negotiate in good faith revisions to the provision or provisions that are in violation. In the event the parties are unable to agree to new or modified terms as required to bring the entire Agreement into compliance, either party may terminate this Agreement without penalty upon thirty (30) days written notice to the other party.

6 of 7

9.16 Debarment. IVPSA hereby represents and warrants that it has not been debarred, suspended, excluded or otherwise determined to be ineligible to participate in federal healthcare programs (collectively, "Debarred") and acknowledges that CCF shall have the right to terminate this Agreement immediately in the event that IVPSA is Debarred.

9.17 Conflict. CCF maintains and adheres to a Conflict of Interest Policy. In that connection, OPTIONEE represents that no CCF employees, officers or directors are employees, consultants, officers or directors of OPTIONEE or serve on any boards or committees of or in any advisory capacity with OPTIONEE. Any payments made to such parties are at fair market value for services rendered.

IN WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement in multiple originals by their duly authorized officers and representatives on the respective dates shown below, but effective as of the Agreement Date.

IVPSA CORPORATION                      THE CLEVELAND CLINIC FOUNDATION
(A Nevada Corporation)

By:  /s/ T J Jesky                     By:  /s/ David R. Strand
---------------------                  ------------------------
Name:    T J Jesky                     Name:    David R. Strand
---------------------                  ------------------------
Title:  President/CEO                  Title:  COO
---------------------                  ------------------------
Date:  April 21, 2008                  Date:  April 30, 2008
---------------------                  ------------------------

                                               APPROVED AS TO FORM
                                                  CCF-OFFICE OF
                                                 GENERAL COUNSEL
                                                      BY KDS
                                                         ---
                                                   DATE 4/25/08
                                                        -------
                                                   CMSI# IVPS 25818
                                                         ----------

7 of 7

Exhibit 23.1

SEALE AND BEERS, CPAs
PCAOB & CPAB REGISTERED AUDITORS
www.sealebeers.com

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the use, in the registration statement on Form 10 of EZJR, Inc., of our report dated October 10, 2009 on our audit of the financial statements of EZJR, Inc. as of June 30, 2009 and 2008, and the related statements of operations, stockholders' equity and cash flows for the years then ended, and from inception on August 14, 2006 through June 30, 2009, and the reference to us under the caption "Experts."

/s/ Seale and Beers, CPAs
-------------------------
    Seale and Beers, CPAs
    Las Vegas, Nevada
    October 28, 2009

Seale and Beers, CPAs PCAOB & CPAB Registered Auditors 50 S. Jones Blvd Suite 202 Las Vegas, NV 89107 Phone: (888)727-8251 Fax: (888)782-2351